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Abstract 
Idiopathic non-infectious uveitis is the spontaneous inflammation of the eye, which can lead 
to blindness if not treated correctly. Due to long-term side effects of corticosteroids, 4 classes 
of off-label immunosuppressive treatments are sometimes used (alkylating agents, inhibitors 
of T-lymphocyte signalling, antimetabolites and biological modifiers). We conducted a 
systematic review and meta-analysis to assess the effectiveness of 3 treatment classes on 
uveitis patients with similar characteristics. Results of the systematic review concurred with 
the conclusions from the meta-analysis, which found that all immunosuppressive treatments 
improved patient vision, with a statistically significant change in logMAR of -0.11 (95% CI 
of -0.152 to -0.061, p=0). The subgroup analysis found antimetabolites and T-cell inhibitors 
improved patient vision which was statistically significant, with antimetabolites showing a 
better change in logMAR of -0.131 (95% CI -0.211 to -0.050, p=0.001. I2=0%). These 
findings could inform policy and help develop concrete guidelines for treating uveitis 
patients.  
 
Keywords 
Idiopathic Uveitis, Anterior, Posterior, Intermediate, Immunosuppressive treatment, 
Alkylating agents, Inhibitors of T-lymphocyte signaling, Antimetabolites, Visual Acuity, 
LogMAR, random effects, raw mean difference, meta-analysis, subgroup analysis, meta-
regression 
  
 iii 
 
Co-Authorship Statement  
The work presented herein was performed solely by the author. As stated in Chapter 5, the 
only exception was the literature search and level 1&2 screening. The search strategy and 
literature search was done with the help of Lorraine Leff, who was the librarian on my 
project. Also, for level 1 screening Andrea Coronado (AC) was the other reviewer alongside 
myself (HS). For level 2 screening the second reviewer was Shruti Sharma (SS) and I was the 
first reviewer. Discrepancies between any of the screenings were dealt with Dr. Hodge.  
 
 
 
 
 
 
 
 
 
 
 
 
 iv 
 
Dedication and Acknowledgments 
 
I would like to acknowledge the department of Epidemiology and Biostatistics for providing 
me with an excellent educational experience. The courses and material helped a great deal 
with my understanding of epidemiology. 
 
I would also like to acknowledge all the help and support I received from Dr. William Hodge 
and Dr. Monali Malvankar. They provided me with valuable advice and enhanced my 
understanding and knowledge on how to conduct a meta-analysis and general aspects relating 
to epidemiology. 
  
  
Dedicated to my loving family for their support through both 
the good and bad times. Special thanks to my brother, 
Balgurinder Singh, for his motivation and support he provided 
to keep me moving forward.  
 
 
 v 
 
Table of Contents 
Abstract ............................................................................................................................... ii 
Co-Authorship Statement................................................................................................... iii 
Dedication and Acknowledgments .................................................................................... iv 
Table of Contents ................................................................................................................ v 
List of Tables .................................................................................................................... xii 
List of Figures ................................................................................................................... xv 
List of Appendices ........................................................................................................... xvi 
List of Abbreviations ...................................................................................................... xvii 
Chapter 1 ............................................................................................................................. 1 
1 Overview of Thesis and Introduction ............................................................................. 1 
1.1 Outline of Thesis ..................................................................................................... 1 
1.2 Introduction to Uveitis ............................................................................................ 1 
 Anatomy ...................................................................................................... 2 
1.2.1.1 Anterior Uveitis ............................................................................ 3 
1.2.1.2 Intermediate Uveitis ..................................................................... 3 
1.2.1.3 Posterior Uveitis and Panuveitis ................................................... 3 
 Etiology ....................................................................................................... 4 
 Epidemiology .............................................................................................. 4 
 Age Range ................................................................................................... 4 
 Final Remarks ............................................................................................. 4 
1.3 Treatments Administered to Uveitis Patients ......................................................... 5 
 Corticosteroids (First Line of Action in Uveitis Therapy).......................... 6 
 Antimetabolites ........................................................................................... 6 
1.3.2.1 Azathioprine (Imuran, Azasan) .................................................... 6 
 vi 
 
1.3.2.2 Methotrexate (Rheumatrex, Trexall) ............................................ 7 
1.3.2.3 Mycophenolate Mofetil (cellcept, Myfortic) ................................ 7 
 Inhibitors of T-lymphocyte Signalling (Calcineurin Inhibitors) ................. 7 
1.3.3.1 Cyclosporine, CsA (Gengraf, Neoral, and Sandimmune) ............ 7 
1.3.3.2 Tacrolimus, FK-506 (Prograf, Advagraf, Protopic) ..................... 8 
1.3.3.3 Sirolimus (Rapamune) .................................................................. 8 
 Alkylating Agents ....................................................................................... 8 
1.3.4.1 Cyclophosphamide (Cytoxan, Endoxan, Cytoxan, Neosar, 
Procytox, and Revimmune) .......................................................... 8 
1.3.4.2 Chlorambucil (Leukeran) ............................................................. 9 
 Final Remarks on Treatments ..................................................................... 9 
1.4 Outcomes Measured for Uveitis Patients ................................................................ 9 
 Anterior/Posterior Inflammation Grade .................................................... 10 
 Visual Acuity ............................................................................................ 11 
 Improved/maintained VA or inflammation grade ..................................... 13 
 Steroid Discontinuation Rate .................................................................... 13 
 Reason for Discontinuation and Discontinuation rate .............................. 13 
 Adverse Events ......................................................................................... 14 
Chapter 2 ........................................................................................................................... 15 
2 Literature Review ......................................................................................................... 15 
2.1 Individual Observational Studies .......................................................................... 15 
2.2 Review of Narrative Reviews on Uveitis .............................................................. 16 
 A Cross-sectional Study of the Current Treatment Pattern in Non-
infectious Uveitis Among Specialists in the United States ....................... 17 
 Immunomodulatory Therapy for the Treatment of Ocular Inflammatory 
Disease: Evidence-based Medicine Recommendations for Use ............... 17 
2.2.2.1 Limitations .................................................................................. 20 
 vii 
 
 Review of Immunosuppressive Drug Therapy in Uveitis......................... 20 
 Cutting-edge Issues in Autoimmune Uveitis ............................................ 21 
 Use of Immunosuppressive Agents in Uveitis .......................................... 21 
 Update on the Principles and Novel Local and Systemic Therapies for the 
Treatment of Non-infectious Uveitis ........................................................ 23 
2.3 Prior “Guidelines” on Uveitis ............................................................................... 24 
 Limitations ................................................................................................ 25 
2.4 Previous Systematic Review on the Effectiveness of Immunosuppressants in the 
Treatment of Autoimmune Posterior Uveitis ........................................................ 25 
 Limitations ................................................................................................ 26 
2.5 Randomized Control Trials (RCTs) ...................................................................... 28 
2.6 Previous “Economic Evaluations” ........................................................................ 29 
 Informal Health Care — Expert Opinion .................................................. 29 
 Limitations ................................................................................................ 30 
2.7 Cost and Effectiveness Based on Data Collected Through Surveys..................... 30 
 Survey Given to the American Uveitis Society ........................................ 30 
 Limitations ................................................................................................ 31 
2.8 Conclusion ............................................................................................................ 32 
Chapter 3 ........................................................................................................................... 33 
3 Justification and Objectives ......................................................................................... 33 
3.1 Justification for This Study ................................................................................... 33 
3.2 Case for Why a Meta-analysis is needed .............................................................. 34 
3.3 Thesis Objectives .................................................................................................. 35 
 Objective 1 – Systematic Review ............................................................. 35 
 Objective 2 – Meta-analysis...................................................................... 35 
3.4 Patient Characteristics ........................................................................................... 35 
3.5 Primary Outcome of Interest for Meta-analysis.................................................... 36 
 viii 
 
Chapter 4 ........................................................................................................................... 37 
4 Literature Review for Methodology............................................................................. 37 
4.1 Overview of Meta-analysis ................................................................................... 37 
4.2 Mechanics of Meta-analysis ................................................................................. 37 
 What is Effect Size? .................................................................................. 37 
 Precision .................................................................................................... 38 
 True Effect Size and Summary Effect Size .............................................. 39 
 How to Measure a Summary Effect Size (Fixed vs. Random Effects 
Model) ....................................................................................................... 39 
 Heterogeneity ............................................................................................ 42 
4.2.5.1 What is heterogeneity ................................................................. 42 
4.2.5.2 How to identity and measure heterogeneity ............................... 43 
 Subgroup Analysis .................................................................................... 44 
 Conducting a Univariate Meta-regression with Multiple Covariates ....... 45 
 Final Remarks for Meta-regression or Subgroup Analysis ....................... 46 
 Power vs. Precision ................................................................................... 46 
 Publication Bias ........................................................................................ 47 
Chapter 5 ........................................................................................................................... 48 
5 Methods ........................................................................................................................ 48 
5.1 Literature Search ................................................................................................... 48 
5.2 Eligibility Criteria ................................................................................................. 50 
5.3 Article Screening .................................................................................................. 51 
5.4 Data Extraction for Descriptive Statistics ............................................................. 52 
5.5 Data Extraction for Meta-analysis ........................................................................ 54 
5.6 Quality Assessment ............................................................................................... 56 
5.7 Meta-analysis ........................................................................................................ 58 
 ix 
 
 Summary Effect Size ................................................................................ 58 
 Choice of Fixed vs. Random Effects Analysis ......................................... 59 
5.8 Sensitivity Analysis of Missing Data .................................................................... 60 
5.9 Heterogeneity ........................................................................................................ 60 
 Subgroup Analysis .................................................................................... 61 
5.9.1.1 Subgroup Analysis: Type of Immunosuppressive Treatment .... 61 
5.9.1.2 Subgroup Analysis: Type of Primary Location .......................... 61 
5.9.1.3 Subgroup Analysis: Previous Treatment .................................... 62 
5.9.1.4 Subgroup Analysis: Average Patient Age .................................. 62 
 Meta-regression......................................................................................... 63 
5.10 Publication Bias .................................................................................................... 65 
5.11 Software ................................................................................................................ 66 
Chapter 6 ........................................................................................................................... 67 
6 Results .......................................................................................................................... 67 
6.1 Study Selection ..................................................................................................... 67 
6.2 Treatment Categories ............................................................................................ 69 
 Inhibitors of T-lymphocyte signalling ...................................................... 70 
6.2.1.1 Cyclosporine A ........................................................................... 70 
6.2.1.2 Tacrolimus .................................................................................. 75 
6.2.1.3 Tacrolimus or Cyclosporine ....................................................... 78 
 Antimetabolites ......................................................................................... 81 
6.2.2.1 Mycophenolate Mofetil .............................................................. 81 
6.2.2.2 Methotrexate ............................................................................... 86 
6.2.2.3 Azathioprine ............................................................................... 90 
 Alkylating Agents ..................................................................................... 93 
6.2.3.1 Chlorambucil .............................................................................. 93 
 x 
 
 Studies with Multiple Treatments ............................................................. 95 
 Studies With No Specification Regarding Which Immunosuppressive Was 
Used .......................................................................................................... 98 
6.3 Risk of Bias within Studies ................................................................................. 100 
 Randomized Controlled Trials ................................................................ 100 
 Observational Studies ............................................................................. 100 
6.4 Meta-analysis ...................................................................................................... 102 
 Results of Individual Studies .................................................................. 102 
 Primary Analysis ..................................................................................... 104 
 Sensitivity Analysis ................................................................................ 104 
 Subgroup Analysis .................................................................................. 104 
6.4.4.1 Subgroup Analysis by Age ....................................................... 104 
6.4.4.2 Subgroup Analysis by Location ............................................... 105 
6.4.4.3 Subgroup Analysis by Treatment ............................................. 105 
6.4.4.4 Subgroup Analysis by Previous Treatment .............................. 106 
 Meta-regression....................................................................................... 114 
 Publication Bias ...................................................................................... 116 
Chapter 7 ......................................................................................................................... 117 
7 Discussion .................................................................................................................. 117 
7.1 Systematic Review .............................................................................................. 117 
7.2 Quality Assessment ............................................................................................. 119 
7.3 Meta-analysis and Subgroup Analysis ................................................................ 120 
7.4 Meta-regression................................................................................................... 123 
7.5 Publication Bias .................................................................................................. 123 
7.6 Strengths ............................................................................................................. 124 
7.7 Limitations .......................................................................................................... 125 
 xi 
 
7.8 Possibilities for future research ........................................................................... 128 
7.9 Conclusion .......................................................................................................... 128 
References ....................................................................................................................... 129 
Appendices ...................................................................................................................... 149 
Curriculum Vitae ............................................................................................................ 165 
 xii 
 
List of Tables 
Table 1: Course of Disease ....................................................................................................... 2 
Table 2: Some Observational Studies and Their Findings...................................................... 16 
Table 3: Recommendation of Quality Levels adapted from Kim and Foster (2006)89 ........... 18 
Table 4: Findings from Kim and Foster (2006)89 ................................................................... 19 
Table 5: Findings from Lustig and Cunningham (2003)92...................................................... 22 
Table 6: Cost of Treatments based on Heo et al (2012)21 ....................................................... 30 
Table 7: Main Results from Esterberg et al (2012)98 .............................................................. 31 
Table 8: Concepts, keywords, and phrases for search strategy ............................................... 49 
Table 9: Visual Acuity Conversion Chart ............................................................................... 55 
Table 10: Number of studies for each treatment category ...................................................... 69 
Table 11: Cyclosporine A Treatment, Study Characteristics.................................................. 72 
Table 12:  Cyclosporine A Treatment, Patient Characteristics ............................................... 73 
Table 13:  Cyclosporine A Treatment, Descriptive Outcomes ............................................... 74 
Table 14: Tacrolimus Treatment, Study Characteristics......................................................... 76 
Table 15: Tacrolimus Treatment, Patient Characteristics ....................................................... 77 
Table 16: Tacrolimus Treatment, Descriptive Outcomes ....................................................... 77 
Table 17: Tacrolimus or Cyclosporine A Treatment, Study Characteristics .......................... 79 
Table 18: Tacrolimus or Cyclosporine A Treatment, Patient Characteristics ........................ 80 
Table 19: Tacrolimus or Cyclosporine A Treatment, Descriptive Outcomes ........................ 80 
 xiii 
 
Table 20: Mycophenolate Mofetil Treatment, Study Characteristics ..................................... 83 
Table 21: Mycophenolate Mofetil Treatment, Patient Characteristics ................................... 84 
Table 22: Mycophenolate Mofetil Treatment, Descriptive Outcomes ................................... 85 
Table 23: Methotrexate Treatment, Study Characteristics ..................................................... 87 
Table 24: Methotrexate Treatment, Patient Characteristics .................................................... 88 
Table 25: Methotrexate Treatment, Descriptive Outcomes .................................................... 89 
Table 26: Azathioprine Treatment, Study Characteristics ...................................................... 91 
Table 27: Azathioprine Treatment, Patient Characteristics .................................................... 92 
Table 28: Azathioprine Treatment, Descriptive Outcomes .................................................... 92 
Table 29: Chlorambucil Treatment, Study Characteristics ..................................................... 93 
Table 30: Chlorambucil Treatment, Patient Characteristics ................................................... 94 
Table 31: Chlorambucil Treatment, Descriptive Outcomes ................................................... 94 
Table 32: Multiple Treatments, Patient Characteristics .......................................................... 96 
Table 33: Multiple Treatments, Patient Characteristics .......................................................... 97 
Table 34: Multiple Treatments, Descriptive Outcomes .......................................................... 97 
Table 35: Immunomodulators, Study Characteristics ............................................................. 98 
Table 36: Immunomodulators, Patient Characteristics ........................................................... 99 
Table 37: Immunomodulators, Descriptive Outcomes ........................................................... 99 
Table 38: Results of Individual Studies: pre- and post-logMAR ......................................... 103 
Table 39: Summary of Pooled Meta-analysis and Subgroup Analysis examining the change 
in logMAR for treating idiopathic patients with immunosuppressive treatments ................ 113 
 xiv 
 
Table 40: Results from fitting 8 random effect univariate meta-regression models that 
examined the effects of covariates on treatment effectiveness measure, logMAR .............. 115 
 
 xv 
 
List of Figures 
Figure 1: Anatomy of the eye and location of Uveitis .............................................................. 2 
Figure 2: The SUN classification for severity of uveitis* ...................................................... 10 
Figure 3: Primsa Diagram ....................................................................................................... 68 
Figure 4: Risk of Bias and Internal/External Validity .......................................................... 101 
Figure 5: Pooled random effects (D+L) Meta-analysis of change in logMAR for idiopathic 
uveitis patients given immunosuppressive treatments (IMM) .............................................. 107 
Figure 6: Sensitivity Analysis (Removal of 6 studies): pooled random effects (D+L) meta-
analysis of change in logMAR for idiopathic uveitis patients given immunosuppressive 
treatments (IMM) .................................................................................................................. 108 
Figure 7: Fixed effects (I+V) subgroup analysis by age examining the change in logMAR for 
idiopathic uveitis patients given immunosuppressive treatments (IMM) ............................. 109 
Figure 8: Fixed effects (I+V) subgroup analysis by location of disease examining the change 
in logMAR for idiopathic uveitis patients given immunosuppressive treatments (IMM)  ... 110 
Figure 9: Fixed effects (I+V) subgroup analysis examining the change in logMAR for 
idiopathic uveitis patients given the different immunosuppressive treatment (IMM) classes
............................................................................................................................................... 111 
Figure 10: Fixed effects (I+V) subgroup analysis by previous treatments examining the 
change in LogMAR for idiopathic uveitis patients given immunosuppressive treatments 
(IMM) ................................................................................................................................... 112 
Figure 11: Publication bias, with Duval and Tweedie (2000)111 Method: Funnel plot with 
pseudo 95% confidence limits .............................................................................................. 116 
 
 xvi 
 
 List of Appendices  
Appendix A: Meta-analysis of Observational Studies in Epidemiology (MOOSE) 
Checklist............................................................................................................................... 149 
Appendix B: Preferred Reporting Item for Systematic Reviews and Meta-analysis 
(PRISMA) guidelines .......................................................................................................... 150 
Appendix C: Search Strategies .......................................................................................... 153 
Appendix D: Study Eligibility Criteria ............................................................................. 159 
Appendix E: Data Extraction Form .................................................................................. 160 
Appendix F: Downs and Black Checklist for Study Quality .......................................... 161 
 
 xvii 
 
List of Abbreviations  
AZA- Azathioprine 
COS- Canadian Ophthalmology Society  
CSA- Cyclosporine 
CUS- Canadian Uveitis Society  
IMM- Immunosuppressives  
I-V- Fixed effects model (for forest plot) 
JIA- Juvenile idiopathic arthritis  
LogMAR- The Logarithm of the Minimum Angle of Resolution 
L+D- Random effects model (for forest plot) 
MMF- Mycophenolate Mofetil 
MTX- Methotrexate 
SD – Standard Deviation 
SMD- Standardized Mean Difference 
SUN- Standardization of Uveitis Nomenclature 
TAC or FK-506- Tacrolimus 
RCT- Randomized Controlled Trial 
WMD- Weighted Mean Difference 
VA- Visual Acuity 
 
1 
 
Chapter 1  
1 Overview of Thesis and Introduction 
1.1 Outline of Thesis 
The primary objective of this thesis is to summarize the effects of the 3 
immunosuppressive treatment groups used to treat idiopathic non-infectious uveitis 
patients. We conducted a systematic review and meta-analysis with studies that met our 
eligibility criteria. This chapter describes the terminology needed to understand what 
uveitis is, how it is treated and how the outcomes are measured for identifying whether 
treatments are effective or not. Then Chapter 2 discusses the literature for uveitis patients 
and gives a clear case as to why an evidence-based approach is required for this particular 
question, which leads into Chapter 3, justifications and objectives for the thesis. Before 
discussing the methods, Chapter 4 describes the concepts and terminology that is vital for 
describing and interpreting our meta-analysis. Chapter 5 outlines the methods used to 
reach our objectives, and Chapter 6 summarizes the results for the systematic review, 
quality assessment, meta-analysis, and publication bias analysis. Finally, Chapter 7 
interprets the results and lists the strengths and limitations of the thesis, alongside 
possibilities for future research.  
1.2 Introduction to Uveitis 
Uveitis is inflammation of the eye, which can result in patients becoming blind if it is not 
treated correctly and it can affect both eyes (bilateral) or it can affect 1 of 2 eyes 
(unilateral).1 To understand how to treat uveitis patients, it is important to understand the 
anatomy of the eye as well as the mechanisms involved in the inflammation caused by 
uveitis. An article published in 2005 presented specific terms and guidelines used to 
define the various components of uveitis, which were updated from the 1987 
International Uveitis Study Group (IUSG) that had developed criteria based mainly on 
anatomy.1, 2 These terms were provided by uveitis specialists whose purpose was to 
develop international consensus for the use of terms associated with uveitis in the 
literature. The phrase coined for the use of these terms was the Standardization of Uveitis 
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Nomenclature (SUN). Two important classifications key to understanding how to treat 
uveitis patients were developed for the progression of the disease and the anatomy of the 
eye.1, 2 A patient with uveitis may experience, acute, recurrent or chronic uveitis. Table 1 
defines each course of disease. 
Table 1: Course of Disease 
Acute Episode characterized by sudden onset and limited duration 
Recurrent Repeated episodes separated by periods of inactivity without 
treatment ≥3 months in duration 
Chronic Persistent uveitis with relapse in <3 months after discontinuing 
treatment 
 Anatomy 
The progression of uveitis can also be associated with the location of the disease within 
the eye. Thus, the 2005 SUN guidelines and the 2007 European classifications 
anatomically classified locations within the eye as posterior, anterior or intermediate.1, 2 
The anatomical location of uveitis is one of the most important clues to the pathogenesis 
and treatment that a patient should receive. 
 
Figure 1: Anatomy of the eye and location of Uveitis 
Source: From http://www.vision-and-eye-health.com/uveitis-treatment.html 
 
Anterior  
Intermediate Posterior 
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1.2.1.1 Anterior Uveitis 
Anterior uveitis involves the anterior chamber, which consists of all structures anterior to 
the iris, as indicated by the purple box in Figure 1.3 Usually, it is acute in nature and only 
1 of the 2 eyes is usually affected (unilateral). About 67% to 90% of patients with uveitis 
have anterior uveitis. These patients are easier to treat than patients with uveitis in other 
locations. The most common symptoms exhibited by patients with anterior uveitis are 
dull pain in the eye, redness of the eye, blurred vision and photophobia.  
1.2.1.2 Intermediate Uveitis 
As shown in the Figure 1, the yellow box contains intermediate uveitis, which involves 
the area where the retina meets the anterior structures of the eye, that is, the pars plana 
and ciliary body. Intermediate uveitis is the least common type of uveitis, accounting for 
only 7-15% of cases.1, 2 Both eyes are usually affected in patients with intermediate 
uveitis, and patients are more likely to have chronic inflammation.1 Furthermore, patients 
with intermediate uveitis commonly experience floaters and may experience painless 
blurred vision.  
1.2.1.3 Posterior Uveitis and Panuveitis 
Posterior uveitis involves the retina and choroid, which can be seen in Figure 1 
surrounded with an orange box. It is seen in 15-22% of uveitis patients.4 Generally, it is 
chronic, recurrent and can affect both eyes. The underlying cause is often the result of an 
abnormal immune disease.4 That is, immune cells enter the eye and become active 
because they detect tissue that they identify as foreign or a threat to the individual. This 
creates a complex immune response that causes inflammation in the eye. Treating 
patients with autoimmune or idiopathic uveitis becomes difficult because it is hard to 
detect the cause of uveitis in these patients, and thus treatment varies between 
ophthalmologists. Posterior uveitis commonly causes blurred vision, floaters, and in some 
cases, severe visual loss.5 Some patients develop scotomata, which are small regions of 
less sensitive or absent vision. 
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Inflammation affecting the entire uvea is called panuveitis. People with panuveitis may 
be more likely to experience vision loss from the condition. Symptoms for patients with 
panuveitis include floaters, blurred vision or loss of vision.4 Generally these patients are 
considered idiopathic in nature, due to their cause being unknown and effecting the entire 
eye.  
 Etiology 
In addition to the anatomy of the eye, uveitis is also differentiated by the etiology. Up to 
50% of cases have underlying causes that are usually inflammatory (eg, Sarcoidosis), 
however there are some causes that are non-inflammatory (eg, syphilis, tuberculosis, and 
toxoplasmosis).6 The other 50% of cases do not have a cause are deemed as idiopathic, 
but the general consensus is that those are autoimmune cases without a simple category.7 
The diagnosis for idiopathic uveitis is done by checking patients for the known causes of 
uveitis, if the workup comes back negative then they are considered idiopathic.8  
 Epidemiology 
Even though uveitis is a rare disease, it is still an important cause of blindness.9, 10 The 
prevalence of uveitis is estimated to be about 115-204/100,000 persons.11, 12 Uveitis is the 
cause of 30,000 new cases of legal blindness every year in the USA, and nearly 10% of 
visual loss in the Western world.10 
 Age Range 
Uveitis can affect any age group, from infants and children (juvenile idiopathic arthritis) 
to young adults (pars planitis and seronegative arthropathies) to the middle-aged 
(sarcoidosis and idiopathic) to the elderly (masquerade syndromes and idiopathic).13-15 
 Final Remarks 
The introduction of the SUN classification in 2005 has made it easier to diagnose patients 
with uveitis. Classification by progression, anatomy and/or cause of disease can facilitate 
diagnosis and treatment.1 For example, infectious uveitis, like herpes simplex viruses, 
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primarily causes acute or chronic anterior uveitis, and is easy to treat.5 However, the 
subset of idiopathic uveitis (spontaneous cause) is much harder to treat.8 
1.3 Treatments Administered to Uveitis Patients 
Treatment depends on the location of the condition, severity, rate of recurrence and 
etiology.8 For single episode anterior uveitis, the use of topical corticosteroid 
preparations usually result in successful treatment. For moderate amounts of 
inflammation involving the intermediate or posterior structures, periocular or even 
intraocular steroids can be used successfully.16 For severe inflammation of the posterior 
part of the eye, especially in bilateral cases, treatment usually involves systemic 
immunomodulation.17 These agents include oral corticosteroids, which can only be used 
in a limited role due to their side effects, which include osteoporosis and bone fractures, 
aseptic hip fractures, induced diabetes mellitus, personality changes, and metabolic 
abnormalities.  
Idiopathic uveitis is more complex to treat since its cause is unknown. Treatment for 
idiopathic uveitis can vary from steroids to immunomodulators. There is still a lot of 
debate regarding what treatment should be used for patients with idiopathic uveitis. Since 
1949, corticosteroids have been used to treat active inflammation of the eye.18 Steroids 
reduce the inflammatory infiltration. However, there are many side effects from the use 
of steroids.19 This has led to advances in the methods by which steroids are administered, 
which has helped to lower the side effects.20 For example, periocular route administration 
(ie, injection around the eye), has reduced side effects since the steroid’s use is limited to 
the inflamed area.20 The ophthalmologist must be comfortable and the injection must be 
given accurately. In general, steroids are usually administered in high doses to patients 
that have acute uveitis. However, with chronic uveitis, high doses of steroids over a long 
period of time can cause severe side effects in patients, thus immunomodulators, such as 
alkylating agents (eg, cyclophosphamide), Inhibitors of T-lymphocyte signaling (eg, 
cyclosporine), antimetabolites (eg, azathioprine) and biological modifiers (eg, TNF-
alpha) are more commonly used.16-21 For the purposes of this thesis we will not be 
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discussing biologics, but they are a new but more expensive way of dealing with uveitis 
patients.  
A brief summary of each treatment group is given below. 
 Corticosteroids (First Line of Action in Uveitis Therapy) 
Corticosteroids have been used since the 1950s. They work on multiple signaling 
mechanisms to inhibit inflammation, but have many adverse effects.19,20 Ocular side 
effects include cataract and glaucoma. The steroid dosage for vision threatening uveitis 
typically starts at 1mg/kg.22 This is the first line of treatment given to patients since it can 
quickly dampen the immune system and aid patients in recovering from acute, mild or 
moderate uveitis. However, steroids are generally only used for 1 to 3 months, after 
which the dosage is tapered. Steroids are not continued for chronic uveitis patients, as 
long term steroid use has significant side effects, both on the eye and on the rest of the 
body (if taken orally).22   
 Antimetabolites 
Patients that continue to experience symptoms while on corticosteroids, or those who 
have taken steroids over a long period of time and exhibit adverse effects, are prescribed 
antimetabolites. Antimetabolites function by inhibiting nucleic acid synthesis, thereby 
hindering the process of DNA synthesis. There are 3 types of drugs included in the 
antimetabolite drug class.  
1.3.2.1 Azathioprine (Imuran, Azasan)  
Azathioprine (AZA) functions as a purine nucleoside analog (basically mimicking the 
structures of DNA and RNA building blocks), thus it interferes with the synthesis of 
RNA and DNA.23 Azathioprine is orally absorbed and the initial dose of AZA is 
1mg/kg/day, up to a maximum dose of 2.5-4mg/kg/day.23-26 Nausea and vomiting are 
common adverse effects, especially at the beginning of treatment.24  
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1.3.2.2 Methotrexate (Rheumatrex, Trexall)  
Methotrexate (MTX) also interferes with DNA production. MTX was introduced first as 
treatment for neoplasm in 1958. It basically functions to reduce cell proliferation, causes 
death to T-cells, and changes the response of B-cells. MTX was first introduced as a 
treatment for ocular inflammation in 1965.27-37 MTX can be given orally, subcutaneously, 
intramuscularly or intravenously, and is usually well tolerated.35 The initial dose of MTX 
is 7.5-12.5 mg/week, and the maximum dosage usually given is 25 mg/week. The most 
common adverse effects include: increased liver enzymes, ulcerative stomatitis and low 
white blood cell count, which can lead to lethargy, infection, nausea, abdominal pain and 
acute pneumonitis.30-37 
1.3.2.3 Mycophenolate Mofetil (cellcept, Myfortic)  
Mycophenolate Mofetil (MMF) inhibits the production of B and T cells by causing 
deletion of nucleotides important for DNA production.38-51 MMF is taken orally and has 
been known to help adults and children. MMF is usually given twice day at dosages 
beginning at 500mg, up to a maximum of 1.5 gm. Among the most common side effects 
of this drug are high blood sugar, increased blood cholesterol levels and gastrointestinal 
tract complications. 
 Inhibitors of T-lymphocyte Signalling (Calcineurin Inhibitors) 
T-cell inhibitors, or calcineurin inhibitors, were originally developed for use in organ 
transplantation.16 They are a class of drugs that inhibit the replication and activation of 
immune cells by inhibiting calcineurin, which is important in the activation and 
maturation of immune cells. Drugs found in this class include Cyclosporine (CsA), 
Tacrolimus (Fk-506), and Sirolmus. 
1.3.3.1 Cyclosporine, CsA (Gengraf, Neoral, and Sandimmune)  
CsA is mostly used as a T-cell suppressant. CsA has an intricate process, but the end 
result is the inhibition of the proliferation and maturation of T-cells.52-58 CsA is mainly 
given orally, and the initial dose ranges from 2.5-5 mg/kg/day, up to a maximum dosage 
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of 10 mg/kg/day [10-12]. Adverse events of CsA consists of nephrotoxicity, 
neurotoxicity, hypertension and increases the risk of infections.55 
1.3.3.2 Tacrolimus, FK-506 (Prograf, Advagraf, Protopic)  
FK-506 is similar to CsA, in that it inhibits certain molecules that are needed for immune 
cell production. FK-506 is usually given orally, and the initial dose ranges from 0.15-0.30 
mg/kg/day, up to a maximum of about .30 mg/kg/day.59, 62 Side effects can be severe and 
include blurred vision, infection, cardiovascular damage, hypertension, and 
nephrotoxicity.59-64 
1.3.3.3 Sirolimus (Rapamune)  
Sirolimus is similar in its effect to the other two drugs in this class. However, the side 
effects of Sirolimus are more severe, including lung toxicity and cancer development.65, 66 
 Alkylating Agents 
Alkylating agents were mainly developed for the treatment of cancer, but were later used 
in the treatment of rheumatologic diseases.67 Alkylating agents work by damaging DNA 
through alkylation, resulting in the inhibition of DNA production and cell death. These 
are commonly used if other treatments fail.67,68 
1.3.4.1 Cyclophosphamide (Cytoxan, Endoxan, Cytoxan, Neosar, 
Procytox, and Revimmune)  
Cyclophosphamide is derived from mustard gas. It alkylates one of the bases in DNA, 
which leads to suppression of the immune system. It is orally and hepatically metabolized 
in the liver. Initially, patients are given about 1-2 mg/kg/day, up to about 3 mg/kg/day.70 
Adverse reactions include nausea and vomiting, bone marrow suppression, stomach ache, 
diarrhea, and lethargy.69-73Fertile aged patients will lose their fertility and so these drugs 
are not used in patients under 40, unless there is no alternative. 
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1.3.4.2 Chlorambucil (Leukeran)  
Chlorambucil was created in 1953 as a less toxic substitute for cyclophosphamide, which 
functions using a slightly different mechanism. Chlorambucil is orally administered at 
initial doses of 0.1mg/kg/day, to maximum of 0.2 mg/kg/day. Bone marrow suppression 
is the most commonly occurring side effect of chlorambucil.74-79 
 Final Remarks on Treatments 
In reviewing the various treatment groups, it becomes apparent that there are a number of 
treatments that one can administer to uveitis patients. However, because the treatments 
are given off-label there are no specific guidelines for the use of these treatments in 
uveitis patients.65 Originally, these treatments were given and prescribed primarily to 
patients with rheumatoid arthritis.16 Due to their immunosuppressive nature, they were 
eventually given to patients with uveitis, as the idiopathic cases were mainly 
autoimmune. Furthermore, the known side effects for immunosuppressive treatment are 
taken from studies on patients with rheumatoid arthritis instead of patients with uveitis. 
In Canada, patients with idiopathic uveitis are referred to a uveitis specialist. These 
patients tend to have similar characteristics when they present with idiopathic uveitis. 
Knowing which treatment will be most effective should also be taken into consideration 
alongside the age, severity of disease, and location of disease. Therefore, this systematic 
review will compile the literature on the various types of immunosuppressive treatments 
and create an environment in which they can be compared amongst each other when used 
to treat a patient with idiopathic non-infectious uveitis.  
1.4 Outcomes Measured for Uveitis Patients 
Once the treatment has been administered, there are a few ways to measure the efficacy 
of the idiopathic uveitis treatment. These measures include inflammation grade, Visual 
Acuity (VA), steroid discontinuation rate, uveitis relapse rate, and the adverse events that 
patients may experience with the treatment. A brief summary of each measure is given 
below. 
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 Anterior/Posterior Inflammation Grade 
Figure 2 below shows a table from the 2005 SUN paper, which allows uveitis specialists 
to numerically quantify the severity of Uveitis.1 
 
Figure 2: The SUN classification for severity of uveitis* 
*Table taken from SUN classification for Uveitis (1) 
Severity of disease is measured by a grade that can range from no inflammation (ie, 0) to 
intense inflammation (ie, 4+). It is usually measured twice, before treatment and after 
treatment, to see if the treatment resulted in any difference in the severity.1  
Before SUN was established in 2005, there were at least 4 other major systems used to 
measure inflammation grade. These systems are similar to SUN, but some of the 
differences make it difficult to compare the systems to one another.1 Thus, SUN was 
established in order to standardize the way the inflammation grade is measured, which 
allows studies to be compared with one another. However, some of the studies included 
in this thesis were conducted before SUN was introduced, which means their systems of 
measuring inflammation will have been less standardized. Also, there is no correlation or 
conversion that can be drawn between pre-SUN studies and post-SUN studies. Thus, it is 
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difficult to compare the inflammation grade data and standardized the data from studies 
using different scales, making it a less viable option to do a meta-analysis on.  
 Visual Acuity  
Visual acuity (VA) describes the sharpness of vision, which is measured by the eye's 
ability to resolve and recognize letters of varying sizes, through a VA test chart. This 
estimate is an essential indicator of ocular health and is used to measure the effectiveness 
of treatment in studies.  
In order to understand which measure of VA is best for mathematical and/or clinical 
settings, it is important to understand which VA test charts are used and how they 
compare. There are many variations of test charts used in the clinical setting when 
evaluating vision. But their variations have been adapted from mainly two chart designs, 
the Snellen chart design and the Bailey–Lovie chart design (also called logMAR 
charts).80 
The Snellen chart design has been around since 1862 and is still used to this day in a 
clinical setting.80 The basics behind the Snellen chart is that there are eleven lines of 
block letters, where the first line consists of a large letter, and subsequent rows have 
increasing numbers of letters that decrease in size. The distance that the eye perceives the 
chart is important as well, with patients being 6 meters or 20 feet away or using a mirror 
to mimic the distance in clinical settings that do not have the spatial capacity to distance 
the patients 20 feet away. Important to note is that visual acuity is indicated by the 
smallest row that can be read accurately and the standard reference that is considered 
“normal” visual acuity for healthy eyes is 20/20 or 6/6, however note that generally 
healthy individuals have vision that is greater than the reference VA.80 6/60 or 20/200 is 
considered “legally blind” and this acuity represents the largest letter on the Snellen 
chart.80 However, due to the charts lack of precision and high test-retest reliability when 
dealing with patients with low vision, it is not used in clinical trials.81 The test-retest 
reliability is defined as the score of VA tested multiple times on the same chart with the 
same patient. With Snellen chart, there can be a discrepancy of up to 1 to 2 rows, from 
one test to the next and would not be considered vision lost or gained but rather this 
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discrepancy would be solely based on chance.81 Also, the Snellen chart follows a 
geometric sequence which is not linear and makes its use in calculations very difficult.  
In 1976 Bailey–Lovie developed a new design that would negate the limitations of the 
Snellen chart, by being more precise and reducing variability (with logMAR chart the 
test-retest reliability is ±0.07 logMAR to ±0.16 logMAR compared to the Snellen chart of 
±0.29 to ±0.33 logMAR unit).81 The charts that were developed with the ideas from 
Bailey–Lovie, are classified as “logMAR charts”, since the charts provide VA on a 
logarithmic scale.82  With logMAR charts, the measure is more precise as the 
ophthalmologist can measure vision letter by letter on the chart, rather than row-by-row 
as on the Snellen chart, with each letter having a value of 0.02 logMAR.82 The logMAR 
charts use a 5 letter per line scheme measuring the acuity letter by letter, which allows for 
more accurate measure of visual acuity then the Snellen method. A Snellen score of 6/6 
(20/20), corresponds to a LogMAR of 0. Positive logMAR values indicate vision loss, 
while negative values denote normal or better visual acuity.83 So in other words the 
logMAR takes the logarithm of each value and converts the geometric scale (Snellen) to a 
linear scale (logMAR).84  
With this said, it is important to note that in earlier case series, due to the logMAR charts 
having increased testing time and the complexity of scoring, logMAR was not typically 
used for routine eye examinations, and Snellen charts were used to measure VA instead.83 
And these case series studies conclude with either “lines lost” or “lines gained” which are 
not scientifically relevant.84 However, as mentioned above due to the precision of the 
logMAR scale, it is used in clinical trials and cohort studies that are planned out to 
measure VA, because it offers a scientific equivalent for amount of “lines lost” or “lines 
gained.”84 
Taking this into account, for our thesis, it was important to choose one scale that can be 
effective at allowing for comparisons and analyses to be made on VA.85 For such a task 
the Snellen scale cannot be used to assess the acuity data accurately from study to study, 
especially in the low-vision range, due it’s a geometric nature and lack of precision, 
however logMAR can since it is linear in nature.84, 85 Also, it is more precise and reliable 
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to reach a scientific conclusion then the Snellen method.83-85 However, we must be 
confident that we can convert from one scale to the other. There have been studies that 
have indicated that one can interchangeably convert from one scale to the other, because 
of a high correlation between the scales85, though one should be cautious of the 
conversion as one method is not as reliable as the other and this could lead to 
methodological heterogeneity between studies.86  
 Improved/maintained VA or inflammation grade 
For descriptive purposes it is also important to include data from studies reporting on 
percentage of patients that maintained/improved inflammation grade or VA. For the 
definition of maintained or improved inflammation grade, it is the percentage of patients 
that remained at the same inflammation grade or improved in inflammation grade (ie. 
having less severe uveitis) after being treated. The two categories are reported together in 
studies because they demonstrate a positive effect of having been given treatment.  
 Steroid Discontinuation Rate 
One of the rationales for using immunomodulators is to spare the use of other agents, 
such as systemic steroids, which have a wide range of adverse effects on the body. Thus, 
some studies measure the effectiveness of treatment using the rate at which steroid use is 
discontinued in patients, or if the dosage of steroid is reduced, after immunomodulatory 
treatment.  
 Reason for Discontinuation and Discontinuation rate 
Reasons for immunosuppressant discontinuation and the discontinuation rate helps 
illuminate the relationship between treatment efficacy and rate at which a treatment is 
discontinued. A treatment could be effective in treating uveitis, but the adverse events 
could be problematic, for example, another aspect of the patient’s health could be worse 
after taking CsA (ie, liver dysfunction).16 
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 Adverse Events  
Adverse events are an important indicator of which treatments are effective and 
advantageous for treating patients with uveitis. Adverse events are usually provided for 
descriptive purposes. 
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Chapter 2  
2 Literature Review 
The literature review has been organized by the level of evidence. First the individual 
studies that have been done on immunosuppressive treatments given to uveitis patients 
are discussed briefly. There have also been narrative reviews and a systematic review 
carried out on this issue, but not necessarily specific to idiopathic uveitis patients. 
Nonetheless, in this literature review, the various narrative reviews and the systematic 
review are summarized, as well as some limitations are discussed as well. Then we 
discuss randomized control trials (RCTs) that are beginning to emerge and we conclude 
with literature pertaining to the cost of immunosuppressive treatments.  
2.1 Individual Observational Studies 
Most of the studies conducted on treatments for uveitis were case series. There were 
various definitions of success amongst the studies. Effectiveness, in most studies, is 
measured in terms of control of ocular inflammation, visual acuity, adverse events, and 
steroid sparing success. 
In Table 2, 4 studies are presented to showcase the efficacy of 4 different treatments and 
the variety of studies encountered. While the presented studies may be valid in their own 
right, they do not specifically look at the patient population we are investigating, rather 
studies look at the entire uveitis or a subset of the population. For example, Bietti et al 
(1976)87 look at the uveitis patients that have Bechet disease, which is a type of uveitis 
with a known cause or Doycheva et al (2007)39 specifically look at the children 
population with uveitis. Basically, the idea presented across with Table 2 is that studies 
are diverse with their choice of patient population, however, there are studies that look at 
a specific patient populations. Thus, organizing and systematically retrieving and 
reviewing the literature would help paint a better picture of efficacy specific to idiopathic 
uveitis patients. In addition, a meta-analysis can be conducted to obtain a standardized 
efficacy (pooled analysis), measured in units of effectiveness that can be compared across 
studies and used in a cost-effectiveness analysis as well. 
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Table 2: Some Observational Studies and Their Findings 
Treatment  Author Study and Sample Size Inflammation Grade change within 1 year 
Methotrexate  Davatchi et 
al, 200329 
Prospective cohort Study, 
comparative 
n=23 Behçet patients associated 
chronic uveitis; historic series: 297 
Behçet associated uveitis 
Decrease in Inflammation Grade, used 
with low dosage of steroids 
Azathioprine  Bietti et al, 
197687 
Case series 
n=23 Behçet patients associated 
posterior uveitis; women 21.7%. 
  -- 
Cyclosporine 
 
BenEzra D. 
et al, 198853 
Randomized Control Trial (RCT) 
n=40 Behçet patients 
 
Did RCT study comparing cyclosporine to 
Chlorambucil/steroid: Found cyclosporine 
to be more effective in 3 year follow-up, 
but greater side effects 
Mycophenolate 
Mofetil 
Doycheva et 
al, 200739 
Case series 
n= 17 patients with chronic uveitis in 
children (32 eyes); mean age 8; 
women 41.2%. 
Improvement in the overall inflammation 
grade, but limited due to small sample 
size.  
2.2 Review of Narrative Reviews on Uveitis 
Studies have been conducted on the majority of idiopathic uveitis treatments. These were 
mainly in the form of patient records, case series, and some retrospective and prospective 
cohort studies. This indicates that the quality of the literature is low to moderate in 
regards to treating patients with idiopathic uveitis. Many narrative reviews have also been 
conducted in this subject area. These reviews tried to establish the use of 
immunosuppressive treatment using the literature, however, since subjectivity and a lack 
of transparency are inherent in the narrative review approach, these reviews were not 
systematic, and thus have significant disadvantages. Detailed explanations of the findings 
for each review are examined below, to present a better picture for the justification of a 
systematic review and meta-analysis.   
The format of these reviews are generally the same; an introduction of the topic is given 
and a description of each treatment is provided, using studies that they deemed 
appropriate for each treatment group. Most of the reviews conclude that more needs to be 
done to understand which treatment is best for treating patients with idiopathic uveitis. 
Also worth noting is that some reviews generalize the disease as ocular inflammation, 
instead of the specific disease types, which limits their usefulness in drawing conclusions 
for any one particular disease, such as idiopathic uveitis. 
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 A Cross-sectional Study of the Current Treatment Pattern in 
Non-infectious Uveitis Among Specialists in the United States 
Nguyen et al (2011)88 looked at the uveitis treatment patterns of 60 ophthalmologists, 
comparing their behaviours to the requirements suggested by guidelines that were 
developed by an expert panel in 2000.16 The study looked at the actual practice patterns 
of physicians treating uveitis, with a particular focus on steroid usage in patients. The 
expert panel established that steroids were the only agents approved for the treatment of 
uveitis by the Food and Drug Administration, and steroids were the most frequently 
prescribed treatment in the study population. The panel recommended that patients be 
treated and maintained with less than 10 mg/day of prednisone, which would allow for 
lower severity of the disease and, more importantly, would lower the frequency of side 
effects. However, this study found that steroid doses greater than 30mg were used in 
about 60% of patients for more than 1.5 years, and only 12% of patients were treated with 
immunomodulators. Furthermore, 3 out of 4 physicians were not aware of the treatment 
guidelines for uveitis. 
The study by Nguyen et al (2011)88 concluded that there is need for education about the 
guidelines for uveitis treatment in the medical community. Even though the guidelines 
(ie, narrative review) are not based on a systematic approach, but rather an expert panel, 
there is a need for greater awareness on the subject so more patients can access the 
recommended type of treatment. Guidelines based on evidence would be more helpful for 
policy makers and for every day practice by physicians. 
 Immunomodulatory Therapy for the Treatment of Ocular 
Inflammatory Disease: Evidence-based Medicine 
Recommendations for Use 
The goal of this study was to provide comprehensive guidelines for the use of 
immunosuppressive treatment for specific ocular inflammatory diseases. In order to 
accomplish this, Kim and Foster (2006)89 summarized the current evidence in the 
literature.  
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Recommendations for the use of each treatment group depended on the strength of the 
recommendations (either supporting or refuting a specific therapy) and on the quality of 
the evidence (type of scientific evidence or trial).89 Table 3, which explains the 
recommendation classifications, was taken from the study. 
Table 3: Recommendation of Quality Levels adapted from Kim and Foster (2006)89 
 
Table 4, on the following page, summarizes what Kim and Foster (2006)89 found in the 
literature for each treatment group. 
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Table 4: Findings from Kim and Foster (2006)89  
Treatment Initial 
Dose 
# of 
studies 
in this 
review 
Adverse 
events 
Improved 
visual 
acuity 
Decreased 
inflammation 
Steroid-
sparing 
response 
Recommendation 
Methotrexate 7.5mg 
once 
per 
week 
7 10-25% – 
fatigue, 
nausea, 
stomach 
ache, and 
anorexia 
90%* 76%* 56%* B2 – Is useful in 
treating patients that 
may be intolerant to 
steroids  
Azathioprine 1 to 
3mg/ 
kg/d 
7 Discontinuati
on due to 
gastrointestin
al side effects 
– 15% to 30% 
-- -- -- B1 – Is appropriate to 
use with some uveitis 
conditions and can be 
used with low-dose of 
steroids.   
Mycophenolate 
Mofetil 
1g 
twice 
daily  
5 Gastrointesti
nal side 
effects – 31% 
-- 65%* 54%* B2 – MMF could be 
used if patients have 
failed combination 
treatment 
CsA 2 to 
5mg/ 
kg/d 
27 Renal toxicity -- -- -- B1 – Low-dose CsA 
can be considered 
first line defense with 
or without steroids.  
Cyclophosphamide 1 to 
3mg/ 
kg/d 
10 Infections -- 68%* 55% C2 
*values obtained from 1 study  
Kim and Foster (2006)89 used the studies from their literature review to formulate their 
recommendations. The most studied treatment in their review was CsA, which 27 studies 
examined. From their review, it is clear that both Azathioprine and CsA are considered 
effective in treating patients with ocular inflammatory disease. In some cases, they also 
indicate the percentage of patients that experienced controlled inflammation or better 
visual acuity as a result of the treatment. Another key factor the review examined is the 
percentage of patients that were able to decrease their use of steroids as a result of the 
treatment.  
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2.2.2.1 Limitations 
Though the study by Kim and Foster (2006)89 reviewed the treatments for ocular 
inflammatory disease in general, it did not specify which treatment group could be more 
helpful for specific disease types (eg, idiopathic uveitis). Furthermore, they did not 
include any methods or explanation for the criteria or suitability of the studies chosen in 
each treatment group, which could create a bias towards any number of variables. A 
systematic approach would help mediate these biases. 
This review also had a broad range for disease type and did not specify which disease 
each study looked at. The results for the different disease types were combined, and 
conclusions were drawn for the overall effectiveness of each treatment for ocular 
inflammatory disease in general. This could lead to doubt in the results, and the findings 
could be inaccurate for patients with idiopathic uveitis. Consequently, because they 
combined patient characteristics, this review cannot be used to directly draw conclusions 
about the efficacy of the treatments for any specific disease. 
 Review of Immunosuppressive Drug Therapy in Uveitis 
Dunn’s review examined the need for immunosuppressive treatment for uveitis patients, 
noting that the results for efficacy and safety of such treatments are often limited by the 
small sample size, weak study quality, absence of control participants, and changes in 
natural course of uveitis.90 
In this review, a literature search was conducted to examine studies published from 2001. 
The summary of each treatment is similar to the review by Kim and Foster (2006)89. 
However, Dunn (2004)90 only used 2 to 3 studies for each treatment group to evaluate the 
effectiveness of each treatment. This could lead to bias, as the studies chosen could be 
positive in nature and the patient population may not be homogenous. Also, as with the 
previous review, no concrete evidence was shown regarding which treatment was better 
for treating patients with uveitis or which treatment was best able to reduce inflammation. 
This may be explained by the lack of homogeneity in the studies in respect to the 
treatment group, patient population, or disease characteristics. Dunn noted that it is 
difficult to know the treatment variables, because the studies were limited by the 
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difficulty in enrolling large numbers of patients in clinical uveitis trials, and the absence 
of a “gold standard” treatment with which to compare the other treatments. These 
limitations can hinder the ability to determine which treatment is best for specific disease 
types (eg, idiopathic uveitis). Dunn’s review stated that standardized diagnostic criteria 
for various types of uveitis, as exists for rheumatologic diseases, would help in the 
development of clinical trials for drug treatment.90 The study also tried to provide 
methodology that could help in deciding which treatment is most effective. However, 
since there is quite a bit of literature that is reviewable, one could simply conduct a 
systematic review/meta-analysis to add knowledge to this field. 
 Cutting-edge Issues in Autoimmune Uveitis 
Levy et al (2011)91, like the others, emphasized the need to investigate the different 
treatments and analyze their effectiveness, as well as their side effects, to better 
understand how to treat patients with uveitis. The review also suggested that newer ways 
to determine the effectiveness of treatments are needed in order to make the best 
judgement about which treatments work the best for these patients. Once again, this 
review was very general regarding patient characteristics, and the studies they used to 
summarize the treatments include the entire patient population with ocular disease.91 
 Use of Immunosuppressive Agents in Uveitis 
Lustig and Cunningham (2003)92 examined the studies from the 5 years preceding the 
study's publication date. This review looked at a few studies for each different uveitis 
treatment (on average, 3-4 studies/treatment), and discussed similar studies to the 
previously mentioned reviews. As with the other reviews, this could result in bias when 
summarizing the findings to specific patient characteristics.92  
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Table 5 below contains a summary of each treatment described by this review. 
Table 5: Findings from Lustig and Cunningham (2003)92 
Treatment Initial 
Dose 
# of 
studies 
in this 
review 
Adverse events Improved 
visual acuity 
Decreased 
inflammation 
Steroid-
sparing 
response 
Cost/ 
year 
US$? 
Methotrexate 7.5 mg 
once per 
week 
3 Serious side 
effects in 8.1% of 
patients 
90%* 76%* 56%* 763 
Azathioprine 1 to 
3mg/kg/
d 
3 25%- leukopenia, 
abnormal LFTs, 
malaise and 
dizziness 
-- -- 47% 763 
Mycophenolate 
Mofetil 
1 g twice 
daily  
5 Gastrointestinal 
side effects- 31% 
94% 65%* 54%* 8748 
CsA 2 to  3 
mg/kg/d 
4 Study 1: Serum 
creatinine, 53% 
Study 3: 17%, 
included renal 
toxicity 
Study 1: 82%* 
After 6 months 
Study 2: 92% 
Study 3: 69% 
Study 2: 76% 
Study 3: 50% 
-- 3252 
Tacrolimus 0.15 to 
0.3 
mg/kg/d 
2 -- 69% 69% -- 13,164 
Cyclophos-
phamide 
1 to 3 
mg/kg/d 
10 Opportunistic 
infections 
-- -- -- 3600 
While this review examined similar studies to those presented above, the key difference 
is that they also examined the costs associated with the different treatments. The costs 
noted in table 5 are based on approximately 1 year of therapy for an individual of an 
average weight of 70kg, using the lowest price from the website, www.cvs.com, or the 
Drug Topics Redbook 2003.92 From the table, it can be seen that methotrexate and 
azathioprine were the cheapest, while tacrolimus was the most expensive, with the lowest 
reported efficacy at 69% of patients experiencing improved visual acuity and decreased 
inflammation. CsA was the most effective in treating visual acuity, ranging from 82% to 
92% improvement.  
23 
 
Overall, Lustig and Cunningham (2003)92 concluded that the choice of 
immunosuppressive agents is complex and dependent upon the cause and severity of 
uveitis, and the patient's prior response to immunosuppressive treatments.  
 Update on the Principles and Novel Local and Systemic 
Therapies for the Treatment of Non-infectious Uveitis 
Although, similar to the other reviews, this review went further in trying to create gold 
standards and determine treatment regime for patients who present with non-infectious 
uveitis.93 Gallego-Pinazo et al (2013)93 summarized that patients who come in with 
uveitis that have relapsed should start treatment as follows: 
1. Oral corticosteroids at low doses: Prednisone, 5-10 mg/day.  
Prevention of cortisone side effects: Vitamin D + Calcium and Bisphosphonates. 
Cyclosporine A, 3-5 mg/kg/day in patients under 40 years of age.  Methotrexate would be 
a good alternative to CsA.  
2. Azathioprine or Mycophenolate, which are the third therapeutic stage if inflammatory 
episodes continue. Tacrolimus is an alternative to these, remembering not to combine it 
with Cyclosporine.  
3. In the event of relapses despite prior treatments, Adalimumab is the treatment of 
choice, although there are other options (infliximab, tocilizumab, rituximab).  
4. Finally, although it is preferable to avoid its use, is the combination of alkylating 
agents such as Chlorambucil or Cyclophosphamide.  
The study further explained that after the use of corticosteroids, patients should be given 
CsA, and if that is not effective, azathioprine or mycophenolate should be prescribed.93 
The fact that there are so many narrative reviews on the treatments for uveitis indicates 
that there is a need for a better understanding regarding the appropriate treatment for 
patients. This is underscored by the number of reviews that try to describe which 
treatment is the most effective. Although this type of review can be beneficial, without a 
definitive consensus on which treatment is best, it is hard to extrapolate anything concrete 
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from the reviews. However, it is still interesting to see which treatments experts would 
recommend and in which order. They also indicate at which stages different treatments 
should be given, which is important for policy building, however, a more systematic 
approach is needed to extract the data from the literature and formulate quantifiable 
results.93 
2.3 Prior “Guidelines” on Uveitis 
As mentioned previously, the more chronic the uveitis, the more likely it is to be 
associated with poor visual prognosis.93 However, no specific guidelines for uveitis and 
its management have been consensually proposed. While the term guideline has been 
used loosely and often without any justification, epidemiologically speaking, these 
guidelines are narrative reviews. For the purpose of the literature review, the studies that 
have had influence and are referenced the most by other studies as guidelines in the 
ophthalmology world, are included within this section. 
From the literature search, one specific proposed guideline that tried to encapsulate the 
data, was offered by Abad et al (2009)94 They attempted to describe and recommend the 
management of uveitis using the experience of ophthalmologists. Their definition of the 
“management of uveitis” consisted of the diagnostic procedure and types of anti-
inflammatory treatments. Their treatment recommendation included the importance of 
identifying any underlying systemic diseases (ie, cause of uveitis). For each treatment 
group they examined the literature for the mechanism of action, pharmacokinetics, non-
ophthalmic use, clinical experience for inflammatory eye disease, dosage and 
administration, and side effects and monitoring.94 However, Abad et al (2009)94 
concluded that a higher level of evidence is essential in order for there to be uniformity in 
clinical practice.  
In 2000, Jabs et al16 also provided recommendations for the use of immunosuppressive 
drugs in the treatment of patients with ocular inflammatory disorders. They had a 12-
person panel of physicians with expertise in ophthalmologic, pediatric, and 
rheumatologic disease, in research, and in the use of immunosuppressive drugs in patient 
care.16 This study included the results not only from uveitis studies, but also from all 
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patients with ocular inflammatory disorders. The panel looked at all the studies from 
1999 to 2000 that they could find through a literature review. Recommendations were 
evaluated according to the strength and quality of available evidence. Jabs et al (2000)16 
concluded that the presence of corticosteroid side effects supports the rationale for using 
immunosuppressive drugs in the management of these patients.  
Because of the potential for side effects, Jabs et al (2000)16 indicated that treatment must 
be tailored and regularly monitored. The careful use of immunosuppressive drugs for the 
treatment of ocular inflammatory disorders can benefit patients by providing either better 
control of the ocular inflammation or a decrease in the corticosteroid side effects. The 
study specifically recommended that the immunosuppressive be commenced if a dose 
greater than 10mg of prednisone was required for control of chronic inflammation. 
 Limitations 
The two studies summarized above (Abad et al94 and Jabs et al16) both presented logical 
arguments in their conclusions; however, a more systematic approach is needed to 
encapsulate the evidence. Their conclusions were not methodologically systematic, and 
their guidelines even state that the recommendations do not constitute treatment 
guidelines, but aim to improve the uniformity of clinical practice for the management of 
uveitis until higher levels of evidence are obtained. Thus, one cannot definitively 
conclude how to treat patients from the findings presented in these guidelines. 
2.4 Previous Systematic Review on the Effectiveness of 
Immunosuppressants in the Treatment of Autoimmune 
Posterior Uveitis 
In 2011, Pato et al95 used a more systematic approach to review the literature from 1961 
until 2007, using Medline (from 1961) and EMBASE (from 1980).  The purpose of this 
review was to try to fill the gap in the literature and provide recommendations for the use 
of immunosuppressant treatment, since no clear recommendation for the management of 
uveitis patients had been done.   
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There were a total of 4235 studies in their initial search. After applying the 
inclusion/exclusion criteria, which consisted of study type (which allowed any type of 
study), disease (which was autoimmune non-infectious uveitis), treatment, and outcome 
measures, they had a total of 265 articles. From the 265 articles, 90 studies pertained to 
immunosuppressive treatments. The majority of the studies were prospective studies and 
case series, with minimal RCTs. The authors summarized the findings of each study in a 
table, which can be found in their supplementary notes. However, they only summarized 
the most frequent etiology, the average dosage, and what outcome variables were 
frequently measured for each treatment studied. As explained below, this does not 
provide information as to which treatment is more effective in treating patients with the 
specific type of uveitis we are concerned about in our study.  
Pato et al (2011)95 tried to formulate a more specific set of guidelines using the 
information they found, however, the conclusion of the study was that, overall, 
immunosuppressants are effective at treating patients with uveitis. Due to the limitations 
described in 2.4.1, they found no superiority for any individual treatment.   
 Limitations 
When interpreting the summarized data in Pato et al (2011)95, one must take into account 
the limitations of this systematic review. The first limitation is that they only searched 2 
databases, which makes it possible that some articles were omitted. This would have 
restricted their findings if they had conducted a meta-analysis, but the main limitation of 
their study is that they were not able to conduct a meta-analysis. Consequently, since they 
did not extract data, but just noted what each study measured for their outcome variable, 
Pato et al (2011)95 could not draw any definitive conclusions; they could only summarize 
some of the findings. Furthermore, they were unable to analyze the data because there 
was no homogeneity in the studies. The authors mentioned that they were unable to 
recommend a drug of choice for each type of uveitis, because the studies included were 
of low quality and the outcome measures that were used to describe the results were 
highly heterogeneous. Visual acuity (VA) was used in most of the studies, but there was 
no uniformity in terms of the scale used to measure it. This could have been converted to 
a standard scale, but no attempt to do so was made. The inflammation grade and number 
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of relapses were other variables frequently used to assess effectiveness. In general, there 
was great diversity in terms of diseases involved and the outcome variables used.  
Pato et al (2011)95 recommended that the measured outcome variable should be 
standardized, which would allow for an objective evaluation of the efficacy of drugs, and 
in turn, would provide more meaningful comparisons between drugs. However, doing 
something of this nature would require a major change in how ophthalmologists conduct 
their studies, and would require them to unify and publish their case series and chart 
reviews, with similar measures of outcome. Furthermore, in the case of VA, the 
measurements could be converted and standardized in the logMAR scale. So, it would 
have been possible to compare the different studies if the authors of the systematic review 
had decided to do the conversion. However, the same cannot be said for inflammation 
grade, as there is no standard conversion between the different scales.  
The quality of the various studies was generally low to moderate. This does not indicate 
whether drugs are effective or not, it just means that the evidence presented in the 
different studies was inadequate due to poor study design of the original articles. Even 
though the authors prioritized RCTs, the number of RCTs in this field is minimal, 
because the number of patients with uveitis who need treatment is small, and diagnoses 
associated with uveitis are varied. 
Other limitations of this key study include heterogeneity in the outcome variables as well 
as heterogeneity in the type of uveitis. Although many of the studies measure VA, there 
is wide variability regarding other outcome variables. The authors also indicated that 
there was no uniformity in relation to the procedures or scales used to measure the 
outcome variables. For example, to measure VA, some authors used the Snellen chart, 
others the logMAR scale, and others described “improvement” without a quantity. This 
heterogeneity in the outcome of measure limits the findings and makes it difficult to 
assess which treatment is best for patients. However, the study’s suggestion to alleviate 
this limitation is to create a more standardized method to measure outcome variables, 
allowing studies of different treatments to be compared.  
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The limitations of this study hampers what could been a pioneer in the literature on 
uveitis. However, these limitations could be overcome by creating inclusion/exclusion 
criteria that limits the heterogeneity found in the literature. One could potentially do this 
by limiting the type of uveitis and creating criteria that allows a more homogenous 
population to be examined from study to study. As for the outcome variables, there may 
be ways to analyze the data that are heterogeneous in nature, for example, by converting 
the different scales for VA to a standardized logMAR scale.  
All in all, the end result of Pato et al (2011)95 is a study that simply summarizes the 
literature. This systematic review was used to establish a good reference of studies within 
the subject area, but the heterogeneity within the patient population makes it harder to 
reach a conclusion. However, it is commendable that an attempt was made to 
systematically collect studies in the field of ocular inflammation.  
2.5 Randomized Control Trials (RCTs) 
Recently there have been RCTs that have been proposed to evaluate the effectiveness of 
various treatment methods for uveitis patients. These treatment methods include the 
immunosuppressive treatments described in this study but are not the focus of most 
RCTs. The RCTs are more focused on biologics, and as discussed in section 1.3, they are 
a new but more expensive method for treating patients. However, since they are a newer 
way of treating patients, there is more focus on the use of biologics and their 
effectiveness on uveitis patients.  
Using the online service Clinicaltrials.gov96, there have been no RCTs done specifically 
on idiopathic uveitis patients, however there have been studies done solely on uveitis 
patients. The Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group 
(2015)97 looked at uveitis patients being treated with immunosuppressive treatment 
alongside steroids, these patients were compared to a new therapy. There were a total of 
255 patients, and the results indicated that this novel therapy helped improve vision more 
than the immunosuppressive treatments. However, it should be noted that this study 
looked at any immunosuppressive treatment, and as noted in the trial, the 
immunosuppressive treatment was given as decided by the individual ophthalmologist. 
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This study indicates that there is still a gap in terms of which immunosuppressive 
treatment one should receive. This further boosts the idea that we should have some 
reference or resource that one can use to help build a more appropriate RCT, with 
specific immunosuppressive treatment.  
According to Clincialtrials.gov96, there are roughly 5 new RCTs recruiting patients for 
uveitis, with some specially examining the immunosuppressive treatments that we are 
examining in this thesis. The earliest completion date for one of the RCTs is 2018, so 
with the results and conclusions of this study, it could help the RCTs have a better picture 
of the treatments, with a more evidence-based approach to existing literature. However, it 
is important to note that none of the RCTs look at specifically idiopathic uveitis patients 
but rather on the uveitis population as a whole, this is something that sets this study apart 
even from the RCTs.  
2.6 Previous “Economic Evaluations”  
There have been no specific cost-effectiveness analyses conducted regarding treatments 
for uveitis. Though, as discussed earlier, there was one study that included the costs of 
treatment, it was not the focus of the study. There is only one other economic evaluation 
study that examined the costs of the treatments for uveitis, which is summarized below. 
Aside from these 2 studies, no other economic evaluations related to the treatments for 
uveitis have been done. 
 Informal Health Care — Expert Opinion 
Heo et al (2012)21 examined the costs of treatment, however, they did not state where the 
cost data was taken from or how it was calculated. They estimated the annual medical 
spending on a uveitis patient with varying treatments. Table 6 below illustrates the data 
that was captured from this review: 
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Table 6: Cost of Treatments based on Heo et al (2012)21 
Treatment Cost (per year) 
Methotrexate  $68 
Azathioprine  $92-132 
Cyclosporine $1948-3400 
Mycophenolate Mofetil $3600 
Adalimumab $15,000 
*costs depend on the frequency of use and dosage (not shown in the review) 
This study demonstrated that biologics have a significantly higher cost compared to 
standard therapy, which creates a barrier for the use of biologics in treating uveitis.  
However, this review did not conduct a cost-effectiveness analysis. Although the authors 
mentioned that cost-effectiveness is low for biologics, they did not provide any measure, 
such as a relative/standardized effectiveness unit (QALY). They also failed to mention 
where they retrieved the data from, which could potentially lead to bias in the cost data. 
 Limitations 
Overall, this review was not very elaborative on how one treatment is comparable to 
another in terms of cost-effectiveness. Though the cost data is provided, it is still very 
questionable as to where the data was obtained. However, the study does look at the costs 
of treatment per year, and it attempts to investigate which treatment should be more 
readily used based on cost. 
2.7 Cost and Effectiveness Based on Data Collected Through 
Surveys  
 Survey Given to the American Uveitis Society 
In this study, Esterberg et al (2012)98 conducted a survey to determine uveitis specialists’ 
practice patterns, preferences, and perceptions of therapies other than corticosteroids for 
initial use in chronic non-infectious uveitis. They distributed the survey to 205 members 
of the American Uveitis Society, of which 45 responded and among which 3% were 
Canadian uveitis specialists. The survey asked about the effectiveness of treatments using 
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an effectiveness rating (0 to 4), which was defined as the ability to control ocular 
inflammation and successfully taper corticosteroids to a maintainable dose. The survey 
also asked which factors limited the specialists’ use of a specific treatment; one such 
factor was cost. 
Table 7: Main Results from Esterberg et al (2012)98 
Treatment Favourable for first line 
of treatment for Anterior 
Uveitis 
Mean Anterior Effectiveness 
Rating (p<0.001)* 
Too expensive- Reason for not 
pre-scribing a specific 
immunomodulatory treatment+ 
Methotrexate  0.6 3 Reference group, least costly 
Azathioprine  0.07 2 0% 
Cyclosporine 0.05 2 13% 
Mycophenolate 
Mofetil 
0.13 3 40% 
Adalimumab 0.06 4 56% 
*Effectiveness Rating: Was determined in the survey by each individual Uveitis Specialist (1=not effective, 
2=somewhat effective, 3= mostly effective, 4= very effective). 
+Cost was another subjective measure, which was asked in the survey to distinguish reasons why a specific 
treatment was favoured over another.  
The reason this study was included in this literature review was to look at the data 
provided by uveitis specialists and examine how subjective the treatment given to a 
patient is. In this study, the authors looked at the treatments with respect to the specific 
anatomy of the disease, with results for anterior uveitis shown above in Table 7. Based on 
this data, uveitis specialists considered methotrexate the primary treatment for uveitis 
among the immunomodulators (Column 2: methotrexate is considered favourable for first 
line of treatment among 60% of respondents), even though its effectiveness is not the best 
(Column 3). A large reason for this can be attributed to the cost of the treatment, as 
methotrexate is the least costly of the more effective treatments. This demonstrates that 
cost is a key factor in the choice of treatment by uveitis specialists. However, this choice 
is very subjective and should be examined in a more systematic way to create a concrete 
basis for choosing one treatment over another. 
 Limitations 
This study examined the patterns of which treatments uveitis specialists would choose to 
treat patients with uveitis. Though the respondents indicated they would use 
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immunosuppressive treatments 100% of the time once the 10mg/day corticosteroids 
treatment was exceeded, the primary cause of concern is the study’s small sample size 
(only 45 respondents). This concern is further highlighted when these survey results are 
compared with the results from a survey conducted on the ophthalmology population in 
the USA, which found that steroid-sparing immunosuppressive treatments were rarely 
used, and an average prednisone maintenance dose of 34mg/day was reported.98 Thus, 
one must ask if more concrete evidence-based guidelines are necessary to maintain 
uniformity in uveitis care, in order to ensure that patients with similar characteristics are 
treated similarly from tertiary care to population based primary care. 
2.8 Conclusion 
The primary conclusion is that treatment choice is dependent on the uveitis specialist, and 
can vary depending on their opinion. However, with the help of a systematic review, a 
more concrete basis for decision-making can be used to create guidelines that all uveitis 
specialists can follow to make the treatment of uveitis more uniform. Furthermore, this 
would enable better judgement when considering the costs and effectiveness of different 
treatments. This leads into Chapter 3, the justifications and objectives of our study.  
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Chapter 3  
3 Justification and Objectives 
3.1 Justification for This Study  
Having summarized the entirety of the relevant literature in Chapter 2, the rationale for 
this thesis becomes apparent. The lack of comparability within and between studies 
requires specific steps to allow for the accurate assessment of the effectiveness of uveitis 
treatments.  
As mentioned above, the lack of existing RCTs in the subject area, due to sample size 
constraints and heterogeneity in etiology and measure of outcome, makes the case 
stronger for conducting a systematic review and meta-analysis. The required information 
can be gathered from existing literature and used to determine which treatment is best for 
treating patients with uveitis. However, there have been new developments in the field, 
and new RCTs are underway.  
All treatments being studied have been shown to be effective in treating patients with 
severe idiopathic posterior uveitis. However, the literature mainly consists of chart 
reviews or case series with very limited sample sizes, and a mixed group of individuals in 
each study (ie, mixture of patients with different severity of disease, cause of disease, and 
difference in location). 
Moreover, no one standard definition of success is used in the literature; effectiveness is 
measured in terms of visual acuity in some studies, inflammation grade in others, and 
corticosteroid-sparing rate in others. This leads to comparability issues, which makes it 
hard to compare separate studies and their various treatments. It also makes it unclear 
which treatment is more effective at treating patients with similar disease attributes. 
Creating a more specific set of inclusion/exclusion questions will make it easier to 
compare different studies that contain more homogenous patient populations.   
The Canadian Uveitis Society (CUS) is the key stakeholder in this study. The leaders of 
the Canadian Uveitis Society are also members of the Canada Ophthalmology Society 
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(COS), and they can put guidelines in place that shift the way all ophthalmologists treat 
patients with this disease. The establishment of these guidelines is important for uveitis 
treatment in Canada, as the treatment given currently depends on the ophthalmologist. 
Having clear guidelines in place would result in the best possible outcome for patients 
with idiopathic uveitis. 
3.2 Case for Why a Meta-analysis is needed  
As indicated in Chapter 2, there have been many reviews on this subject area, dating back 
as far as 1985. There are so many review articles with exactly the same studies, and most 
of them come to similar conclusions, emphasizing the importance of forming evidence-
based guidelines that accurately assess which treatment is ideal for treating the desired 
patients.  
From the literature review in Chapter 2, it is clear that observational studies individually 
are not powerful enough, in part because they do not include a large enough sample of 
patients and in part because of the heterogeneity in the patient and outcome 
characteristics. In addition, the reviews and guidelines offered in the observational 
studies are not able to draw conclusions, as the literature does not have a standardized 
way to measure effectiveness of treatments. This gap in the literature prompted the 
systematic review that attempted to encompass all the available data about treatments for 
uveitis patients, specifically those with idiopathic posterior uveitis. However, due to the 
heterogeneity in the study outcomes and patient characteristics, a conclusion regarding 
the best treatment could not be determined. This begs the question, if a more specific 
group of patients with a main outcome of measure are studied, could we form a more 
concrete conclusion that might allow us to create guidelines and policy? This thesis was 
undertaken to answer this question, using a systematic review and meta-analysis. Other 
means to find the best treatment, such as RCTs, were not an option at this time, since it is 
not possible to gather the required patient sample size with similar patient characteristics 
and administer an array of treatments in a short amount of time.   
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3.3 Thesis Objectives   
 Objective 1 – Systematic Review 
To systematically review the literature to summarize the effectiveness and adverse events 
of the different treatments used for patients with non-infectious idiopathic uveitis. For 
descriptive purposes, the outcomes that summarize the effectiveness of the treatment 
groups is outlined in section 1.4.  
 Objective 2 – Meta-analysis  
a) To systematically identify, review, and quantitatively synthesize the evidence 
available pertaining to the pre- and post-change in VA after different 
immunosuppressive treatments are administered. 
b) To explore and categorize other factors that may contribute to differences seen in VA 
after treatment is administered to patients, including location of disease, age, previous 
treatment given, and primary immunosuppressive treatment given. 
c) To systematically identify, review, and quantitatively synthesize the evidence 
available pertaining to the pre- and post-change in inflammation grade after different 
immunosuppressive treatments are administered. This can be done if there are enough 
studies that have the same standardized scale for inflammation grade.   
3.4 Patient Characteristics 
An important component to this study is the ability to specify and focus on the patient 
population that is most in need of a specific immunosuppressive treatment. This patient 
population consists of: 
1) Patients of any age. 
2) Patients that have either posterior, intermediate or panuveitis (anterior uveitis 
responds to simple steroid treatment, since it is mainly acute uveitis, and thus 
studies looking solely at anterior uveitis patients will be excluded). 
36 
 
3) Patients that have chronic non-infectious idiopathic uveitis.  
4) Patients that were given oral immunosuppressive treatment by an 
ophthalmologist.  
The studies included will also have a percentage of patients with other disease types, or 
where the location of the disease could include anterior uveitis patients, however, this is 
only if the majority of the patients in the study were patients with intermediate or 
posterior non-infectious idiopathic uveitis. This will ensure that the patient population is 
similar, so the various studies will be more comparable to each other. 
3.5 Primary Outcome of Interest for Meta-analysis 
For the completion of Objective 2a and b, as outlined in section 3.3.2, efficacy of 
treatments will be measured by visual acuity (VA), measured in logMAR.82-84 The unit of 
measure for effectiveness is the difference between pre-logMAR and post-logMAR once 
treatment is given and the weighted mean difference of logMAR will be the effect size. 
This will be used to pool the data from the various studies and allow for comparability 
among the treatment groups, using subgroup analysis.82-84 As discussed in detail in 
section 1.4.2, the reason this measure is used is because the different scales used in other 
studies can be easily converted to logMAR, so comparability exists and logMAR scale 
gives a more precise and accurate assessment of change in vision.80 For a more detailed 
discussion of logMAR and VA, see section 1.4.2.  
Secondary Outcome: Inflammation grade will also be pooled from the various studies if 
there is enough data available. This secondary outcome will provide a means to measure 
the change in pre- and post-inflammation grade (based on a 0 to 4 scale), indicating 
whether an increase or decrease in inflammation occurred after treatment. The 
inflammation grade measures severity of disease. The measure of inflammation ranges 
from 0 to 4+. Patients with a grade 3 or more are considered to have severe uveitis. If the 
treatment shows a mean change in inflammation of 2 grades or more, then the treatment 
is deemed effective.1 See section 1.4.1 for more detail. 
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Chapter 4  
4 Literature Review for Methodology 
4.1 Overview of Meta-analysis 
Before we go into the methodology, it is important to understand how to conduct a meta-
analysis and know some of the terminology that is used within a meta-analysis. Thus, this 
chapter will do a brief introduction of the methodology used in this thesis and how to 
interpret a meta-analysis.  
A meta-analysis can be conducted on an area of research where the studies have low 
power due to small sample size or intervention effect. When the studies are combined, the 
estimated intervention effect becomes more precise, and power is increased if the studies 
have similar variability and similar effects. However, when the results of the combined 
studies show inconsistency/heterogeneity, represented as 𝐼2, then measures must be taken 
to assess where the heterogeneity originates. There are 2 methods that can be used to 
assess heterogeneity; the first is a subgroup analysis, and the second is meta-regression. 
Subgroup analysis allows you to measure the variability using subgroups that may be 
present in the collected data, which could account for the heterogeneity. Meta-regression 
uses regression to evaluate if a relationship exists between 1 or more covariates 
(moderators) and the effect size in the studies. 
4.2 Mechanics of Meta-analysis  
Once the summary data is collected, an understanding of the mechanics of meta-analysis 
will allow one to assess the data smoothly and accurately. The first step is to understand 
how the summary data can be used to obtain an effect size for each study.  
 What is Effect Size? 
Effect size is what encodes the relationship of interest into a common index.99  
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It is important to determine an index of how the effect size will be measured. The effect 
size can be presented in many ways; it depends on the data that is extracted. Some effect 
size indexes include standardized mean difference (SMD), correlation coefficient, and 
effect size based on binary data (ie, risk ratio or odds ratio).100 Choosing the index is 
straightforward, as the summary data in general will dictate the index. For example, if the 
data are based on a standardized meaningful outcome, then using a raw mean difference 
(WMD) could be beneficial as the outcome is standardized and is on a meaningful scale 
that is widely used, like blood pressure.100 However, in the case of other indexes like 
binary, where there are many choices like odds ratio, relative risk, risk differences, or 
number needed to treat, it becomes rather controversial to choose an index and care must 
be taken in order to pick the index for the meta-analysis.101  
 Precision 
Variance, standard error, and confidence intervals are all measures of precision. How 
precise the effect size of a study is depends on a variety of things, however, the rule of 
thumb is the greater the sample size, the narrower the confidence intervals and the more 
precise the effect size is. As the sample size is reduced, it loses power and the confidence 
intervals become larger, and therefore the overall precision is lower.99 This relationship is 
important for identifying error within studies, which is needed to calculate the summary 
effect size and confidence intervals found in a forest plot. In addition, study design could 
affect the precision as well. For example, a cluster trial would have larger variance then a 
study with 2 independent groups, since an entire cluster of participants is assigned to one 
condition or another. It is important to understand that both sample size and study design 
can affect precision, which is intrinsic to that study.   
The forest plot consists of the reviewed studies and their effect sizes, their precision, 
which is indicated by confidence intervals, the inverse of the study’s variance by the area 
of the box, and the inverse of the study’s error indicated by any side of the box.  
Another key component of a meta-analysis is the variance or error that is within each 
study.100 In this study, the variance of the difference was calculated in STATA by using 
the individual standard deviations for the pre-post logMAR. 
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 True Effect Size and Summary Effect Size 
True effect size is the effect size in the underlying population for that study, and it is the 
effect size that we would observe if the study had an infinitely large sample size (thus, no 
error within or between studies if assuming random effects model). A study’s observed 
effect size is the effect size that is actually observed. The summary effect size is the 
calculated weighted mean of the observed effect sizes of all the studies combined. The 
true overall effect size is the summary effect if all the studies had a common effect size 
(ie, true effect size). These calculations were done using Stata.102 Below, we explain the 
different models available to compute the summary effect size, the precision associated 
with each model, and which model was chosen for our study. 
 How to Measure a Summary Effect Size (Fixed vs. Random 
Effects Model) 
When computing the summary effect size and assessing heterogeneity, it is important to 
note that the same methodology is used no matter which index is chosen.103 For the meta-
analysis, there are 2 models for computing the summary effect size. One is the fixed 
effects model and the other is the random effects model.103 Fixed effect assumes that the 
true effect size is the same with every study and the only variance that is present is due to 
within-study variance.103 For example, if all the studies were conducted the same way, 
and all the factors that could influence the effect size were the same in all the studies, 
then the true effect size would be the same in all studies. Under the fixed effects model, 
all the studies share the same true effect sizes, so the observed effect size varies from one 
study to the other only because of the random error intrinsic in each study. The difference 
seen between the observed effect size and the true effect size (Xi), is contributed by the 
error (Ei), thus the observed effect size (Yi), is simply: 
Yi = Xi + Ei 
We assume that the error is placed in a normal curve about the true effect size for each 
study, with the width based on the variance in that study. Performing a meta-analysis 
when calculating the summary effect size using the fixed effects model, we take into 
account the variance by taking the inverse variance, which is the weight of that study, and 
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multiplying it by the observed effect size.103 In our study, we assigned weights so we 
could minimize the within-study error; in other words, we tried to obtain a more precise 
estimate of the population effect. The next step is to take the sum of the product and 
divide it by the sum of the weights. Then, to determine the variance of the summary 
effect, we take the reciprocal of the sum of the weights. The null hypothesis that the z-test 
is trying to test is that the common effect is zero for the differences, or 1 for ratios.  
Though the basis for the summary effect size calculation in a fixed effects model 
accounts for within-study error, it is not a valid reason to assume that all the studies will 
have the same true effect size.99 Unless certain, there is another model, which allows the 
true effect size to vary from study to study. The random effects model assumes that there 
may be between-study variations as well as within-study variation.104 This model is 
usually more valid, because studies may differ in study design, type of intervention, age, 
or another factor, and effect sizes are assumed to be different among the different 
studies.103 For example, the effect size might be higher (or lower) when the participants 
are older, more educated, healthier, or when a more intensive variant of an intervention is 
used, and so on. Because the studies will differ in the combination of participants and 
types of treatment, there may be different effect sizes for the different studies. A key 
assumption of the random effects model is that the true effect is normally distributed.104 
For our study, we calculated the between-study variance and included that in our weight 
before doing any further calculations. Dersimonian and Laird (1996)105 have presented a 
method to calculate between-study variance, or the heterogeneity. This will be discussed 
in the next part of the thesis.  
However, the main equation for the random effects model and the change from fixed 
effects model is the addition of the between-study variance, as shown below: 
Yi = X+ E + B 
So, the observed effect Yi is the true mean (X), the deviation of the study’s true mean 
(E), and the deviation of the study’s observed effect from the studies’ true effect (B).103 
Weight assigned to each study via the random effects model is: 
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Wi*= 1/Vyi* 
Where, Vyi* is the within-study variance for study i (Vyi), plus the between-studies 
variance (T2), 
Vyi* = Vyi + T2 
And the weight is reciprocal of the Vyi*.  
The weighted mean is calculated the same way as in the fixed effects model, taking the 
sum of the weight (Wi*) and the effect size (Yi), and then dividing that by the sum of the 
weights. The variance of the summary effect is estimated as the reciprocal of the sum of 
the weights.  
Thus, the goal was to use the weight of the studies to minimize both sources of study 
variance. The random effects model suggests that the studies in the analysis represent a 
random sample of effect sizes from all the effect sizes that could have been observed.  
Not only does the random effects model take the weight of the study into consideration, 
but it also considers the weight of the variance between one study and the other studies in 
the meta-analysis. In contrast, the fixed effects model uses the weight of the studies by 
considering sample size and only the within-study variance. If the variances between 
studies is large and the fixed effects model is used, then a study with a larger sample size 
will be assumed to possess greater precision. In reality, it means that 1 study might 
dictate the summary effect size. With the random effects model, that larger study will not 
be given as much weight depending on the between-study variance compared to the other 
hypothetical studies. Thus, it is more accurate to use the random effects model in the case 
of notable or a priori predictions of the heterogeneity of studies.  
In the fixed effects model, more weight is given to studies that are more precise, because 
it is assumed that the true effect size is the same among all the studies. However, in the 
random effects model, we are looking for the mean of the distribution of the effect sizes. 
Since each study provides information about a different effect size, we want to make sure 
every effect size is taken into consideration when determining the summary effect size. 
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Consequently, small studies are given more weight and large studies are not given as 
much weight, which allows for more balance. Extreme studies lose influence when we 
move from the fixed to the random effects model. Confidence intervals will be larger, as 
there are 2 errors associated with the model, unless the between-study variance (T2) is 
zero, then the fixed and random effects model will be the same.  
Conceptually, it is important to note that if the sample size reaches infinity, it would 
make the error in the fixed effects model narrower. However, in the random effects 
model, there would need to be an infinite amount of studies for the error to narrow. The 
null hypothesis in the fixed effects model is that there is zero effect in every study, 
whereas in the random effects model, the mean effect is zero.   
 Heterogeneity 
In order to understand the implications of our study, it is important to observe if there is 
consistency in the studies or if there is heterogeneity in the true effect sizes. This is not to 
be mistaken with precision since that term is solely used for within-study variance, 
whereas heterogeneity is used for the variation found in true effect sizes.104 If there is 
heterogeneity, can we pinpoint what is causing it? In a random effects model, we allow 
that the true effect size may vary from study to study, and suggest that there will be 
heterogeneity; therefore, heterogeneity can be defined as between-study error. However, 
how do we identify it in a meta-analysis?  
 
4.2.5.1 What is heterogeneity  
In the context of a meta-analysis heterogeneity is defined as statistical heterogeneity or 
inter-study variance. In a meta-analysis it is assumed that statistical heterogeneity is a 
consequence of clinical or methodological variation. Clinical variation is heterogeneity 
due to differentiations in interventions or patient characteristics. These variations can 
affect the between study variance and true treatment effect will be different study to 
study. This can be reduced by having stringent inclusion/exclusion criteria, which would 
allow for similar patient characteristics from study to study. There would still be clinical 
variation with the type of treatment given, since there are many in our study. 
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Methodological factors, such as how the outcomes are measured and defined could lead 
to differences in the observed treatment effects. For example, having different scales to 
measure VA could lead to methodological heterogeneity as one study could measure 
using Snellen and another via logMAR. Thus being aware of the kind of heterogeneity 
that could be present is important, and would allow one to choose the appropriate model 
to conduct their meta-analyses. If we know that there will be heterogeneity, then a 
random effects model would be chosen and would allow for between-study error. 
However, we need to know how to identity it and measure it statistically. 
 
4.2.5.2 How to identity and measure heterogeneity  
There are many methods to identify heterogeneity. One is to look at the forest plot and 
examine how the studies are dispersed from one another, but in order to objectively 
identify heterogeneity, we must separate the true variance (between-study variance) from 
the random error (within-study variance). For the purposes of this thesis, it not important 
to understand how the calculations are done, but to understand conceptually how 
heterogeneity is identified. 
One method to identify heterogeneity is the Q method, which is the dispersion that is 
excess to the within-study error and is standardized, which means it is not affected by the 
metric of the effect index, but it suffers from low power if there are too few studies.99, 103 
The null hypothesis using the Q can be rejected when the p value is set at less than the 
alpha, which is set to 0.05. Q will follow a chi-squared distribution with degrees of 
freedom equal to k-1. This is called the homogeneity test; if we reject the null hypothesis, 
then the distribution of the effects is heterogeneous. 
However, the Q statistic could be used to compute a ratio or dispersion on the same scale 
as the effect index itself. One such way Q is calculated is the method of moments or the 
DerSimonian and Laird method, which converts the Q to the same scale as the effect 
index.103 This method calculates the between-study variance found in the random effects 
model and the standard deviation of the summary effect size. This between-study 
variance is represented by T2. The T2 is used in the random effects model and is defined 
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as the between-study variance that is not explained by excess error found in the study. It 
is used to describe the heterogeneity found in the studies in most meta-analyses because it 
is easy to calculate, however, it is not the best way to discuss the variance, since it is on 
the same scale as the effect index and cannot make comparisons to other indexes. A new 
method is used to describe the heterogeneity using ratios with Q value; this value is 
represented as I2. It allows one to make a conclusion about whether any of the total 
variation that we see is due to the true variation or heterogeneity. This is a way to identify 
heterogeneity, and the reason it is often used to talk about heterogeneity is because it is 
not sensitive to the number of studies, unlike the method of moments, and it is not 
sensitive to the metric of the effect size.  
Once the heterogeneity is identified, we can further explore where the heterogeneity 
could be coming from. For this, there are 2 methods: subgroup analysis and meta-
regression.  
 Subgroup Analysis 
Subgroup analysis is the set of studies divided via a particular subgroup, such as 
treatment classes. Subgroups can be used to determine whether the heterogeneity can be 
explained by a particular subgroup. However, there is a lot of debate concerning the test 
of heterogeneity with any method in a subgroup, as subgroups may be too small to be 
significant or it may be unreasonable to make a comparison from one group to another 
(for example, 1 subgroup could contain only 2 studies, while another subgroup contains 
more then 10). The use of fixed effects models with subgroups has been debated for some 
time. However, the use of random effects models with subgroups has recently been 
applied, with certain assumptions. For example, if we assume that each study within the 
subgroup shares a common effect size, then we can apply a fixed effects model, but if we 
do not make that assumption, then the random effects model can be applied. With the 
random effects model, if we assume that the between-study variance is the same for all 
subgroups, then we compute the T2 for the subgroups, pool them together and use the 
same estimate for all subgroups. If not, then we use a separate T2 for each subgroup.  
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For the purposes of our thesis, if any between-study variance existed, for practical 
reasons (which will be explained below), it was assumed that it was the same. Some 
heterogeneity authorities do not believe that subgroup analysis is a strong measure for 
comparing the different subgroups due to the low number of studies per subgroup.100,101 
One rule of thumb is that if there are fewer than 5 studies per subgroup, there is an 
assumption that the between-study variance is the same for all subgroups.101 Thus, the 
fixed effects method is used for subgroups; this is one of the only valid methods to test 
for heterogeneity, as using random effects would make the test of power even lower.101 
When there are a low number of studies within a subgroup, it may be wise to just conduct 
a pooled meta-analysis. However, it reasonable to use the random effects model if each 
subgroup has more than 5 studies.100, 104  
 Conducting a Univariate Meta-regression with Multiple 
Covariates 
Meta-regression in a meta-analysis assesses the relationship between study-level 
covariates and effect size. Meta-regression is similar to regression conducted in primary 
studies, the key difference being that each study is weighted, depending on which model 
is selected (fixed vs. random effects). Knowing which model to pick is important, as it 
will affect the results (more even weights among studies when using the random effects 
model, and larger studies do not impact the summary effect size or the regression line). 
Under the null hypothesis, using the random effects model, the mean is the same for all 
values of the covariates.105 When conducting a random effects model meta-regression, it 
is important to understand some technical issues, the first being that Z-distribution is only 
appropriate for the fixed effects model, where the source of error is within-study.7 For the 
random effects model, the dispersion across the studies should be accounted for using the 
t-distribution. There are many methods to accomplish this, the most well-known and 
accepted is from Knapp and Hartung (2003).107 Two modifications are made to the 
standard error for the random effects model. The first is the between-study variance 
component, which is multiplied by a factor so it corresponds to the t-distribution rather 
than the Z-distribution. The second is that the test statistic is compared against the t-
distribution, which expands the width of the confidence intervals and moves the p-value 
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away from zero. Another method, by Higgins and Thompson (2004)108, is to bypass the 
sampling distribution and use a permutation test to yield a p-value. Using this test, a z-
score that corresponds to the observed covariate is computed, then the covariate is 
randomly distributed among the studies to see what proportion yield a z-score that 
exceeds the one that was obtained.107 This is the true p-value.  
 Final Remarks for Meta-regression or Subgroup Analysis  
The absence of statistical significance should never be interpreted as evidence that an 
effect is absent. This is important to keep in mind since power to detect heterogeneity in 
effect sizes or between covariates or subgroups is very low. In other words, failure to 
obtain a statistically significant difference among subgroups or covariates should never 
be interpreted as evidence that the effect is the same across subgroups or that there is no 
relationship between the covariate and the effect size. Also, the reverse is true, even with 
a statistically significant relationship between effect size and subgroups or between effect 
size and covariates is observational and cannot be used to prove causality. This holds true 
even if all studies in the analysis are RCTs. Some studies employ a strategy of starting 
with the fixed effects model and then modifying to use the random effects model if the 
test for heterogeneity is insignificant for meta-regression or subgroup analysis. This 
approach has significant disadvantages; instead, the model that is initially chosen should 
be based on knowledge of the subject matter. 
 Power vs. Precision 
To ensure that a study has good statistical power (a sufficiently high likelihood of 
yielding a statistically significant result), observe whether a meta-analysis has sufficient 
statistical power to test the null hypothesis of no effect.99 Although it is not always 
mandatory to conduct a power analysis for a meta-analysis, especially one with multiple 
treatment groups, it can help determine whether a study is likely to yield statistically 
significant results. This is particularly important in primary studies. In meta-analysis, it is 
more appropriate to look at the effect size and its precision, as that provides a clearer 
indictor regarding whether or not the result was significant.  
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 Publication Bias 
Publication bias can have a pronounced effect on the results of a study, as some studies 
could have been overlooked in the screening phase, which could lead to bias that is 
known as publication bias. The consequences of publication bias include precision and 
validity. There could also be bias due to larger studies being included and smaller studies 
not being included because they are not as easy to find. One way to mitigate the precision 
issues related to publication bias is to use a random effects model to ensure that all 
studies are evenly weighted, but this doesn’t take into account the amount of publication 
bias that might exist or how the data would look if those theoretical studies were not 
missing. 
There are methods that have been established to determine if publication bias has taken 
place, and some methods can even adjust for the bias. A funnel plot is used by these 
methods to detect any asymmetry, and to examine whether the asymmetry is due to 
chance. There are also tests, such as Begg and Mazumdar (1994)109 and Egger et al 
(1997).110 However, these methods do not provide estimates about the number or 
characteristics of the missing studies, nor do they provide an estimate of the underlying 
(biased) effect. One such method, developed by Duval and Tweedie (2000), 111 does 
address these issues.  
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Chapter 5  
5 Methods 
We conducted this review in accordance with the Meta-analysis of Observational Studies 
(MOOSE) recommendations and the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines (completed checklists in Appendices A and B).  
5.1 Literature Search  
A comprehensive and pre-planned search strategy from 6 databases (MEDLINE, 
EMBASE, Cochrane Library, CINAHL, Scopus, BIOSIS and Web of Science) was 
created to obtain the maximum return of relevant studies related to our question. Free text 
key words and medical subject headings were tailored to each of the electronic databases. 
The search strategy was performed in collaboration with a medical librarian with 
searching expertise, ophthalmologists within the Canadian Uveitis Society, and 
information specialists. The search strategy consisted of the terms listed in Table 8 
below. 
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Table 8: Concepts, keywords, and phrases for search strategy 
 Keywords/Phrases 
the concept of: 
idiopathic uveitis 
Idiopathic uveitis 
Chronic uveitis 
Non-infectious uveitis 
Ocular inflammation 
Ocular inflammatory disorders 
Intraocular inflammation 
the concept of: 
immunosuppressive 
treatments 
Immunosuppressive drugs 
Immunosuppressive therapy 
Immunomodulators 
Pharmaceutical Family Generic Name Brand Name 
Antimetabolites:  Azathioprine Imuran 
Azasan 
Methotrexate (abbreviated MTX and formerly known 
as amethopterin.mp.) 
Rheumatrex 
Trexall 
Mycophenolate Mofetil Cellcept 
Mycophenolic Acid  Myfortic 
Alkylating Agents: Cyclophosphamide (also known as cytophosphane.mp.) Cytoxan 
Endoxan 
Cytoxan 
Neosar 
Procytox 
Revimmune 
Chlorambucil  Leukeran 
Inhibitors of t-
lymphocyte signaling 
(Calcineurin Inhibitors) 
Cyclosporine 
  
Gengraf 
Neoral 
Sandimmune 
Tacrolimus (also FK-506 or fujimycin) Prograf 
Advagraf 
Protopic 
Sirolimus (rapamycin) Rapamune 
Using these terms enabled the development of a comprehensive search strategy for each 
database, which can be found in the Appendix C. The original search was performed in 
June 2012, and it continued to gather articles via monthly updates until March 2013. 
Searches were not restricted by publication type, date or language. To ensure all relevant 
studies were identified, unpublished studies were also searched through manual searches 
of electronic abstracts and dissertations from the American Academy of Ophthalmology 
and the Association for Research in Vision and Ophthalmology meetings. To further 
ensure all studies relevant to the systematic review were included, bibliographies of 
eligible studies and relevant systematic reviews retrieved in the literature search were 
manually screened.  
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5.2 Eligibility Criteria 
With the help of ophthalmologists within the Canadian Uveitis Society, the study 
eligibility criteria were established by identifying key components that needed to be 
fulfilled to answer our study’s question: how immunosuppressive treatments affect 
patients with non-infectious idiopathic uveitis. The key components consisted of patients, 
Intervention, Comparison, Outcomes and study design (or PICOS). These terms needed 
to be fleshed out completely before we could answer question. PICOS is a helpful tool to 
help focus on what is important to our question and create the appropriate eligibility 
criteria. Our eligibility criteria was: 
Participants: As discussed in section 3.4, we looked at studies that specifically examined 
non-infectious idiopathic uveitis patients. This would ensure that the patients who were 
studied were the patient population that we wanted to look at, and would allow for 
homogeneity within the study population. Patients with uveitis that was not exclusively 
idiopathic in nature were included. Studies with fewer than 50% of patients with diseases 
other than non-infectious idiopathic uveitis were included in order to capture existing 
evidence from mixed populations (see Appendix D for the list of diseases that were 
excluded). 
The focus was on posterior and intermediate uveitis patients, as they were the 2 locations 
of uveitis where it was most unclear regarding treatment efficacy. Studies solely focused 
on anterior uveitis patients were excluded because they are easier to treat, and there is 
little equipoise regarding treatment choices. If posterior or intermediate uveitis patients 
accounted for 50% or more of the patients examined within a study, then that study was 
included.  
Interventions: The studies that examined any 1 of the 3 main groups of 
immunosuppressive treatment (ie, antimetabolites, alkylating agents, inhibitors of t-
lymphocytes) were included. The treatment must have been orally administered (which is 
the most common method of administering immunosuppressive treatment) to ensure 
homogeneity, because some patients can be receive treatment via other means, such as 
injections.  
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Outcomes: Measured via changes in visual acuity (VA) and/or inflammation grade, 
relapse rate, corticosteroid-sparing rate, and adverse events. As discussed in section 1.4, 
these outcomes were specific to determining the effectiveness of the treatment given to 
patients and what was used in different studies to describe effectiveness. And as 
discussed in section 3.5, the primary main outcome of measure used for the meta-analysis 
was change in VA, measured in logMAR. The rest of these outcomes were used for 
descriptive purposes under the systematic review.  
Study Design: All study designs were included, except narrative reviews. There were no 
restraints on year of publication, as any treatment given in the past or present would be 
administered in a similar fashion. Also, we only looked at studies from the English 
language. Also, studies that were done in either North America, Western Europe, Hong 
Kong, Japan, New Zealand, Australia or Singapore, were included. This was done as 
developing countries may not have similar clinical practices as these countries, and 
would further the clinical heterogeneity.   
Therefore, this study included primary studies that assessed the effectiveness (measured 
via changes in visual acuity (VA) and/or inflammation grade, relapse rate, corticosteroid 
sparing rate, and adverse events) of treatments (antimetabolites, alkylating agents, t-
lymphocyte inhibitors) for patients with non-infectious idiopathic uveitis. 
5.3 Article Screening 
Two levels of screening were performed to eliminate articles that did not meet the 
inclusion criteria. Level 1 consisted of screening through the titles and abstracts to seek 
out articles potentially relevant to the study. From the articles included in level 1, the full-
text of the articles were retrieved to more closely assess inclusion and exclusion criteria 
for level 2 screening. Two reviewers screened citations (AC and HS) and full-text articles 
(SS and HS) in an independent fashion, and to examine inter-rater agreement using 
Cohen’s kappa coefficients. The kappa values were interpreted as follows: 0.40 to 0.59 
reflected fair agreement, 0.60 to 0.74 reflected good agreement, and ≥0.75 reflected 
excellent agreement.112, 113 Once the screening was conducted, the 2 reviewers reconciled 
the discrepancies through discussion. Both levels of screening were done in duplicate to 
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increase accuracy and reduce measurement bias. An experienced ophthalmologist (WH) 
was consulted to resolve any remaining disagreements.  
Studies were excluded if: (i) greater than 50% of the patients were diagnosed with any of 
the diseases listed under Appendix D, (ii) location of disease was mainly anterior uveitis 
(greater than 50% of patients), (iii) studies having less than 5 patients with idiopathic 
uveitis, (iv) studies were conducted in developing countries, (v) the treatment was not 
given orally, (vi) not a primary study, and (vii) studies did not provide the outcome of 
interest. The entire list of inclusion/exclusion criteria for both level 1 and level 2 can be 
found in Appendix D.  
5.4 Data Extraction for Descriptive Statistics 
To extract data from the eligible studies, we created a data extraction form. Two 
reviewers (HS and AC) dependently conducted a “trial pilot” of the extraction form on a 
subset of the eligible studies. Based on the changes in the pilot study, the final version of 
the data extraction form was developed (see Appendix E). For the purpose of this thesis, 
the data extracted from the studies was organized by the treatment given to the majority 
of patients in a particular study. The following information was collected in the final data 
extraction form:  
Study Characteristics: included the study design, setting/data source, and the accrual 
period of the study and sample size. This was relevant because it gave an idea of the 
types of studies we examined.  
Participant Characteristics: As mentioned in section 3.4, the patient characteristics 
included the number of patients with idiopathic uveitis (sample size), mean age, standard 
deviation of age and/or the maximum and minimum age range, frequency of female 
patients, mean follow-up time in months, mean follow-up standard deviation and/or 
maximum and minimum range for follow-up time, primary cause of uveitis, with 
majority having idiopathic uveitis, frequency of patients with the primary cause, primary 
location of diseases (could be posterior uveitis, intermediate, panuveitis, or a combination 
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of them), frequency of patients with primary location of disease, and lastly, which if any 
previous treatments were given to patients before the immunosuppressive treatment.  
It was important to collect these characteristics for the purposes of describing the findings 
in our study. They allowed us to understand the patient characteristics, and allow for 
comparisons to be made between patients from different treatment groups. So, where 
possible only data from idiopathic patients were extracted from the studies, if the results 
were of the entire patient population, then we made sure that 50% or greater of the 
patients were idiopathic in nature, which was a part of our article screening process.  
Baseline Characteristics (Before Treatment): included location, cause and type of uveitis, 
and any previous treatment given. This allowed us to ensure homogeneity was present 
within patient populations, as most of the data collected should have been similar.  
Treatment: included treatment given, dosage, and length of treatment time. These 
variables were important to obtain, so a study with a particular treatment could be 
compared to another with the same treatment, knowing that the dosages were similar.  
Outcomes (after treatment): As discussed in section 1.4, outcomes measuring 
effectiveness included reduction in severity of disease indicated by frequency of patients 
that improved or maintained Visual Acuity and/or inflammation grade, reason for 
discontinuation, steroid usage, clinically-relevant adverse events and the frequency of 
patients that experienced each adverse event, and anything else the study used to measure 
outcome. For the purposes of the systematic review, all outcomes that were present in the 
study were extracted for descriptive purposes. 
Relapse rate, corticosteroid-sparing rate, and adverse events were extracted for 
descriptive analysis as opposed to meta-analysis. However, relapse rate and 
corticosteroid-sparing rate were not included in the final descriptive statistics due to a 
lack of sufficient data. 
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5.5 Data Extraction for Meta-analysis 
For this study, the primary outcome for the meta-analysis, as outlined in section 3.5, is 
presented in the form of pre-/post-logMAR with the respective standard deviations. This 
allowed us to use the unstandardized mean difference or raw mean difference because the 
summary data was in a meaningful scale. An SMD index was not used because we knew 
that some studies used different scales, which we accounted for and standardized. 
However, most of the data used the logMAR scale, and the studies that did not were 
converted to logMAR. Thus, raw mean difference was used. The unit of analysis is the 
pre-/post-logMAR. The advantage to this design is that each pair serves as its own 
control, reducing the error term and increasing the statistical power. Also, regardless of 
study design, the computed effect size and variance from each study could be included in 
the same analysis, since the scale is the same. The conversion of scales to logMAR was 
done in MS Excel, before being imported into Stata. 
On the extraction form found in Appendix D, pre-VA and post-VA, or change in VA, 
were extracted as well. Alongside the VA itself, the respective standard deviations were 
also extracted. The majority of the data collected were taken for descriptive purposes, and 
pre- and post-VA became useful for the meta-analysis. As described in section 1.4.2, VA 
can be measured in different scales and due to the high correlation between the scales VA 
can be interchanged. Thus, using Table 9, VA which was not in logMAR was converted 
to logMAR scale and also as a rule of thumb the formula  to convert from decimal to 
logMAR is –log10(Decimal).80  
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Table 9: Visual Acuity Conversion Chart 
20 ft. 6 m Decimal 4 m Log MAR 
20 / 630 6 / 190 0.032 4 / 125 +1.5 
20 / 500 6 / 150 0.04 4 / 100 +1.4 
20 / 400 6 / 120 0.05 4 / 80 +1.3 
20 / 320 6 / 95 0.06 4 / 63 +1.2 
20 / 250 6 / 75 0.08 4 / 50 +1.1 
20 / 200 6 / 60 0.1 4 / 40 +1.0 
20 / 160 6 / 48 0.125 4 / 32 +0.9 
20 / 125 6 / 38 0.16 4 / 25 +0.8 
20 / 100 6 / 30 0.2 4 / 20 +0.7 
20 / 80 6 / 24 0.25 4 / 16 +0.6 
20 / 63 6 / 19 0.32 4 / 12.5 +0.5 
20 / 50 6 / 15 0.4 4 / 10 +0.4 
20 / 40 6 / 12 0.5 4 / 8 +0.3 
20 / 32 6 / 9.5 0.63 4 / 6.3 +0.2 
20 / 25 6 / 7.5 0.8 4 / 5 +0.1 
20 / 20 6 / 6 1.0 4 / 4 0 
20 / 16 6 / 4.8 1.25 4 / 3.2 -0.1 
20 / 12.5 6 / 3.8 1.6 4 / 2.5 -0.2 
20 / 10 6 / 3 2.0 4 / 2 -0.3 
As discussed in section 1.4.2., in order for analysis to be conducted on VA, logMAR is 
the most reliable and precise scale because of its logarithmic nature, which offers a more 
accurate estimate of VA compared to other scales used to measure VA. On the logMAR 
scale, better vision means a lower logMAR value (ie, a -0.01 change in logMAR means 
an improvement in visual acuity). 
In studies that did not record the measure of visual acuity outcome directly, it was 
extrapolated from the graphs within the studies. This was done using online software 
called graph digitizer™, which allowed us to input the data from the x-axis and the y-axis 
to re-create the graphs to scale.114 Then, by manually clicking on the graph at the point of 
importance, the software produced the pre- and the post-value of VA for the missing data. 
In addition, for data reported as means, standard deviation was also recorded. If standard 
deviation was not reported for outcome measures, raw data was extracted from graphs 
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and used to calculate standard deviation where available. The standard deviation of age 
was also found for studies that did not report it, using range, which is another measure of 
variability. In some cases, we also attempted to gather missing information by contacting 
the study authors. 
5.6 Quality Assessment 
We used the Downs and Black scale to evaluate the risk of bias in the included studies. 
Deek et al (2003)115 conducted a systematic review where they identified 182 quality 
assessment tools for assessing non-randomized studies. From 182, 14 tools were 
considered the “best tools” according to their pre-specified criteria, but only 5 were 
considered suitable for systemic reviews. From the 5, 2 tools, the Newcastle-Ottawa scale 
and the Downs and Black scale, were found to be able to differentiate between the 
reporting bias, selection bias and external bias. From these, Downs and Black scale 
provides a numeric score for overall study quality that is easy to interpret. 
We used the Downs and Black scale to access methodological quality and evaluate the 
risk of bias in the studies we included, because it has excellent test-retest reliability (r = 
0.88), inter-rater reliability (r = 0.75) and internal consistency (Kuder-Richardson 20 r = 
0.89).116 The Downs and Black scale can be used to assess both randomized and non-
randomized studies. It contains 27 questions, divided among the following 5 sub-
sections:  
a. Reporting (10 questions): Is the information provided in the study sufficient for the 
reader to make an unbiased assessment of the findings? 
b. External Validity (3 questions): Examines the extent to which the findings of the 
study subjects can be generalized to the population.  
c. Internal Validity/Bias (7 questions): Examines whether the measurement of the 
intervention and outcome of the study are biased.  
d. Internal Validity/Confounding (6 questions): Examines whether selection bias is 
present within the study. 
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e. Power (1 question): Assesses whether the negative findings in the study are due to 
chance. 
Total scores usually range from 0 to 31; however, we adapted the final question relating 
to power from a scoring scale of 0 to 5 to a scale of 0 to 1. Other studies have modified 
the Downs and Black, however, it should be noted that when changing or modifying the 
tool, it compromises the reliability and validity.117 Thus our modifications could have 
comprised the reliability and validity. The modified Downs and Black scale (maximum 
score of 28) in other studies is evaluated with grade of “excellent” if studies scored 24–28 
points, “good” for 19–23 points, “fair” for 14–18 points or “poor” if <14 points. For our 
study we took the frequency that was translated from the grades provided by Tully et al 
(2015)117 to give meaning to our results, and differentiate the quality of our studies. 
A study scored 1 if a power or sample size calculation was conducted, while 0 was 
assigned if no calculation was done. Therefore, our adapted Downs and Black scale for 
RCT ranged from 0 to 27, with a higher score indicating higher study quality. The quality 
of an RCT would be “excellent” if the a frequency of  83% to 100% was obtained, 
“good” would be 65% to 82%, “fair” if frequency would be 51% to 64% points or “poor” 
if <50%.  
For observational studies, 3 questions from the internal validity section were removed, 
along with 2 questions from the selection bias section, as they were topic sensitive and 
pertained mainly to randomized trials. Questions 14-16 were removed from internal 
validity, because they pertained to whether the patients and those measuring the main 
outcome were blinded by the intervention given. In the majority of the studies we 
examined, patients were given treatment due to the severity of the disease and both the 
administrator and the patient knew which treatment they received. Questions 23 and 24 
were removed from selection bias, because they referred to patients being randomized, 
which did not take place in the majority of the observational studies. Therefore, our 
adapted Downs and Black scale for observational studies ranged from 0 to 22. The 
quality of an observational would be “excellent” if the a frequency of  83% to 100% was 
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obtained, “good” would be 65% to 82%, “moderate” if frequency would be 51% to 64% 
points or “poor” if <50%. 
 For the purpose of this thesis, when organizing the figures, the 4 categories were 
displayed with the frequency of studies that had been assigned “yes” or “1” in a particular 
category, instead of looking at individual questions and their respected frequencies. This 
was done because it allowed us to assess the quality of the study using the 4 main 
categories that encompass the individual questions. The Downs and Black tool116 is 
attached in Appendix F. 
5.7 Meta-analysis 
 Summary Effect Size 
All extracted outcomes were treated as continuous data. VA, measured as a logMAR 
value, and inflammation grade, measured on SUN’s grading scheme for anterior chamber 
cells and its variations, were reported as pre- and post-means. However, not many studies 
had pre- and post-inflammation grade on one scale that could be standardized, so we 
were unable to conduct a meta-analysis on inflammation grade. As discussed in Chapter 4 
section 4.2.1, since the effect size was reported on a meaningful scale (logMAR), and all 
studies were converted to the same scale, we were able to perform a meta-analysis 
directly on the raw mean difference (D), rather than requiring a standardized mean 
difference (Cohen’s d). The explanation behind the computing of the raw mean score is 
that the scale is intuitively meaningful (ie, blood pressure, which is a known 
measurement scale, similar to logMAR for VA). Because the unit of analysis is the pair 
(ie, pre- and post-logMAR), the advantage of this design is that each pair serves as its 
own control, reducing the error term and increasing the statistical power. The calculations 
for the effect size and its variance were done via STATA, which required individual 
pre/post VA and pre/post SD data. So, it was important that all studies had the individual 
data in order for the analysis to be undertaken. 
So, in studies where only the change in standard deviation and mean visual acuity were 
given, we imputed the data using the average pre-VA from the studies that had the data to 
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obtain the missing VA, and the post-VA was inferred using the change in VA that the 
particular study had provided. 
To perform meta-analysis, both the pre- and post-VA and the individual standard 
deviation data was required for both pre- and post-means. When possible, missing VA 
and standard deviation data was computed using extracted raw data. However, when 
studies did not provide sufficient information for individual pre- and post-means and 
standard deviations, we had to impute the means and standard deviations for VA, keeping 
in the mind the change from pre-VA to post-VA was already calculated or provided, as 
was the SD. 
With some studies, we knew the mean change, but did not know the specific pre- and 
post- values. Since these were required for meta-analysis, we imputed missing pre-visual 
acuity as an average of all available pre-data, then used change to infer post- data. We felt 
that using mean pre-data fairly estimated the visual acuity of patients prior to treatment, 
since the patients had similar conditions and could be used as an indicator of the visual 
acuity of patients prior to any treatment. 
If a study did not include a change in standard deviation at all, and one could not be 
calculated with the raw data, then the Furukawa et al method was used for the missing 
pre- and post-SD. Furukawa et al (2006)118 showed that using imputed standard 
deviations from other studies in the same meta-analysis resulted in approximately correct 
results when compared to non-imputed (actual) standard deviations.4 We reviewed the 
possible standard deviation data from other included studies and imputed the highest pre-
standard deviation as a conservative estimate for missing standard deviations. We 
recognized that this would lead to lower weighting of the study within the meta-analysis; 
however, we believed that to be a fair trade-off for its inclusion within the results rather 
than excluding the study if it did not include standard deviation. 
 Choice of Fixed vs. Random Effects Analysis 
As discussed in section 4.2.4 of Chapter 4, meta-analysis was performed using a random 
effects model because we anticipated significant heterogeneity across studies. The 
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random effects model appropriately accounts for the differences in observed effects 
between studies that are beyond the expected heterogeneity due to sampling error alone. 
The studies ranged in areas such as participant mix (eg, juvenile/senile, etc.) and 
prescribed treatment and dosage, leading to different possible true effect sizes. Therefore, 
we assumed that the reported raw mean differences were simply a random subset of all 
possible effect sizes and we assumed the effect sizes were normally distributed. The 
random effects model, using the DerSimonian and Laird method, determines the mean 
and standard deviation of this distribution, or in other words, the summary effect.   
5.8 Sensitivity Analysis of Missing Data  
We repeated the analysis while omitting studies that required imputed pre and post VA or 
standard deviations. If we saw changes, we checked for any change in heterogeneity; if 
none was found, the results were similar to the original analysis, so we reported the 
original analysis. 
5.9 Heterogeneity 
Heterogeneity between studies was visually assessed through paired forest plots. 
As stated in section 4.2.5, to quantify the degree of statistical heterogeneity we used the 
Cochran Q (X2 test) and the Higgins I2 statistic. Cochran Q allowed us to test the null 
hypothesis and obtain an estimate of the excess variance. The I2 statistic is the proportion 
of observed dispersion that is real rather than spurious, and it is expressed as a ratio with 
a range of 0 to 100%. As a general rule, suggested by Cochrane an I2 value of less than 
25% is considered low heterogeneity; I2 between 25 and 50% is moderate heterogeneity; 
and I2 greater than 50% is high heterogeneity.119 However, as Higgins and Thompson 
(2002) noted there is no universal rule for the definition for mild, moderate and severe 
heterogeneity and that these suggestions are tentative.120 So, care must be taken when 
concluding with I2 and one should also consider size and direction of the effect alongside 
the I2.120,121  
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Once quantified, we explored potential sources of heterogeneity using subgroup analysis 
and meta-regression. We defined several patient and study characteristics as potential 
relevant subgroups and covariates. These are described in the following section. 
 Subgroup Analysis 
As stated in the Cochrane handbook119, it is important to note that our first meta-analysis 
is broad, examining the effect size of all the interventions together. However, this is 
similar to computing an effect size with apples and oranges, as the treatments are all 
different, and so a subgroup analysis was planned for the 3 main classes. A subgroup 
analysis can reduce the power, but it allows us to draw a more satisfactory conclusion.   
Subgroup analysis was done by dividing the data into subgroups to indirectly identity if 
any heterogeneity was associated with any of the subgroups, or if there was positive 
change in logMAR due to any of the categories in the subgroup analysis. Because there 
were a limited number of studies in each subgroup, it was more appropriate to use a fixed 
effects model. Using a random effects model with subgroup analysis would yield poor 
precision, whereas the fixed effects model can be assumed to be accurate because the 
subgroups are expected to be homogenous.   
5.9.1.1 Subgroup Analysis: Type of Immunosuppressive Treatment 
To determine the individual effects of the different types of immunosuppressive 
treatment on logMAR, we assigned a value of 0 to 4 to each of the different types of 
treatment options, for analysis. The effects of individual treatment group on logMAR is 
important to understanding if a specific group had a more profound effect on logMAR, 
and ultimately on treating uveitis. The treatment types that were added were: 
antimetabolites (0), alkylating agents (1), T-lymphocytes inhibitors (2), steroid use only 
(3), or a combination of treatments (4).  
5.9.1.2 Subgroup Analysis: Type of Primary Location 
This analysis was used to determine the effects of the location of uveitis on logMAR. We 
assigned a value of 0 to 5 to each of the different types of location of uveitis options, for 
analysis. If there was a difference in the subgroups, it allowed us to draw conclusions 
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about which location responded better to immunosuppressive treatment. The different 
categories examined for the location of uveitis were: intermediate uveitis, posterior 
uveitis, panuveitis uveitis, not specified, or combination of the 2 or more of the locations 
in the study.  
5.9.1.3 Subgroup Analysis: Previous Treatment 
This analysis was used to determine whether any previous treatment that was 
administered to patients impacted the effectiveness the overall immunosuppressive 
treatment had on logMAR. We assigned a value of 0 to 2 to each of the different types of 
previous treatment options, for analysis. If there was a difference in the subgroups, it 
allowed us to draw conclusions about whether previous treatments affected the overall 
logMAR score (for better or worse) after patients were given the immunosuppressive 
treatment. The subgroups for previous treatments were: steroids only, not specified, or 
combination of steroids and immunosuppressive. 
5.9.1.4 Subgroup Analysis: Average Patient Age 
This analysis was used to determine if immunosuppressive treatment had differing effects 
on logMAR with regards to differences in the average age of patients. We assigned a 
value of 0 to 1 to each of the different types of age options, for analysis. If there was a 
difference in the subgroups, it allowed us to draw conclusions about which average age 
of patients was more positively affected by the treatment, if any. The subgroups for 
average age of patients were: either less than or equal to 18 years of average age (0), or 
greater than 18 (1). The reason we chose to stratify at 18 years of age is because pediatric 
uveitis and adult uveitis can be very different conditions, and thus evaluating whether a 
particular treatment is more effective in a younger or older age group is important. 
Once the subgroup analysis was complete, we were able to compare the results using (1) 
the Z-test, (2) a Q-test for heterogeneity. If there were more than 2 subgroups, the Z-test 
was not used, as it is only used when comparing 2 groups. Instead, a Q-test was used to 
test the hypothesis.  
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 Meta-regression 
As discussed in Chapter 4, a meta-regression allows us to assess the relationship between 
different covariates and effect size.  
In our study, most of the covariates were categories. In order to do this in Stata, dummy 
variables were coded and used for categorical univariate meta-regression, using the 
Knapp and Hartung (2003)107 method to take modifications to the variance into account, 
given our use of the random effects model. Thus, we used the t distribution instead of the 
normal distribution. In the Knapp and Hartung (2003)107 method of meta-regression, the 
restricted maximum likelihood is used to estimate the between-study component of 
variance. The restricted maximum likelihood was used over other methods, since it is 
allows for greater caution when extrapolating the results for future patients or studies.122 
This is because this method results in conservatively wide confidence interval of the 
estimated beta coefficient.123 We performed a t-test to assess the null hypothesis of no 
effect on logMAR for the different covariates discussed below. A p-value <0.05 (two-
tailed) was considered statistically significant. 
It is important to be aware of the issue of multiple comparisons, in which more than 2 
covariates are compared and we want to measure the significance of each covariate 
(where the actual alpha may exceed the normal alpha). There is not much consensus as to 
which method should be used when dealing with this issue. One way is to conduct a joint 
test for all covariates, and obtain a p-value for the overall model, which would assess 
whether there is evidence for an association of any of the covariates with the outcome. 
However, when a small p-value indicates that there is evidence of that nature, it is hard to 
know which and how many of the covariates are implicated. Recently, some other 
methods have been established to examine the multiple comparison problems. One such 
method is to conduct the permutation test, developed by Higgins and Thompson (2004), 
108 to calculate the p-values, as described above. This test allows us to adjust for false 
positive findings when there are multiple covariates or variables, by using random 
permutations and comparing each t-statistic for every covariate with the largest t-statistic 
for any covariate in each random permutation.  
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So, in addition to the meta-regression for each of the covariates, we created dummy 
variables, and a univariate random effects model using the Higgins and Thompson 
(2004)108 permutation test was done to account for multiple testing.  
The following covariates were used in the univariate random effects meta-regression to 
assess the impact of uveitis patients receiving immunosuppressive treatment on logMAR:  
1) Location of Study: Even though there is no evidence that the practice in North 
America is different from other continents and countries, a meta-regression on the 
location of study was still done. One category was North America; the other was 
any other location included in the study.  
2) Year of Publication: We abstracted the year the study was published. Even though 
there was no change in practice before or after 2005, we still conducted a meta-
regression. 2005 was chosen because that was the year the SUN classification was 
published, and we speculated that there could be a difference in the studies due to 
that publication. There were 2 categories, 1 for studies conducted after 2005 and 1 
for studies conducted before.  
3) Type of Study: Comparing studies that were observational to RCTs. This was to 
understand whether the type of study affects the quality of study, and a change in 
logMAR.  
4) Sex: We modelled sex distribution based on the percentage of females in the 
study population. 
5) Mean Age: Mean age was dichotomous, with patients divided into those younger 
than 18 and those equal to or older than 18.  
6) Location of Disease: There were 5 categories for location of disease: a) 
intermediate uveitis, b) posterior uveitis, c) panuveitis uveitis, d) not specified, or 
e) combination of the 2 or more of the locations in the study. 
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7) Previous Treatment: There were 3 categories for previous treatments given to 
patients: a) steroids only, b) not specified, or c) combination of steroids and 
immunosuppressives. 
8) Primary Treatment: There were 5 categories for the primary treatment given to 
patients: a) antimetabolites, b) alkylating agents, c) T-lymphocytes inhibitors, d) 
steroid use, or e) a combination of treatments. 
A permutation test with 5000 permutations on the covariates p-value was conducted to 
alleviate any false negatives that may have been present due to multiplicity.  
5.10 Publication Bias 
Publication bias could have a pronounced effect on the results of our study, as some 
studies could have been missed in our screening phases. This could result in less 
information, wider confidence intervals, and less powerful tests. There could be bias due 
to larger studies being included and smaller studies being excluded, because they are not 
as easy to find. One method to manage publication bias is to use random effects model, 
which ensures that all the studies are evenly weighted, but that does not take into account 
how much publication bias may exist or how the data would look if those studies were 
not missing. Other methods have been developed to determine if publication bias has in 
fact taken place, and some methods can even adjust for the bias. These methods use a 
funnel plot to identify any asymmetry. To determine whether the asymmetry is due to 
chance, there are tests, such as Begg and Mazumdar (1994)109 and Egger et al (1997).110 
However, these methods do not provide estimates of the number or characteristics of the 
missing studies, nor do they provide an estimate of the underlying (unbiased) effect.  
Duval and Tweedie (2000)111 developed the Trim and Fill method to estimate adjusted 
effect size, and that is what we used to assess publication bias in our study. The Trim and 
Fill method works by removing small studies (trimming), which yields a publication bias-
adjusted effect size. Because this trimming underestimates the variance, the studies are 
then added back with an imputing mirror study (filling), such that the funnel plots 
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become symmetrical and the variance is corrected. This allows us not only assess the 
presence of publication bias, but also to measure its impact on the observed effect size. 
5.11 Software  
For systematic review and meta-analysis, we used EPPI version 4.3 (EPPI Centre, 
Institute of Education, London, UK; 2013)124 as our reference management program, 
used for collection, sorting and screening. Statistical analysis was performed using 
STATA 13 (Stata Corp, Austin, TX USA). In STATA special codes were used to do the 
random effects meta-analysis (metan, with specification to use the random effects 
model). For the meta-regression using the Knapp and Hartung (2003)107 method, we used 
the metreg command. With the publication bias, the metatrim command was used.  
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Chapter 6  
6 Results 
6.1 Study Selection  
Upon completion of the database search, 2215 articles were included from the databases 
and grey literature. No articles were added after extensive snowballing and the grey 
literature search. After removing duplicate records, there were 1518 unique articles for 
level 1 screening. After level 1 screening was complete, 1248 articles were removed 
(kappa for the 2 independent reviewers was 0.89; 95% confidence interval 0.81 to 0.94). 
Most articles that were removed during level 1 screening were review articles (over 
>80% of the removed articles), biologic treatment (which are not relevant to the study 
question), animal studies and/or surgical procedures. The remaining 270 articles were 
considered for full article review (ie, level 2). 
After level 2, 45 articles satisfied the inclusion criteria (kappa for the 2 independent 
reviewers was 0.72; 95% confidence interval 0.65 to 0.79). The 225 excluded articles 
were removed for the following reasons: Not English (n=29), fewer than 5 patients 
(n=19), location of disease (n=20), not idiopathic uveitis (n=31), other diseases (n=54), 
not in humans (n=2), not oral treatment (n=17), not primary article (n=34), not the 
outcome considered (n=9), not the treatment considered or not specific enough (n=6), 
missing articles (n=4). All of the total 45 studies were used for descriptive outcomes, 
however, only 26 articles had sufficient data for the purpose of conducting a meta-
analysis. Figure 3 showcases the Prisma diagram that details the selection process. 
 
 
 
68 
 
 
 
Figure 3: Primsa Diagram 
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6.2 Treatment Categories 
Of the 45 studies that were included in the systematic review, the antimetabolites 
treatment group consisted of 23 studies, which broke down further to specific treatments, 
with 12 studies for MMF, followed by 9 studies for MTX, and 2 studies for AZA. All of 
these treatments were treating mostly idiopathic uveitis patients (77.6% of the patients 
from the studies specifically had idiopathic uveitis). Also, important to note most studies 
presented results on the patient level either with subjects or with eyes.  
Sixteen studies fell within the inhibitors of T-lymphocyte signalling treatment group, 
which broke down to 12 studies for CsA, 3 studies for TAC, and only 1 study that 
examined both TAC and CsA. Only 1 study used the alkylating agent, Chlorambucil.  
There were 2 studies that looked at multiple treatment groups; BenEzra et al examined 
Chlorambucil, AZA and CsA, while Dick et al examined CsA, or CsA plus AZA. There 
were 3 studies that examined various combined immunosuppressive treatments. This is 
summarized in Table 10. 
Table 10: Number of studies for each treatment category 
Treatment Class Treatment 
Antimetabolites (n=23) 
  
  
Azathioprine (n=2) 
Methotrexate (n=9) 
Mycophenolate Mofetil (n=12) 
Alkylating Agents (n=1) Chlorambucil (n=1) 
Inhibitors of t-lymphocyte signaling (n=16) 
  
Cyclosporine (n=12) 
Tacrolimus (n=3) 
Multiple Treatment Groups (n=2)  -- 
Combined Immunosuppressive Treatment (n=3) -- 
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 Inhibitors of T-lymphocyte signalling 
6.2.1.1 Cyclosporine A 
6.2.1.1.1 Study Characteristics 
Twelve studies reported solely on CsA. Seven studies were conducted in the USA, 2 in 
Canada, and 3 in the UK. Studies were conducted between 1979 and 2010. 
The study designs included: One study was an RCT, 7 studies were prospective cohort 
studies, 2 studies were retrospective cohort studies, and 2 studies were retrospective case 
series. The total sample size was 711. Study characteristics are summarized in Table 11 
on the following page.  
6.2.1.1.2 Study Size and Patient Characteristics 
Two studies included patients <16 years of age (Kilmartin et al (1998)125 had patients 
with an average age of 8.7, while Walton et al (1997)126 had patients aged around 12.9). 
In all the other studies, the mean age ranged from 34 to 49 years. Ten of 12 studies 
provided gender proportions ranging from 29-63% female. Reported follow up time 
ranged from 3 to 227 months, with 2 studies not reporting any follow up. Cause of uveitis 
was mainly uveitis with 7 of the 12 studies, where 100% of the patient’s uveitis was 
idiopathic in nature. Uveitis type was classified as intermediate in 4 studies, non-
classified in 3 studies, posterior in 2 studies, and mixed in the remaining studies. Six 
studies had steroid usage, 2 had steroid combined with immunosuppressive, 1 used 
immunosuppressive treatment exclusively, and 3 used no oral drugs. Table 12 presents a 
summary of the patient characteristics. 
6.2.1.1.3  Descriptive Outcomes 
Eight studies did not report how many patients experienced improvement to or 
maintained VA. Four studies mentioned frequency of patients that got better, of which, 
Walton et al showed 82.1% of patients improved or maintained VA, and Kilmartin et al 
(1998)125 showed that 92% of patients had improved or maintained VA. Leznoff et al 
(1992)127 reported only 20% of patients improving or maintaining VA, while Rocha et al 
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(1997)128 showed 43.75% of patients improving or maintaining VA. Three studies 
reported the frequency of patients that had maintained or improved inflammation grade. 
Kacmaz et al (2010)129 reported improvement in inflammation grade in 51.9% of patients 
overall, ranging from 45.5% to 58.5%. The second study reported that 76% of patients 
had maintained or improved inflammation grade, and the third study reported that 49% of 
patients had improved or maintained inflammation grade.  
6.2.1.1.4 Reason for Discontinuation and Adverse Events 
Four studies reported cases of treatment discontinuation due to intolerance (ie, side 
effects). In Palestine et al (1985)130, about 30% of patients had to discontinue due to 
intolerance. In Rosales (2011)131, 11% of patients had to discontinue because of 
intolerance. In Kacmaz (2010)129, renal toxicity was a cause of discontinuation in 4.3% of 
patients, while side effects in general were the cause of discontinuation in 11.1% of 
patients in Kilmartin et al (1998)125, and within the same study 11.1% of patients 
discontinued due to the treatment being ineffective.  
Nephrotoxicity was the primary adverse events mentioned in 2 studies. 80% of patients in 
1 study experienced nephrotoxicity, and 31.3% of patients experienced it in the other. 
Hypertension was the primary adverse event mentioned in 4 studies, ranging from 19-
80% of patients afflicted. Other adverse events included tremors (40%), increased 
creatinine levels (28%), and digestive intolerance in 38% of patients. Table 13 
summarizes the descriptive outcomes, including the adverse events. 
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Table 11: Cyclosporine A Treatment, Study Characteristics 
Citation Design Setting/Data 
source 
Accrual Period Sample 
Size 
Derary et al, 1992132 PCS France 1986 to 1990 16 
Isnard et al, 2002133 PCS France April 1986 to December 1997 41 
Leznoff et al, 1992127 PCS Canada 1987 18 
Rubin et al, 1993134 PCS USA -- 32 
Palestine et al, 1985130 PCS USA -- 60 
Rosales et al*, 2011131 RCS USA January 1992 to October 2010 -- 
Walton et al, 1997126 RCaseS USA 1983 to 1993 75 
Rocha et al, 1997128 PCS Canada August 1992 to January 1995 8 
Kacmaz et al, 2010129 RCS USA 1979 and 2007 62 
Kilmartin et al, 1998125 RcaseS UK -- 373 
Nussenblatt et al, 1985135 PCS USA -- 14 
Ramadan et al, 1996136 Double-masked, 
RCT 
USA -- 12 
Legend: RcaseS= retrospective case series, RCS= retrospective cohort study, PCS= Prospective cohort study *= 
abstract 
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Table 12:  Cyclosporine A Treatment, Patient Characteristics 
 
 
 
Citation Mean Age Age SD % Female Mean 
Follow-up 
(Mo.) 
Mean 
Follow-up 
SD 
Prim 
Cause 
% Location 
of disease 
% Previous 
Treatment 
Derary et al, 1992132 45.6 2.7 56 24 -- Idio 100 Int or Pos 100 Corticosteroids  
Isnard et al, 2002133 49 10 56 55.4 0.2 Idio 100 Pos 100 None 
Leznoff et al, 1992127 45 13.5 40 -- -- Idio 100 --  Prednisone 
Rubin et al, 1993134 33.8 -- 62.5 14 -- Idio 59.4 Pos, Int, 
and Pan 
46.9 Prednisone 
Palestine et al, 1985130 35 16.8 -- 3 -- Idio 100 Int 100 -- 
Rosales et al*, 2011131 42 19.7 54.7 226.8 -- NAU 100 -- -- -- 
Walton et al, 1997126 12.9 2.5 46.7 44.5 7.3 CU 100 Int 47 Prednisone 
Rocha et al, 1997128 39 14 62.5 16 10 Idio 75   Corticosteroids/ 
azathioprine 
resistant 
Kacmaz et al, 2010129 36.1 19 62.7 10.8 -- Idio 92.4 Pos or Int 45.8 Prednisone+ 
Immunosuppressive 
Kilmartin et al, 1998125 8.7 12.4 28.6 26.8 21.2 PP 55.7 Int 57.1 Systemic steroids 
Nussenblatt et al, 
1985135 
35 16 55.8 -- 2.3 Idio 50.4 Int 40.4 Immunomodulatory 
Ramadan et al, 
1996136 
35.7 11.2 -- 13.3 6.6 Idio 100 Pos 100 Corticosteroids  
Legend: SD= Standard Deviation, a= CsA with Ketoconazole, Idio= Idiopathic, NAU= Non-infectious autoimmune uveitis, CU= Chronic uveitis, PP= Pars Planitis, Pos= 
Posterior, Int= Intermediate, Pan= Panuveitis, *= Abstract 
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Table 13:  Cyclosporine A Treatment, Descriptive Outcomes 
Citation IMVA IMI Discontinuation 
Reason 
Prim. 
reason 
% Sec. reason  % Adverse events 
prim. 
% Adverse events 
sec. 
% 
Derary et al, 1992132 -- -- -- -- -- -- -- Nephrotoxic  80 Hypertension 80 
Isnard et al, 2002133 -- -- -- -- -- -- -- -- -- -- -- 
Leznoff et al, 1992127 20 -- -- -- -- -- -- Increased 
hypertension 
20 -- -- 
Rubin et al, 1993134 -- -- -- -- -- -- -- Renal toxicity  31.25 Hypertension 18.75 
Palestine et al, 
1985130 
-- 49 -- Intolerance 30 -- P Parasthesia -- Gastrointestinal 
distress 
-- 
Rosales et al*, 
2011131 
-- -- -- Intolerance 11 -- -- Digestive 
intolerance 
38 Increase of 
creatinine level 
28 
Walton et al, 1997126 82.1 -- -- -- -- -- -- Increases in 
serum creatinine 
53 Hyperplasia 40 
Rocha et al, 1997128 43.8 -- -- -- -- -- -- Tremor 0.4 -- -- 
Kacmaz et al, 2010129 -- 51.9  Side effects Renal 
toxicity 
4.3 Hypertension 3.2 -- -- -- 21 
Kilmartin et al, 
1998125 
92 76 -- Side effects 11.1 Ineffective 11.1 Hypertrichosis 29 Fatigue -- 
Nussenblatt et al, 
1985135 
-- -- -- -- -- -- -- -- -- -- -- 
Ramadan et al, 
1996136 
-- -- -- -- -- -- -- -- -- -- -- 
Legend: IMVA= Improving or maintaining Visual Acuity, IMI= Improving or maintaining Inflammation, Prim Reason= Primary, Sec= Secondary, %= Frequency of 
patients, *= Abstract 
 
 
75 
 
6.2.1.2  Tacrolimus 
6.2.1.2.1 Study Characteristics 
There were 3 studies that had administered TAC to patients as the main treatment. Two 
of these were conducted in the UK, while location was not specified in the other. The 
studies were conducted between 2004 and 2009. The designs of the 3 studies were as 
follow: 1 RCT, 1 retrospective case series, and 1 prospective cohort study. The RCT 
compared steroid and TAC usage to TAC with steroids. The total sample size was 61. 
Study characteristics are summarized in Table 14. 
6.2.1.2.2 Study Size and Patient Characteristics 
The mean age in the studies ranged from 38 to 40.6 years. The RCT with TAC and 
steroid use had an average age of 31.3 years. The gender proportions ranged from 50-
90.9% females. Only 1 study reported follow up time, which was 45 months. The cause 
of uveitis was idiopathic in 67% of the patients. Uveitis type was classified as 
intermediate in 1 study and posterior in the other 2 studies, where 1 reported all patients 
as posterior, and the other 37.1%. One study only had prior steroids usage, while another 
study had both prior steroids and CsA usage, and the last 1 had prior steroid and other 
immunosuppressive treatments. Patient characteristics are summarized in Table 15. 
6.2.1.2.3 Descriptive Outcomes 
Of the 3 studies, only Figueroa et al (2007)137 mentioned the percentage of patients who 
improved or maintained VA and inflammation grade. With 80.95% of patients improved 
or maintained VA and 54.5% of patients improved or maintained in inflammation grade. 
6.2.1.2.4 Reason for Discontinuation and Adverse Events 
With the RCT, TAC + steroids, treatment failure accounted for 50% of patients 
discontinuing the treatment, while with just TAC in the RCT, 100% of the patients had to 
discontinue.  
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Lack of efficacy was the cause of discontinuation for the other 2 studies, which 
accounted for 36.4% and 24.2% of patients having to discontinue the treatment, 
respectively.  
In the RCT, 12.5 % of the patient population experienced cramps, and 10.5% experienced 
tremors with TAC and steroids in the RCT. Tremors and headaches were the main 
adverse events in patients of the other 2 studies, with 72.7% of patients experiencing 
hand tremors in Figueroa et al. In addition, 54.5% of patients in Figueroa et al 
experienced headaches. Descriptive outcomes, including the adverse events, are 
summarized in Table 16. 
Table 14: Tacrolimus Treatment, Study Characteristics 
Citation Treatment Design Setting/Data source Accrual Period Sample Size 
Lee Richard et al, 
2012138 
Steroid + 
Tacrolimus 
RCT* UK May 2004 to 
January 2009 
19 
 Tacrolimus    16 
Figueroa et al, 2007137 Tacrolimus PCS -- November 2000 to 
November 2005 
15 
Hogan et al, 2007139 Tacrolimus RCS Bristol Eye Hospital, 
United Kingdom 
April 2000 and 
April 2004 
11 
Legend: RCT*= Randomized, controlled, phase 2b, open-label, dual-center no inferiority trial, PCS= Prospective 
Cohort Study, RCS= Retrospective Case Series 
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Table 15: Tacrolimus Treatment, Patient Characteristics 
Citation Treatment Mean 
Age 
Age 
SD 
%Female Mean 
Follow-up 
(Mo.) 
Mean 
Follow-up 
SD 
Prim. 
Cause 
% Location 
of 
disease 
% Previous Treatment 
Lee Richard et al, 
2012138 
Steroid + Tacrolimus 31.3 -- 52.6 -- -- Idio 63.2 Int 42 Prednisone 
 Tacrolimus 39.8 -- 50 -- -- Idio 68.9 Int 62.5 Prednisone 
Figueroa et al, 2007137 Tacrolimus 40.6 14.7 90.9 45 11.3 Idio 63.6 Pos 100 Pred+CsA 
Hogan et al, 2007139 Tacrolimus 38 13.8 72.5 -- -- Idio 70.96 Pos 37.1 Pred+ 
immunosuppressive 
Legend: Idio= Idiopathic, Pos= Posterior, Int= Intermediate, Pred = Prednisone, %= Frequency of patients  
 
Table 16: Tacrolimus Treatment, Descriptive Outcomes 
Citation Treatment IMVA IMI Reason for 
discontinuation 
Primary 
reason 
% Primary 
Adverse 
events  
% Secondary 
Adverse 
events  
% 
Lee Richard et al, 
2012138 
Steroid + Tacrolimus -- -- Treatment failure: 50% 
due to drug intolerance 
Intolerance 50 Cramp 12.5 Tremor 10.5 
 Tacrolimus -- -- Disease Failure: 100% due 
to disease reactivation  
Lack of efficacy  100 Cramp  12.5 Tremor 6.3 
Figueroa et al, 2007137 Tacrolimus 80.95 54.5 Efficacy Efficacy 36.4 Hand tremor 72.7 Headache 54.5 
Hogan et al, 2007139 Tacrolimus -- -- -- Efficacy 24.2 Tremor 8.06 Headache 6.45 
Legend: IMVA= Improving or maintaining Visual Acuity, IMI= Improving or maintaining Inflammation, %= Frequency of patients 
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6.2.1.3 Tacrolimus or Cyclosporine 
6.2.1.3.1 Study Characteristics 
One study compared TAC to CsA in a prospective RCT, which was conducted in the UK 
between 2001 and 2003. Study characteristics are summarized in Table 17. 
6.2.1.3.2 Study Size and Patient Characteristics 
In this study, 19 patients were administered TAC and 18 patients were administered CsA. 
The average age of the patients that were given TAC was 48 years, while the average age 
for patients that were given CsA was 38 years. 58% of female patients were given TAC 
and 56% of female patients were given CsA. The mean follow up for the TAC patients 
was 7 months, and it was 4 months for CsA patients. Idiopathic uveitis made up 53% of 
the patients that were given CSA, and 57% that were given TAC. All 3 locations were 
treated in this study. The previous treatment used in this study was steroids. Patient 
characteristics are summarized in Table 18. 
6.2.1.3.3 Descriptive Outcomes 
The post-VA was maintained or improved in 68% of the patients given TAC and in 67% 
of the patients given CsA. 
6.2.1.3.4 Reason for Discontinuation and Adverse Events 
No mention of discontinuation of treatment was discussed. However, adverse events were 
reported for both CsA and TAC. The main adverse events for patients treated with CsA 
were fatigue at 56%, and tremors, which occurred in 44% of patients. 37% of the patients 
given TAC had paresthesia, and 32% of patients developed tremors after being given 
TAC. Descriptive outcomes, including the adverse events, are summarized in Table 19. 
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Table 17: Tacrolimus or Cyclosporine A Treatment, Study Characteristics 
Citation Treatment Design Setting/Data source Accrual 
Period 
Sample Size 
Murphy et al, 2005140 Tac Prospective 
randomized 
trial 
United Kingdom (Bristol Eye 
Hospital [Bristol, England] and 
Aberdeen Royal Infirmary 
[Aberdeen, Scotland]) 
May 2001 and 
April 2003 
19 
 CsA    18 
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Table 18: Tacrolimus or Cyclosporine A Treatment, Patient Characteristics 
Citation Treatment Mean 
Age 
Age 
SD 
%Female Mean 
Follow-up 
(Mo.) 
Mean 
Follow-up  
SD 
Prim. 
Cause 
% Location of disease % % Previous 
Treatment 
Murphy et al, 
2005140 
TAC 48 4.8 58 7 3.5 Idio  57 Posterior, intermediate 
and panuveitis 
100 74 Prednisone 
 CsA 38 6 56 4 2.5 Idio  53 Posterior, intermediate 
and panuveitis 
100 78 Prednisone 
Legend: Idio= Idiopathic, Pos= Posterior, Int= Intermediate, Pred= Prednisnone 
 
Table 19: Tacrolimus or Cyclosporine A Treatment, Descriptive Outcomes 
Citation Treatment IMVA Primary Adverse 
event  
% Secondary Adverse 
events 
% 
Murphy et al, 
2005140 
TAC 68 Paraesthesia 37 Tremors 32 
 CsA 67 Fatigue 56 Tremors 44 
Legend: IMVA= Improving or maintaining Visual Acuity, %= Frequency of patients 
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 Antimetabolites 
6.2.2.1 Mycophenolate Mofetil 
6.2.2.1.1 Study Characteristics 
Studies that administered MMF for uveitis were conducted in Germany (n= 5), other 
parts of Europe (n=3), and the USA (n=4). The studies collected patient data from as 
early as 1995, and the latest data was collected at the end of 2007. Four studies did not 
provide an accrual period. The full paper could not be attained for 1 study (Capriotti et 
al18). Eight studies were retrospective case series, 3 were cohort studies, of which 2 
studies were prospective cohort studies and 1 was a retrospective cohort study. Study 
characteristics are summarized in Table 20. 
6.2.2.1.2 Study Size and Patient Characteristics 
The total sample size for the MMF studies was 607. The mean age of the patients that 
were given MMF across the studies ranged from 8 to 57.3 years. Most studies had a mean 
age in the 40s, while 1 study that looked at juvenile idiopathic patients had a mean age of 
8 years. In most studies, females accounted for about 50% of the patient population 
(ranging from 33% to 68.8%). Mean follow up time reported ranged from 21.4 months to 
69.7 months, with 1 study not reporting. One study considered patients with panuveitis, 
while the other 10 looked at idiopathic uveitis. There was an average of 73% of 
idiopathic uveitis patients. 
Uveitis type was classified as intermediate in 4 studies, as mixed posterior and 
intermediate in 1 study, and was non-classified in 2 studies. One study divided their 
patient population by location of disease, so they had patients with posterior uveitis (n= 
23), intermediate uveitis (n=53), and panuveitis (n=6). Five studies had prior steroid 
usage, 4 had steroid with immunosuppressive treatment and 1 used immunosuppressive 
treatment exclusively. Patient characteristics are summarized in Table 21. 
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6.2.2.1.3 Descriptive Outcomes 
One measure of effectiveness used was the frequency of patients for whom VA was 
improved or maintained. Ten studies demonstrated that MMF was effective in treating 
patients, with 76.3% to 94.7% of patients having maintained or improved VA, and with 2 
studies not reporting. Seven studies had improvement to inflammation grade, with a 
range of 60.9% to 94.2%, with 5 studies not reporting. 
6.2.2.1.4 Reason for Discontinuation and Adverse Events 
Five studies indicated that MMF was discontinued in 12-35% of patients due to lack of 
efficacy. Another 5 studies indicated that lack of efficacy was the most common adverse 
effect in patients with MMF use. The secondary adverse event that was quite common 
was fatigue. Descriptive outcomes, including the adverse events, are summarized in 
Table 22. 
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Table 20: Mycophenolate Mofetil Treatment, Study Characteristics 
Citation Treatment Design Setting/Data source Accrual Period Sample 
Size 
Capriotti et al, 
2005*141 
MMF RCaseS USA -- 41 
Bhat et al, 2009142 MMF RCaseS Massachusetts Eye 
Research and Surgery 
Institute 
2005 to 2007 7 
Neri et al, 2009143 MMF RCaseS The Eye Clinic of the 
Polytechnic University of 
Marche 
2003 to 2007 19 
Benson et al, 
2006144 
MMF RCaseS Bristol Eye Hospital’s 
Regional Ocular 
Inflammatory Service, 
United Kingdom 
2000 to 2006 
(consecutive 
100 patients) 
100 
Daniel et al, 
2010145 
MMF RCS USA 1995 to 2007 236 
Deuter et al, 
2009146 
Mycophenolate 
sodium 
RCaseS Germany -- 35 
Doycheva et al, 
2012147 
MMF RCaseS Germany -- 38 
Zierhut et al, 
2011148 
MMF RCaseS Germany -- 60 
Stuebiger et al, 
2007149 
MMF RCaseS Germany 2000 to 2005 17 
Forrester et al, 
1998150 
MMF RCS Aberdeen Royal Hospitals, 
Scotland 
-- 9 
Siepmann et al, 
2006151 
MMF PCS Germany Between 1998 
and 2003 
51 
 MMF PCS Germany Between 1998 
and 2003 
23 
 MMF PCS Germany Between 1998 
and 2003 
6 
Llinares-Tello et al, 
2004152 
MMF PCS USA -- 12 
Legend: RCaseS= Retrospective Case series, RCS= Retrospective Cohort Study, PCS= Prospective Cohort Study, 
*=abstract 
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Table 21: Mycophenolate Mofetil Treatment, Patient Characteristics 
Citation Treatment Mean 
Age 
Age 
SD 
%Female Mean 
Follow-up 
(Mo.) 
Mean 
Follow-up 
SD 
Prim. Cause % Location of 
disease 
% Previous Treatment 
Capriotti et al, 
2005*141 
MMF -- -- -- 26.8 -- Idio 100 --  Corticosteroids 
Bhat et al, 2009142 MMF 49 17.25 57 39.6 9.6 Panuveitis 100 --  Immunomodulatory 
Neri et al, 2009143 MMF 32.9 8.9 42.8 30 6 Idio 56.3 Int 21 Steroids, CsA, AZA, 
MTX 
Benson et al, 2006144 MMF 39 14.3 65 24 4.75 Idio 61 Pos and Int 71 Pred, CsA, AZA, MTX 
Daniel et al, 2010145 MMF 47.1 19.0 64 21.6 4.5 Idio 100 Int and Pos 51.7 Pred+ 
46.2% had prior 
immunosuppressive 
treatment 
Deuter et al, 2009146 MMF 42.7 14.5 62.8 68.8 9.6675 Idio 77.1 Int 66 Corticosteroids 
Doycheva et al, 
2012147 
MMF 42.42 17 68.8 69.7 61.5 Idio 71.1 Int 73.7 Corticosteroids 
Zierhut et al, 2011148 MMF 40 17.8 61.7 71 4.5 Idio 61.7 Int 68.3 Corticosteroids 
Stuebiger et al, 
2007149 
MMF 8 2.8 41.2 36 13.75 Idio 64.7 Int 58.8 Prednisolone 
Forrester et al, 1998150 MMF 39.5 -- 78.9 72.7 9 Idio 66.6 Not 
specified 
 Corticosteroids 
+CSa 
Siepmann et al, 
2006151 
MMF 40.1 12.3 49 -- 55.75 Idio 80.4 Int 25 -- 
  44.8 11 43.5 -- -- Idio 62.2 Pos 22 -- 
  57.3 8.5 33 -- -- Idio 50 Pan 6 -- 
Llinares-Tello et al, 
2004152 
MMF 40 16.5 42 21.4 3.5 Idio 67   Corticosteroids 
Legend: Idio= Idiopathic, Pos= Posterior, Int= Intermediate, Pan= Panuveitis, Pred= Prednisone, %= Frequency of patients 
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Table 22: Mycophenolate Mofetil Treatment, Descriptive Outcomes 
Citation Treatment IMVA IMI Primary 
Discontinuation 
reason 
% Secondary 
Discontinuation 
reason 
% Primary 
Adverse events  
% Secondary  
Adverse 
events 
% 
Capriotti et al, 
2005*141 
MMF 81.1 60.9 Intolerance 16 -- -- -- -- -- -- 
Bhat et al, 2009142 MMF 64.3 100 -- -- --   Leukopenia 43     
Neri et al, 2009143 MMF 94.7  -- -- -- --   Dyspepsia 31.6 Tiredness 26.3 
Benson et al, 2006144 MMF -- -- Gastrointestinal      Gastrointestinal  Headache  
Daniel et al, 2010145 MMF -- 73.1  
  
  
Side Effects 12 Ineffectiveness 9.7 Gastrointestinal -- -- -- 
Deuter et al, 2009146 Mycophenolate 
sodium 
92.3 94.2 -- -- -- -- Gastrointestinal 14.3 Fatigue 0.1 
Doycheva et al, 
2012147 
MMF 76.3 -- Herpes zoster 
dermatitis, kidney 
infection, and 
gastrointestinal 
8.9 -- -- Gastrointestinal  Fatigue   
Zierhut et al, 2011148 MMF 81.7 72 Efficacy 35 Inefficacy 20 Gastrointestinal 23.3 Muscle 
pain 
8.3 
Stuebiger et al, 
2007149 
MMF 76.5 82.3 -- -- -- -- Headache 23.5 Rash 11.8 
Forrester et al, 
1998150 
MMF 86.7 86.7 -- -- -- -- Myalgia 44.4 Fatigue 22.2 
Siepmann et al, 
2006151 
MMF 100 -- -- -- -- -- Gastrointestinal  Headache -- 
  100 -- -- -- -- -- -- -- -- -- 
  66.6 -- -- -- -- -- -- -- -- -- 
Llinares-Tello et al, 
2004152 
MMF 83 -- Therapeutic 
failure  
17     Diarrhoea 25 Agitation  25 
Legend: IMVA= Improving or maintaining Visual Acuity, IMI= Improving or maintaining Inflammation, %= Frequency of patients 
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6.2.2.2 Methotrexate 
6.2.2.2.1 Study Characteristics 
Of the studies that examined MTX, 7 studies were conducted in the USA, 1 study in 
Germany, and the other in Israel. The studies collected patient data from as early as 1986 
(Friling et al153), and the latest data was collected in Khan et al in 2008. The full paper 
could not be attained for 2 studies, Khan et al (2010)154 and Schmitt et al (1990)155 For 
these 2 studies we only had abstracts, however they contained the essential information. 
Seven studies were retrospective case series, whereas 1 study was a prospective 
randomized pilot study, and the other was randomized control trial, double-masked study. 
Study characteristics are summarized in Table 23.  
6.2.2.2.2 Study Size and Patient Characteristics 
The total sample size for the MMF studies was 691. Across the studies, the mean age of 
patients that were given MTX ranged from 16.7 to 49 years. Most studies had a mean age 
in the 40s, while 1 study that looked at juvenile idiopathic patients had a mean age of 
16.7 years. In all studies, females made up the majority of the patient population (ranging 
from 64% to 91%). Mean reported follow up time ranged from 3.9 to 164 months, with 2 
studies not reporting  
All studies included patients with idiopathic uveitis, with 1 study specifically looking at 
juvenile idiopathic uveitis, averaging at 78% of patients having idiopathic uveitis. Uveitis 
type was not specified in 5 of the studies, while intermediate, posterior, and mixed were 
each reported in 1 study. Seven studies had prior steroid usage, 1 had steroid with 
immunosuppressive treatment, and 1 did not specify prior treatment. Patient 
characteristics are summarized in Table 24. 
6.2.2.2.3 Descriptive Outcomes 
One measure of effectiveness used was the frequency of patients for who VA was 
improved or maintained. Five studies indicated that MTX was effective in treating 
patients, ranging from 76% to 100% of patients experiencing maintained or improved 
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VA, with 4 studies not reporting. The improvement or maintaining of inflammation grade 
was exhibited in 2 studies. Yu et al (2005)156 indicated that the inflammation grade for 
50% of patients had improved or maintained, while Dev et al (1999)157 indicated that the 
inflammation grade for 95% of patients had improved or maintained.   
6.2.2.2.4 Reason for Discontinuation and Adverse Events 
Five out of 10 studies indicated that MTX was discontinued in some patients due to lack 
of efficacy, with frequency ranging from 13% to 48% of patients. With one study having 
had patients discontinue treatment due to side effects. Five studies reported adverse 
events of MTX. Some patients experienced higher leukopenia (14% of patients), higher 
anemia (14%), mild increase in SGOT (13%), minimal increase in creatinine (7%), 
fatigue (19%), mild nausea (19%), and gastrointestinal issues (20%). Descriptive 
outcomes, including the adverse events, are summarized in Table 25.  
Table 23: Methotrexate Treatment, Study Characteristics 
Citation Treatment Design Setting/Data 
source 
Accrual Period Sample 
Size 
Baker et al, 2006158 Methotrexate Retrospective 
case series 
Casey Eye Institute 
(Portland, Oregon, 
USA) 
2003 107 
Foeldvari et al, 
2004159 
Methotrexate Retrospective 
case series 
Germany July 1, 2002 to 
December 31, 
2002 
467 
Friling et al, 2005153 Methotrexate Retrospective 
Case Series  
Israel 38 consecutive 
children between 
1986 to 2002 
15 
Khan et al*, 2010154 Methotrexate Retrospective 
Case Series 
USA 1997 to 2008 36 
Quinones et al, 
2010160 
Methotrexate Prospective 
Randomized Pilot 
Study 
USA -- . 
Schmitt et al*, 
1990155 
Methotrexate Retrospective 
Case Series 
USA -- 15 
Yu et al, 2005156 Methotrexate Retrospective 
Case Series 
Massachusetts Eye 
and Ear Infirmary, 
USA 
1981 and 2001 23 
Dev et al, 1999157 Methotrexate Retrospective 
non-comparative 
case series 
USA 1989 to 1997 11 
Foster et al, 2003161 Methotrexate 
+Placebo 
Randomized 
control trial, 
Double masked 
USA -- 10 
*abstract  
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Table 24: Methotrexate Treatment, Patient Characteristics 
Citation Treatment Mean 
Age 
Age 
SD 
%Female Mean 
Follow-up 
(Mo.) 
Mean 
Follow-up 
SD 
Prim. Cause % Location of 
Disease 
% Previous Treatment 
Baker et al, 
2006158 
MTX 49 17.6 70 164.3 -- Idio 58 -- -- Corticosteroids  + 
immunomodulatory 
Foeldvari et al, 
2004159 
MTX -- -- -- -- -- JIA 100 -- -- Corticosteroids  
Friling et al, 
2005153 
MTX -- -- 67 3.9 2.8 Idio 100 -- -- Prednisone 
Khan et al*, 
2010154 
MTX 43.5 14.25 64 -- -- Idio 53 Posterior, 
intermediate 
and 
panuveitis 
100 -- 
Quinones et al, 
2010160 
MTX 34.54 11.75 57 5.44 
1.2 
Idio 85.7 Intermediate 100 Corticosteroids 
Schmitt et al*, 
1990155 
MTX 47 12 80 9 
5.5 
idio 53.3 -- -- -- 
Yu et al, 2005156 MTX 16.7 10 91 7.3 2  JIA 100 -- -- Corticosteroids 
Dev et al, 1999157 MTX 38 11.5 81.8 <12 
months 
-- Panuveitis -- Posterior -- Corticosteroids 
(were resistant) 
Foster et al, 
2003161 
Methotrexa
te +Placebo 
45 -- 90 -- -- Idio 70 -- -- Methotrexate 
Legend: Idio= Idiopathic, JIA=  Juvenile idiopathic arthritis, Pos= Posterior, Int= Intermediate, Pan= Panuveitis, Pred= Prednisone, *abstract 
 
 
89 
 
Table 25: Methotrexate Treatment, Descriptive Outcomes 
Citation Treatment IMVA IMI Prim. Reason 
for discon. 
% Sec. reason 
for discon. 
% Primary 
Adverse events  
% Secondary 
Adverse events. 
% 
Baker et al, 2006158 MTX -- -- Lack of efficacy  36 Adverse 
events 
26 -- -- -- -- 
Foeldvari et al, 
2004159 
MTX 76 -- Lack of efficacy  16 -- -- -- -- -- -- 
Friling et al, 2005153 MTX 87 -- -- -- -- -- -- -- -- . 
Khan et al*, 2010154 MTX -- -- -- -- -- -- -- -- --  
Quinones et al, 
2010160 
MTX -- -- Lack of efficacy  44 . . Higher leukopenia  14 Higher anemia 14 
Schmitt et al*, 
1990155 
MTX -- -- Lack of efficacy  13 -- -- Mild increase in 
SGOT (2) 
13 A minimal 
increase in 
creatinine (1) 
7 
Yu et al, 2005156 MTX 86 50 Lack of efficacy  48 -- -- Fatigue 19 Mild nausea 19 
Dev et al, 1999157 MTX 90 95 Side effects -- -- -- Nausea 14 Cytopenia  
Foster et al, 2003161 Methotrexate 
+Placebo 
100 -- -- -- -- -- Gastrointestinal 0.2 -- -- 
Legend: IMVA= Improving or maintaining Visual Acuity, IMI= Improving or maintaining Inflammation, Prim Reason= Primary, Sec= Secondary, %= Frequency of 
patients, MTX= Methotrexate, discon= discontinuation *abstract 
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6.2.2.3 Azathioprine 
6.2.2.3.1 Study Characteristics 
Two studies used solely AZA, and both studies were conducted in the USA, between 
1977 and 2008. One study was a case series, while the other was a retrospective cohort 
study. Study characteristics are summarized in Table 26. 
6.2.2.3.2 Study Size and Patient Characteristics 
The total combined number of patients in both studies was 153. Across the studies, the 
mean age of patients that were given AZA ranged from 12.6 years to 50.6 years. 88% of 
the patients were female in the study with the juvenile patients, while 67.9% of patients 
were female in the second study. Reported mean follow-up time ranged from 7.67 
months to 84 months. Uveitis type was only classified in 1 study as mixed, while the 
other did not specify. One study had prior steroid usage, while the other had steroid with 
immunosuppressive treatment. Patient characteristics are summarized in Table 27. 
6.2.2.3.3 Descriptive Outcomes 
Only 1 of the studies reported on the frequency of patients for who VA was improved or 
maintained, which was about 83.3%. The other study was the only one that reported on 
inflammation grade, for which about 62.2% of patients had improved or maintained. 
6.2.2.3.4 Reason for Discontinuation and Adverse Events 
Pasadihika et al (2009)162 indicated that 24% of patients given AZA discontinued 
treatment due to side effects, while 15% of patients discontinued treatment due to lack of 
efficacy. Descriptive outcomes, including the adverse events, are summarized in Table 
28. 
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Table 26: Azathioprine Treatment, Study Characteristics 
Citation Treatment Design Setting/
Data 
source 
Accrual Period Sample 
Size 
Hemady et al, 1992163 Azathioprine Case Series USA January 1977 to 
September 1989 
8 
Pasadhika et al, 
2009162 
Azathioprine Retrospective cohort study USA 2005 to 2008 145 
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Table 27: Azathioprine Treatment, Patient Characteristics 
 
Table 28: Azathioprine Treatment, Descriptive Outcomes 
Citation Treatment IMVA IMI Primary 
reason for 
discon. 
% Secondary 
reason for 
discon. 
% Primary 
Adverse events  
% Secondary 
Adverse events  
% 
Hemady et al, 
1992163 
Azathioprine 83.333 -- -- -- -- -- Gastrointestinal  -- -- 
Pasadhika et al, 
2009162 
Azathioprine -- 62.2 (50.5 to 
74.0) 
Side Effects 24 Ineffectiveness 15 Gastrointestinal 9 Bone marrow 
suppression 
5 
Legend: IMVA= Improving or maintaining Visual Acuity, IMI= Improving or maintaining Inflammation, %= Frequency of patients, discon= discontinuation 
Citation Treatment Mean 
Age 
Age 
SD 
%Female Mean 
Follow-up 
(Mo.) 
Mean 
Follow-up 
SD 
Prim. 
Cause 
% Location of disease  % Previous Treatment 
Hemady et al, 
1992163 
Aza 12.6 5.2 88 84 28 JIA 100 -- -- Corticosteroids  
Pasadhika et al, 
2009162 
Aza 50.6 19.2 67.6 7.67 5.2 -- -- Posterior/Panuveitis
/Intermediate 
48.3 Corticosteroids+ 
40% prior 
immunosuppressive 
Legend: Prim.= Primary, % = Frequency of patients, JIA=  Juvenile idiopathic arthritis  
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 Alkylating Agents 
6.2.3.1 Chlorambucil 
6.2.3.1.1 Study Characteristics 
One study explored the use of Chlorambucil. It was a non-comparative interventional 
case series conducted in the USA, between 1987 and 2000. Study characteristics are 
summarized in Table 29. 
6.2.3.1.2 Study Size and Patient Characteristics 
There were 28 patients in the study, with a mean age of 28.8 years, and 92.8% female 
patients. The mean follow-up was 46 months. Juvenile rheumatoid arthritis patients with 
idiopathic uveitis accounted for 66% of the patients. Location of the disease in all 
patients was panuveitis. Patients had previously been treated with steroids, CsA, AZA, 
and/or MTX. Patient characteristics are summarized in Table 30. 
6.2.3.1.3 Descriptive Outcomes 
VA was maintained or improved in 82.1% of patients, and the inflammation grade 
maintained or improved in 67.9% of the patients. 
6.2.3.1.4 Reason for Discontinuation and Adverse Events 
Gastrointestinal intolerance and leukopenia accounted for AZA treatment being 
discontinued in 14.2% of patients. Descriptive outcomes, including adverse events, are 
summarized in Table 31. 
Table 29: Chlorambucil Treatment, Study Characteristics 
Citation Treatment Design Setting/Data source Accrual Period Sample 
Size 
Miserocchi et al, 
2002164 
Chlorambucil Non-comparative 
interventional case 
series 
Ocular 
Immunology and Uveitis 
Service of the 
Massachusetts Eye and 
Ear Infirmary 
1987 to 2000 28 
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Table 30: Chlorambucil Treatment, Patient Characteristics 
Citation Treatment Age Age 
SD 
%Female Mean 
Follow-up 
(Mo.) 
Mean 
Follow-up 
SD 
Primary Cause % Location of 
disease 
% Previous 
Treatment 
Miserocchi et 
al, 2002164 
Chlorambucil 28.75  16.3 92.8 46 40.5 Juvenile rheumatoid 
arthritis–associated 
uveitis 
55.7 Posterior/ 
Panuveitis/ 
Intermediate 
60.7 Pred, CsA, 
AZA, MTX 
 
Table 31: Chlorambucil Treatment, Descriptive Outcomes   
Citation Treatment IMVA IMI Reason for 
discontinuation 
Primary reason 
for discon. 
% Secondary 
reason  
for discon. 
% Primary 
Adverse events  
% Secondary 
Adverse 
events  
% 
Miserocchi 
et al, 
2002164 
Chlorambucil 82.1 67.9 Side effects Gastrointestinal 
intolerance 
7.1 Leukopenia 7.1 Gastrointestinal 7.1 Leukopenia 7.1 
Legend: IMVA= Improving or maintaining Visual Acuity, IMI= Improving or maintaining Inflammation, %= Frequency of patients, discon= discontinuation 
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 Studies with Multiple Treatments 
The majority of patients in the studies were idiopathic uveitis patients, with 3 studies 
having 100% of the patients being idiopathic in nature. Two studies included individual 
patients who were administered multiple treatments in the same study. The first, BenEzra 
(1990)165, was a retrospective case series conducted in Israel between 1979 and 1987. 
Three treatments were prescribed to patients: Chlorambucil (n=46), AZA (n=23), and 
CsA (n=24). The treatment administered to patients prior to Chlorambucil and AZA was 
corticosteroids; patients were given corticosteroids with AZA or Chlorambucil before 
they were given CsA. VA was maintained or improved in 83% of patients treated with 
Chlorambucil, in 50% of patients treated with AZA, and in 90% of patients treated with 
CsA. Inflammation grade was maintained or improved in 83% of patients treated with 
Chlorambucil. The study did not report any improvement to inflammation grade for 
patients treated with AZA and CsA. Lack of efficacy led to treatment discontinuation in 
23% of Chlorambucil-treated patients. 
The second study, Dick et al (1997)166, was a retrospective case series conducted in 
Scotland between 1992 and 1996. The first group contained 54 posterior uveitis patients 
with a mean age of 44.6 years. They were administered steroids and CsA. The second 
group contained 24 posterior uveitis patients with a mean age of 46.2 years. They were 
administered steroids, CsA and AZA. There were no outcomes reported, however, 
measurements of pre-treatment and post-treatment VA were reported in the meta-
analysis. Study and patient characteristics for multiple treatments are summarized in 
Tables 32 and 33, respectively, and descriptive outcomes, including adverse events, are 
summarized in Table 34. 
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Table 32: Multiple Treatments, Patient Characteristics 
Citation Treatment Design Setting/Data 
source 
Accrual Period Sample 
Size 
BenEzra, 
1990165 
Chlorambucil Retrospective 
Case series 
Israel 1979-1987 (patients 
followed for 2 years) 
46 
 AZA Retrospective 
Case series 
Israel 1979-1987 (patients 
followed for 2 years) 
23 
 CsA Retrospective 
Case series 
Israel 1979-1987 (patients 
followed for 2 years) 
24 
Dick et al, 
1997166 
Prednisone + 
Cyclosporine A 
Retrospective 
case series 
Scotland, Europe 1992 to 1996 54 
 Prednisone + 
Cyclosporine A + AZA 
Retrospective 
case series 
Scotland, Europe 1992 to 1996 24 
Legend: AZA= Azathioprine, CsA= Cyclosporine 
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Table 33: Multiple Treatments, Patient Characteristics 
Citation Treatment Mean 
Age 
Age 
SD 
%Female Mean 
Follow-up 
(Mo.) 
Mean 
Follow-up 
SD 
Primary 
Cause 
% Location 
of disease 
% Previous 
Treatment 
BenEzra, 
1990165 
Chlorambucil -- -- 34 8 4 Idiopathic 67 -- -- Corticosteroids  
 Azathioprine --  -- -- -- -- -- -- -- -- 
 Cyclosporine A -- -- -- -- -- -- -- -- -- -- 
Dick et al, 
1997166 
Prednisone + 
Cyclosporine A 
54 13.6 -- -- -- Idiopathic 100 Posterior -- Corticosteroids  
 Prednisone + 
Cyclosporine A +  
Azathioprine 
24 19.9 -- -- -- Idiopathic 100 Posterior -- Corticosteroids  
 
Table 34: Multiple Treatments, Descriptive Outcomes 
Citation Treatment Improved or maintained 
VA # 1 
Controlling intraocular 
inflammation # 1 
Primary reason 
for discon. 
% 
BenEzra, 
1990165 
Chlorambucil 83 83 Lack of efficacy  23 
 Azathioprine 50 -- -- -- 
 Cyclosporine A 92 -- -- -- 
Dick et al, 
1997166 
-- -- -- -- -- 
Legend: Discon= Discontinuation  
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 Studies With No Specification Regarding Which 
Immunosuppressive Was Used 
Three studies only mentioned that immunosuppressives were used as treatment, without 
specifying the exact treatment group. Two studies were a retrospective case series, 1 was 
a retrospective cohort study. Two studies were conducted in the USA between 1978 and 
2005. The total sample size across the 3 studies was 174. Two studies included the ages 
of the patients; 1 was conducted with JIA patients, so the mean age was 9 years, with a 
range of 1 to 17 years. The other was conducted with panuveitis uveitis patients, where 
the mean age was 45 years, with a range of 9 years to 80 years. Gender proportions 
ranged from 75.8-82% female. Only 1 study specified the uveitis location classification 
as panuveitis. Corticosteroids were used as prior treatment in all 3 studies. One study 
reported that VA was maintained or improved for 100% of patients. None of the studies 
reported on treatment discontinuation or adverse events. Study and patient characteristics 
for non-specific immunosuppressive treatments are summarized in Tables 35 and 36, 
respectively, and descriptive outcomes are summarized in Table 37. 
Table 35: Immunomodulators, Study Characteristics 
Citation Treatment Design Setting/Data source Accrual 
Period 
Sample 
Size 
Michel et al, 
2002167 
Immunomodulators Retrospective, 
non-comparative, 
interventional 
case series 
USA 
 
1978 to 2000 19 
Kump et al, 
2006169 
Immunomodulators Retrospective 
Case Series 
USA 1985 through 
2003 
89 
Throne et al, 
2006168 
Immunosuppressive 
drug therapy 
Retrospective 
Cohort Study 
Ocular Immunology 
at the Wilmer Eye 
Institute 
January 1984 
and June 2005 
66 
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Table 36: Immunomodulators, Patient Characteristics 
Citation Treatment Age Age 
SD 
%Female Mean 
Follow-up 
(Mo.) 
Mean 
Follow-up 
SD 
Primary Cause % Location of 
disease 
% Previous 
Treatment 
Michel et al, 
2002167 
Immunomodulators 9 4.5 82 35.52 -- Juvenile 
idiopathic 
arthritis  
53 -- -- -- 
Kump et al, 
2006168 
Immunosuppressive 
drug therapy 
45 17.8 75.8 -- -- Panuveitis 100 Panuveitis 100 Corticosteroids 
Throne et al, 
2006169 
Immunomodulators --  -- 78.9 72.7 55.8 Panuveitis 100 -- -- Corticosteroids 
 
Table 37: Immunomodulators, Descriptive Outcomes 
Citation Treatment Improved or 
maintained VA # 1 
Michel et al, 
2002167 
Immunomodulators -- 
Kump et al, 
2006168 
Immunosuppressive drug therapy -- 
Throne et al, 
2006169 
Immunomodulators 100 
100 
 
6.3 Risk of Bias within Studies 
The quality of the studies included in this systematic review was analyzed using a 
modified Downs and Black checklist. Of the 45 studies we looked at, only 41 were 
included in the assessment; the 4 excluded studies were abstracts. 
 Randomized Controlled Trials 
When we applied the modified Downs and Black checklist, the median score for the 
quality of the 5 RCT studies was 60%, with an interquartile range of 7%. The risk of bias 
in the RCTs is presented in Figure 4 on the following page.  
The RCT studies included additional questions specifically about randomization and 
blinding of patients. 
Only 2 of the 5 RCT studies did all of the following: randomized and blinded patients to 
the treatment, listed confounders, blinded those measuring the main outcome, and 
randomized intervention assignment that was concealed from the patients and staff until 
the recruitment was complete.  
Three studies had adequate adjustment for confounding in analysis; losses of patients to 
follow-up were not taken into account, and no power calculation was done. Of the 10 
reporting bias questions, 7 questions were answered yes in all 5 studies. The 3 questions 
pertaining to external validity were answered yes in all studies. Of the 7 internal validity 
bias questions, 1 question was answered yes for all studies, while 2 other questions were 
answered yes for only 3 studies. As for selection bias, only 1 of the 6 questions had a yes 
from all studies, and was poorly rated in the studies overall. 
 Observational Studies 
After using the checklist on the 37 observational studies, the median score for the quality 
of the studies was 48%, with an interquartile range of 5%. The risk of bias in the 
observational studies is presented in Figure 4.  
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Three questions from the internal validity section were removed, and 2 questions from 
the selection bias section were removed, as they pertained mainly to randomized trials. 
The principal confounders were clearly described in 10% of studies. Patients that were 
lost to follow-up were described in 12.5 % of studies. 15% of studies listed the 
probability values for the main outcomes, 5% indicated follow-up of patients was the 
same for all study participants, and 17.5% used appropriate statistical tests to assess the 
main outcomes.  
Of the 10 reporting bias questions, 7 questions were answered yes in >80% of studies. 
The 3 questions pertaining to external validity were answered with yes in >80% of 
studies. Of the 4 internal validity bias questions, 1 question was answered yes in >80% of 
studies. As for selection bias, only 1 of the 4 questions had a yes in 87.5% of studies.  
 
Figure 4: Risk of Bias and Internal/External Validity 
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6.4 Meta-analysis 
 Results of Individual Studies 
Majority of the patients were idiopathic uveitis patients, with posterior or intermediate 
uveitis, this can be seen with the data from the systematic review. As discussed in section 
5.5, VA was used as the primary outcome to measure efficacy. VA was measured using 
logMAR in some studies, while in other studies VA was converted to logMAR from 
other scales. Inflammation grade change was not reported among enough studies having a 
standardized scale for inflammation grade to allow for any meaningful conclusions. Table 
38 indicates the results from the 26 individual studies. 
For our study, we had independent subgroups within a study, which allowed them to be 
viewed as independent studies. Because of this, the count of studies went from 26 to 32. 
However, 6 studies had some missing data, either with pre- and post-logMAR, or pre- 
and post-logMAR standard deviation, thus it was extrapolated, and these studies are 
noted in bold print in Table 38.   
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Table 38: Results of Individual Studies: pre- and post-logMAR  
Study Year N  Prim Treatment Prev Age (year) Loc Pre-logMAR Pre-SD Post-logMAR Post-SD 
Friling R et al153 2005 15 MTX Steroids 10.5 Into 0.357 2.18 0.052 0.103 
Lee Richard et al138 2012 19 Steroid + Tac Steroids 32.3 Pos 0.57 2.18 0.561 2.42 
Lee Richard et al138 2012 16 Tac Steroids 41.8 Pos 0.57 2.18 0.579 2.245 
Murphy et al140 2005 19 tac Steroids 49 Pan 0.335 0.225 0.248 0.304 
Murphy et al140 2005 18 CsA Steroids 38 Pan 0.45 0.289 0.326 0.302 
Quinones et al160 2010 7 MTX Steroids 34.5 Int 0.57 2.18 0.514 2.292 
Rosales et al131 2011 75 CsA Steroids 42 NS 0.57 2.18 0.47 2.61 
Walton et al126 1998 15 CsA NS 12.9 Int 0.176 0.265 0.218 0.262 
Yu et al156 2005 23 MTX Steroids 16.7 NS 0.968 0.824 0.803 0.974 
Bhat et al142 2009 7 MMF Imm 49 Pan 0.52 0.72 0.43 0.77 
Dev et al157 1999 11 MTX Steroids 38 Pos 0.415 0.491 0.23 0.361 
Kump et al169 2006 89 Comb NS 5.7 NS 0.471 0.42 0.403 0.393 
Rocha et al128 1997 8 CsA Imm 39 Pan 1.19 0.97 1.04 1.02 
Neri et al143 2009 19 MMF Imm 32.9 Int 0.34 0.14 0.67 0.18 
Deuter et al146 2009 35 MMF Steroids 42.7 Comb 0.38 0.47 0.38 0.51 
Figueroa et al137 2007 11 Tac Imm 40.6 Pos 0.868 0.623 0.913 0.652 
Hogan et al139 2007 62 Tac Imm 38 Pos 0.297 0.322 0.233 0.319 
Kilmartin et al125 1998 14 CsA Steroids 8.7 Int 0.5688 0.561 0.405 0.539 
Miserochhi et al164 2002 28 Chlorambucil Imm 28.8 Comb 0.776 0.761 0.63 0.844 
Siepmann et al151 2006 51 MMF NS 40.1 Int 0.458 0.33 0.293 0.299 
Siepmann et al151 2006 23 MMF NS 44.8 Pos 0.545 0.352 0.465 0.39 
Siepmann et al151 2006 6 MMF NS 57.3 Pan 0.613 0.273 0.546 0.368 
Doycheva et al147 2012 38 MMF Steroids 42.4 Int 0.564 0.509 0.427 0.547 
Hemady et al163 1992 8 Aza Steroids 12.6 NS 0.834 0.664 0.551 0.527 
Dick et al166 1997 54 Steroids + CsA Steroids 45.6 Pos 0.593 0.68 0.549 0.654 
Dick et al166 1997 24 Steroids + CsA + AZA Steroids 47.2 Pos 0.489 0.624 0.615 0.683 
Ramadan et al136 1996 6 CsA Steroids 35.7 Pos 0.57 2.18 0.67 2.306 
Ramadan et al136 1996 6 CsA + Ketoconazole Imm 35.7 Pos 0.57 2.18 0.697 2.21 
Forrester et al150 1998 9 MMF Imm 39.5 NS 0.584 2.18 0.452 1.02 
Nussenblatt et al135 1985 52 CsA Imm 35 Int 0.824 0.47 0.571 0.455 
Stuebiger et al149 2007 17 MMF Steroids 8 Int 0.57 2.18 0.464 2.45 
Rubin et al134 1993 32 CsA Steroids 33.8 Comb 0.877 0.496 0.52 0.422 
*Pre- and post-logMAR and logMAR SD were used to calculate change in logMAR, and the change in SD in Stata and excel. The bolded studies were missing either 
logMAR SD (n=1) or pre-/post-logMAR (n=5); the highest SD for the missing SD and mean pre-/post-logMAR was used for missing pre/post data.  
Legend: Prim= Primary, Prev= Previous treatment, Loc= Location of disease, pre or post-logMAR= logMAR before or after primary treatment, SD= Standard deviation, 
MTX= Methotrexate, TAC= Tacrolimus, CsA= Cyclosporine, MMF= Mycophenolate Mofetil, Comb= Combination of treatments given at the same time/or patients with 
different locations, AZA= Azathioprine, Imm= Immunomodulatory, NS= not specified, int= Intermediate uveitis, pos= positive uveitis, pan= panuveitis 
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 Primary Analysis 
The summary of the results from the pooled meta-analysis and the subgroup analysis is 
shown in Table 39. Figure 5 below displays the forest plots of random effects pooled 
meta-analysis of the weighted mean difference in logMAR, where a negative change in 
logMAR is improvement in vision and positive change in logMAR is deteriorated vision. 
The studies with an asterisk (*) on them, are studies that have independent subgroups 
within the study. From the forest plot, it is also important to note that I+V means fixed 
effect model, whereas D+L means random effects model, and IMM means 
immunosuppressive treatments.  
Since 6 studies had missing pre- and post-SD data, we imputed SD by using the highest 
SD reported among the overall results. The total sample size was 817 patients across all 
32 analyzed studies. In the pooled random effects analyses, the immunosuppressive 
treatment was significantly associated with a decrease in change in logMAR (WMD -
0.107 with 95% CI of -0.152 to -0.061, p= 0) and the I2 was 0%, p=0.987. Of note, 25 
studies (78.3%) reported that immunosuppressive treatment reduced logMAR.  
 Sensitivity Analysis 
Out of the 26 studies, 6 had extrapolated data, so they were removed to conduct a 
sensitivity analysis. From the overall total of 32 studies, 8 studies were removed because 
they did not have the pre-/post-VA or SD, leaving only 24 studies in the sensitivity 
analysis. The adjusted WMD was similar to the WMD from the original pooled data that 
included the 8 studies (WMD -0.107 with 95% CI of -0.155 to -0.062, p=0). The I^2 of 
the sensitivity analysis was 0% as well. This can be seen in Figure 6 below.  
 Subgroup Analysis 
6.4.4.1 Subgroup Analysis by Age 
Ten studies included patients with a mean age younger than 18 years. Twenty-two studies 
included patients that were older than or equal to 18 years old. For patients older than or 
equal to 18 years old, immunosuppressive treatment had a positive statistically significant 
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impact on logMAR, with vision improving by -0.147 logMAR (WMD -0.147, 95% CI -
0.208 to -0.097, p=0, I2=0%, p=0.990). For patients younger than 18 years, there was a 
slight increase in logMAR, but it was not significant (WMD -0.052, 95% CI -0.122 to 
0.015, p=0.128 and I2=76.5% p=0.954). This can been seen in Figure 7. 
6.4.4.2 Subgroup Analysis by Location 
Nine studies containing intermediate uveitis patients indicated that patients had improved 
vision, with a WMD of -0.146 logMAR, which was statistically significant (95% CI -
0.226 to -0.0666, p=0, I2=0%, p=0.677). Ten studies containing posterior uveitis patients 
had a WMD of -0.069, which was not significant (95% confidence interval -0.15 to 0.01 
p=0.191, I2=0% p=0.996). Five studies containing patients with panuveitis had a WMD 
of -0.10, p=0.098 (95% CI - 0.22 to 0.018, I2=0%). Three studies included a combination 
of all 3 locations, and the patients that had uveitis in 1 of the 3 locations experienced 
improved vision, with a WMD of -0.172 and a p-value of 0.021 (95% CI -0.419 to 0.074, 
I2= 57.9% p= 0.093). It should be noted that the p-value for the z-score was calculated 
using the fixed effects model. Since there was heterogeneity present in this subgroup, the 
random effects model was used to test the significance of the results, because it takes into 
account the between-study variance. The random effects model had a broader CI, which 
was not statistically significant. Finally, there were 3 studies that did not specify the 
location of uveitis; they had a WMD of -0.081 (95% CI -0.192 to 0.031 p=0.157, I2=0%). 
Heterogeneity was found in 1 of the 5 categories, which was the combination of 
locations, which showed an I2 measure of 57.8%, but it was not significant. This can been 
seen in Figure 8. 
6.4.4.3 Subgroup Analysis by Treatment 
Fourteen studies that used antimetabolites as the primary treatment indicated that patients 
had a statistically significant improvement in vision, with a WMD of -0.131 change in 
logMAR, p=0.001 (95% CI -0.211 to -0.050, I2=0%). Fifteen studies where patients were 
given T-cell inhibitors as the primary treatment showed a statistically significant 
improvement in vision, with a WMD of -0.109, p=0.001 (95% CI -0.172 to -0.045, 
I2=0%, p=0.680). In one study, in which patients were given an alkylating agent, the 
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WMD was -0.146, p=0.497 (95% CI -0.567 to 0.275). Two studies, where patients were 
given a combination of various immunosuppressive treatments had a WMD of -0.050, 
p=0.497 (95% CI -0.163 to 0.064, 0% p=0.328). This can been seen in Figure 9. 
6.4.4.4 Subgroup Analysis by Previous Treatment 
All 3 categories: steroids, not specified, and a combination of steroids and 
immunomodulatory treatment demonstrated a statistically significant improvement in 
vision after primary treatment was given. However, there was no heterogeneity in any of 
the categories. Fifteen studies that had given only steroids as the previous treatment had a 
WMD of -0.120, p=0.002 (95% CI -0.198 to -0.042, I2=0%). Five studies within 
unspecified previous treatments had a WMD of -0.100, p=0.018 (95% CI -0.157 to -
0.018, I2=0%), while the treatments with steroids plus various immunosuppressive 
treatment had a WMD of -0.120, p=0.008 (95% CI -0.209 to -0.031, I2=0%). This can 
been seen in Figure 10. 
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Figure 5: Pooled random effects (D+L) Meta-analysis of change in logMAR for idiopathic uveitis patients given 
immunosuppressive treatments (IMM) 
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Figure 6: Sensitivity Analysis (Removal of 6 studies): pooled random effects (D+L) meta-analysis of change in logMAR 
for idiopathic uveitis patients given immunosuppressive treatments (IMM) 
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Figure 7: Fixed effects (I+V) subgroup analysis by age examining the change in logMAR for idiopathic uveitis patients 
given immunosuppressive treatments (IMM)  
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Figure 8: Fixed effects (I+V) subgroup analysis by location of disease examining the change in logMAR for idiopathic 
uveitis patients given immunosuppressive treatments (IMM) 
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Figure 9: Fixed effects (I+V) subgroup analysis examining the change in logMAR for idiopathic uveitis patients given 
the different immunosuppressive treatment (IMM) classes 
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Figure 10: Fixed effects (I+V) subgroup analysis by previous treatments examining the change in LogMAR for 
idiopathic uveitis patients given immunosuppressive treatments (IMM)   
113 
 
Table 39: Summary of Pooled Meta-analysis and Subgroup Analysis examining the change in logMAR for treating 
idiopathic patients with immunosuppressive treatments   
Meta-analysis on: Subgroup Number of 
Studies* 
WMD  
(95% CI) 
Significance test of WMD = 0 
(p-value) 
Test of heterogeneity, I^2 
(p-value) 
Pooled -- 32 -0.107  
(-0.152 to -0.061) 
z= 4.61 
(p=0.0) 
0% (p= 0.987) 
Sensitivity  -- 24 -0.107 
 (-0.153 to -0.062) 
z= 4.61 
 (p= 0.0) 
0% (p=0.854) 
Age Greater than or equal to 18 22 -0.147  
(-0.208 to -0.087) 
z=4.79  
(p=0.0) 
0% (p=0.990) 
 Less than 18 10 -0.053  
(-0.122 to 0.015) 
z=1.52  
(p=0.128) 
0% (p=0.954) 
Previous Treatment Immunmodulatory 9 -0.120  
(-0.209 to -0.031) 
z=2.64 
(p=0.008) 
0% (p=0.859) 
 Steroids 15 -0.120  
(-0.198 to -0.042) 
z= 3.03  
(p=0.002) 
0% (p=0.962) 
 Not Specified 5 -0.087  
(-0.157 to -0.015) 
z=2.37  
(p=0.018) 
0% (p=0.482) 
Location of Disease Panuveitis 5 -0.100  
(--0.218 to 0.018) 
z= 1.65 
(p=0.098) 
0% (p=0.998) 
 Combination of Locations 3 -0.172  
(-0.419 to 0.074) 
z=2.31 
(p=0.021) 
57.9% (p=0.093) 
 Posterior Uveitis 10 -0.057  
(-0.143 to 0.029) 
z=1.31 
(p=0.191) 
0% (p=0.996) 
 
 Intermediate Uveitis  9 -0.146  
(-0.226 to -0.066) 
z=3.57  
(p=0.0) 
0% (p=0.677) 
 Not Specified 3 -0.081 
(0.194 to 0.031) 
z=1.42  
(p=0.157) 
0% (p=0.962) 
Primary Treatment 
Class 
Anti-Metabolites  14 -0.131 
 (-0.211 to -0.050) 
z= 3.18 (p=0.001) 0% (p=0.999) 
 T-cell Inhibitors 15 -0.109  
(-0.172 to -0.045) 
z= 3.36 (p=0.001) 0% (p=0.680) 
 Combination of Treatments 2 -0.050  
(-0.163 to 0.064)  
z= 0.86 (p=0.392) 0% (p=0.328) 
 Alkylating Agents 1 -0.146  
(-0.567 to 0.275) 
z=0.68 (p=0.497) --(only 1 study) 
Legend: WMD= Weight Mean Difference, *Number of studies including the independent subgroups in some studies (n=32) 
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 Meta-regression 
Even though there was no heterogeneity found in the pooled analysis, meta-regression 
was still undertaken, as it was predefined on the onset of the study. There were 8 
univariate random effect meta-regressions that we conducted.  Furthermore, since there 
was heterogeneity found, which was found to be not significant, it was wise to have 
undertaken a meta-regression. As seen in Table 40 below, none of the pre-specified 
covariates were found to be significant and no heterogeneity was found in any of the 
covariates (as can be seen with the 0% I2 value).  
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Table 40: Results from fitting 8 random effect univariate meta-regression models 
that examined the effects of covariates on treatment effectiveness measure, logMAR 
Meta-
regression on: 
Covariate Regression 
Coefficients  
(95% CI) 
P-
value 
Joint 
P-
value  
I^2 Adjusted 
R^2 
T2 
Location of 
Study 
North America (1) vs. 
Other (0) 
-0.0410 
(-0.145 to 0.0627) 
0.426 -- 0% .% 0.0067 
Year of study  After 2005 (1) vs. 
before or on 2005 (0) 
0.0389 
(-0.0578 to 0.136) 
0.364 -- 0% .% 0 
Type of Study  Observational (1) vs. 
RCT (0) 
0.0373 
(-1.36 to 0.210) 
0.663 -- 0% .% 0 
%Female %Female Distribution 0.000667 
(-0.0285 to 
0.00418) 
0.700 -- 0% .% 0 
Mean Age Greater than or equal 
to 18 (1) vs. 
Less than 18 years old 
(0) 
-0.0941 
(-0.189 to 0.0132) 
0.053 -- 0% .% 0 
Previous 
Treatment 
   0.751 0% .% 0.00139 
 Immunmodulatory* -- -- -- -- -- -- 
 Steroids 0.00658  
(-.129 to 0.142) 
0.922  0% --  
 Not Specified 0.0436  
(-0.0916 to 0.180) 
0.515  0% --  
Location of 
Disease 
   0.531 0% .% 0 
 Panuveitis 0.0774 
(-0.1223 to 0.278) 
0.435  0% --  
 Combination of 
Locations* 
-- -- -- -- -- -- 
 Posterior Uveitis 0.120  
(-0.0615 to 0.301) 
0.187  0% --  
 Intermediate Uveitis  0.0957  
(-.101 to .292) 
0.722  0% --  
 Not Specified 0.0957  
(-0.101 to 0.292) 
0.327  0% --  
Primary 
Treatment 
   0.744 0% .% 0.000621 
 Anti-Metabolites  0.0957  
(-0.2371 to 0.724) 
0.285  0%   
 T-cell Inhibitors -0.630 
(-0.208 to 0.0821) 
0.381  0%   
 Combination of 
Treatments* 
-- -- -- -- -- -- 
 Alkylating Agents -0.987  
(-0.560 to 0.361) 
0.664  0% -- -- 
*Not included due to collinearity  
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 Publication Bias 
Publication bias was assessed using Duval and Tweedie’s trim and fill method. Once the 
algorithm was complete there was no trimming to be done, however, there was 1 study 
that was filled in, which can be seen in Figure 11 in the study that has a square around it. 
This indicates that a study was added to make the funnel plot symmetrical and less 
biased.   
 
Figure 11: Publication bias, with Duval and Tweedie (2000)111 Method: Funnel plot 
with pseudo 95% confidence limits 
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Chapter 7  
7 Discussion 
7.1 Systematic Review 
This study is unique in that it is the first systematic review and meta-analysis conducted 
on immunosuppressive treatments given to non-infectious idiopathic uveitis patients 
(averaging 78% of the patients having idiopathic uveitis with all the studies combined). 
There were 2251 citations screened using the inclusion/exclusion criteria. The 45 studies 
included in the systematic review were found to have moderate quality of evidence 
according to the Downs and Black checklist. The 45 studies were divided into different 
immunosuppressive treatment groups. 
Also, most studies were done on the subjects that analyzed both eyes of each patient 
rather than each eye individually. Issues with measuring per eye could lead to 
discrepancies and heterogeneity, if they do not correlate the outcome between eyes. 
Recently, Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group (2015)97 
was very careful to make this distinction accounting for the likely correlation in 
responses between eyes from subjects with disease in both eyes. This distinction needs to 
be there or else it could lead to heterogeneity if not accounted for.  
The patient and study characteristics were very similar among the various 
immunosuppressive treatment groups, with the antimetabolites having the greatest 
number of studies (23) and a sample size comprising of 1451 patients. The treatment 
group with the second greatest number was the inhibitors of T-lymphocyte signalling, 
with 15 studies and 772 patients. Given their similarity in size, these 2 treatment groups 
could be compared fairly but are limited to descriptive statistics as no statistical inference 
was carried out. The year, the type, and the location of where the studies were conducted 
were similar across the different treatment groups. In most treatment groups the 
frequency of patients that had idiopathic uveitis were similar along with factors such as 
age. In most studies, location of uveitis in patients was almost evenly divided between 
posterior uveitis and intermediate uveitis, and majority were idiopathic in nature. This 
118 
 
enabled a systematic review to focus on studies that were specific to our question, and 
allowed for as much homogeneity that could be facilitated with the data available.  
The antimetabolite treatment group showed the most positive effect on VA: in 5 studies 
with MTX, VA improved or maintained in 88% of the patients with a sample size of 526 
patients, while in 10 studies with 271 patients given MMF, VA improved or maintained 
in 85.5% of patients. In 4 studies with 474 patients given CsA, which belonged to the 
inhibitors of T-cell signalling treatment group, VA improved or maintained in 59.5% of 
the patient population. In 1 study, 81% of patients who received TAC, another treatment 
belonging to the same treatment group, improved or maintained VA. These findings 
suggest that MTX and MMF, which belong to the antimetabolite treatment group, are the 
most effective in treating uveitis patients 
Inflammation grade, which is a more direct measure of improvement from uveitis, also 
maintained or improved with antimetabolite treatment, with MTX having a positive effect 
on 72.5% of the patient population in 2 studies, and MMF on 77.5% of the patient 
population in 7 studies. However, the frequencies presented cannot be used as the sole 
means to detect efficacy, as a more analytical approach should be used to assess efficacy 
of the different treatment groups. But, in past narrative reviews, due to the heterogeneity 
in patient types and outcomes measures, no real comparison was ever done. While our 
systematic review of smaller patient groups and different treatments allows these values 
to be compared descriptively, definitive conclusions are difficult to make. 
Discontinuation rates were low for both MTX and MMF, with lack of efficacy as the 
main reason for the treatments being discontinued. MTX contained 6 studies, with 13% 
to 48% of patients discontinuing treatment, while the 5 MMF studies indicated that 12% 
to 35% of patients discontinued treatment. CsA was discontinued mainly due to 
intolerance and side effects (specifically renal toxicity). This accounted for 11% to 30% 
of patients discontinuing in the 5 studies that used CsA. The RCT with TAC indicated 
that treatment failure lead to discontinuation of treatment in 50% of patients. Lack of 
efficacy was another reason some of the patients that were given TAC were removed 
from the study. MTX and MMF caused mild adverse events in about 14% of patients, 
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while CsA and TAC had a greater number of patients for whom adverse events could be 
harmful, such as renal toxicity. This corresponds with many studies that suggest CsA can 
cause severe side effects, and larger doses of CsA can be more harmful to patients.  
7.2 Quality Assessment  
The quality of the studies was examined using the Downs and Black checklist, which 
indicated that there were some low quality papers present (10%). However, the majority 
of the papers were of moderate quality. All studies were included in the meta-analysis 
and systematic review. The systematic review also indicated that many of the studies 
were not of high quality, as evident from the literature search of the systematic review.  
The methodological quality of included studies in the meta-analysis was at least 
moderate. As discussed in section 5.6, the median score of observational studies being 
48%, indicated that the quality of the studies were “poor to moderate”. However, the 
internal validity of the observational studies was very poor, with 19% of studies having 
scored a “yes” in the validity section. This suggests that there is a bias in intervention 
measures for the primary outcome. This was either due to the fact that the analysis related 
to the measure of choice for the VA scale or alternatively, how they analyzed the 
patients’ data, such as per eye or subject level. This could indicate that there was in fact 
heterogeneity related to our meta-analysis, when comparing intervention groups and the 
outcomes. However, most of these validity questions were specific to randomized control 
trials, and having case series and cohort studies could limit how interventions are dealt 
with and measured, but does not mean that it would cause major discrepancies that would 
hinder our results.  
 A meta-regression of the types of studies were compared (RCTs and observational 
studies), and although nothing significant was found, there was a slight difference 
between the change in logMAR between the 2 groups, with RCTs demonstrating a more 
positive effect on logMAR post-treatment. However, it is important to note that there was 
no heterogeneity between the 2 groups (12= 0%). This further strengthened our 
confidence in the results. 
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7.3 Meta-analysis and Subgroup Analysis  
There were 26 studies included in the meta-analysis, dealing with change in logMAR, 
once idiopathic uveitis patients are given immunosuppressive treatments. Of these, 5 
studies did not include either pre-treatment or post-treatment logMAR, but did include 
the change in logMAR, which was added postoperatively by using the mean pre-logMAR 
calculated by the 20 studies that were present in the meta-analysis. Also, the pre- and 
post-SD was missing from 1 study, so we had to use the highest SD given in 1 of the 26 
studies, which allowed for a conservative value for the missing SD. The studies with 
missing pre- and post- data did in fact demonstrate a change in logMAR and the 
respective SD, so we did not make up values, but used the information provided and 
extrapolated the data, which is advised when partial data is missing.  
Some of the studies had independent subgroups (ie, 1 study included a subset of patients 
treated with antimetabolites and another subset of patients treated with T-cell inhibitors), 
which were included as individual studies, increasing the total study count to 32 studies. 
From these 32 studies, 78.3% indicated a reduced logMAR (improved vision) when 
patients were given immunosuppressive treatments. Using the weighted mean difference 
in the overall use of treatment of any kind indicated a reduction in logMAR of -0.11, 
which was significant (p=0). This suggests that there was an improvement in vision with 
a change in 1.5 lines or -0.11 logMAR. Generally speaking a clinically relevant change 
in vision may be described as 2 lines or -0.2 logMAR.   
The sensitivity analysis, when the studies with missing data were removed and the 
analysis was run again on only 24 studies, supported these results as well. Even with the 
removal of those studies, there was no difference in the overall effect, which was still 
significant. There was also no difference in heterogeneity. These results support results 
found in the existing literature, which indicate that immunosuppressive treatments are 
effective in treating patients with inflammatory eye disease.  
While our results indicated there was no heterogeneity, it was not significant. To better 
understand this, we conducted a subgroup and meta-regression to verify that 
heterogeneity was not present and to evaluate whether any of the subgroup categories 
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were more positively or negatively affected by the immunosuppressive treatment (for 
example, did treatment affect different age groups differently, or did location of the 
disease have an impact on effect size).  
The results from the subgroup analysis for age indicated that individuals greater than or 
equal to 18 years of age were affected more positively by the treatment than patients 
under 18 years of age. Patients in the former group also demonstrated a statistically 
significant change in logMAR of -0.147 with a p-value of 0. The heterogeneity in patients 
greater than 18 years was 0%, which indicates that the different treatment groups had a 
similar effect on this patient subgroup. This suggests that any immunosuppressive 
treatment is likely to be effective for patients older than 18 years, and that the results are 
statistically significant. In contrast, even though patients younger than 18 years 
experienced improvement in vision, the improvement was not statistically significant. In 
this thesis, 10 of the studies we examined contained patients below 18 years of age. Six 
studies used antimetabolites, and they indicated that antimetabolites may not be 
appropriate for patients younger than 18 years. (Most of these patients were JIA with 
uveitis, and some were uveitis patients with no JIA involved, which could also explain 
the non-significance).  
Results from the subgroup analysis of previous treatment given to patients was also 
important, as patients that were given just steroids before receiving the treatment of 
choice had a statistically significant positive change in logMAR (WMD= -0.120, p=0.002 
with I^2=0%). This was also seen in patients given steroids and other immunosuppressive 
treatments before receiving the treatment of choice (WMD= -0.120 p=0.008). 
Furthermore, studies that did not specify also showed a statistically significant positive 
change. This could be explained by the fact that no matter which treatment they were 
previously given, what mattered at the end was the impact the primary treatment had on 
patients.  
Subgroup analysis by location indicated that the only category that contains heterogeneity 
is the combination of locations patient group (I^2=57.9%, p=0.093). This could be 
explained by the fact that there were 3 different groups of patients within a study, and 
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since there were only 3 studies in the subgroup, it could have resulted in the 
heterogeneity seen in the subgroup analysis. Also, interestingly, intermediate uveitis was 
shown to be the group most effectively treated by immunosuppressive treatment, and it 
was statistically significant (WMD= -0.146. p=0). This means that patients with 
intermediate uveitis have a better chance of responding to treatment from any of the 
treatment groups, more so than the other 2 locations. However, as is noted in Figure 8, 
there were 6 studies where intermediate uveitis patients were given antimetabolites, 
whereas patients with posterior uveitis were mainly given T-cell inhibitors. This suggests 
that antimetabolite treatment may play a role in why intermediate uveitis patients 
demonstrated a greater change in logMAR, and thus improvements in vision, or it may 
suggest that it is easier to treat patients with intermediate uveitis than those with posterior 
uveitis.  
Subgroup analysis by treatment found that patients given antimetabolites were more 
positively (WMD= -0.131, p=0.001) treated then patients given inhibitors of T-cell 
signalling (WMD= -0.109, p=001). This finding is similar to descriptive outcomes found 
in the systematic review with frequencies, which indicated that antimetabolites are more 
effective in maintaining or improving VA in patients. However, comparing the pre- and 
post-logMAR treatment is a more accurate measure of the number of patients who got 
better after treatment was administered. This supports the subgroup analysis of location 
of disease discussed above, as intermediate uveitis patients also responded positively 
when treated with immunosuppressive treatments, and since they were given 
antimetabolites, it seems fair to conclude that antimetabolites were more effective overall 
than other treatments. However, it is interesting to note that both subgroup treatment 
groups experienced a statistically significant positive effect on vision. This suggests that 
being given either of the 2 treatments is beneficial to patients, with antimetabolites 
having a slight advantage in treating patients, especially those with intermediate uveitis. 
Since the other 2 treatment groups only contained 1 to 2 studies, it is not fair to compare 
those groups.  
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7.4 Meta-regression 
With the meta-regression, although there was no heterogeneity to begin with, some doubt 
remained because it was not statistically significant in the pooled meta-analysis. After 
running the meta-regression, none of the covariates were found to be associated with 
change in logMAR. Furthermore, there was no heterogeneity found in the regression 
models with all the covariates. We also determined joint p-values, as the meta-regression 
was done with multiple categories with a covariate, for example, primary treatment had a 
joint p-value of 0.744, which indicates that there is very little evidence the change in 
logMAR differs among the 4 categories. The same conclusion can be drawn for all the 
covariates that we examined. This suggests that the heterogeneity of 0% found in the 
pooled analysis was accurate to a certain extent, since the goal of a meta-regression is to 
investigate the heterogeneity between results of multiples studies and one or more 
characteristics of a study can alter that heterogeneity. Since no heterogeneity was found, 
meta-regression was not necessary for this study, but it added a layer of further 
understanding by indicating that heterogeneity was not present.  
Finally, although it was stated in the methods that a permutation test would be done, 
since none of the covariates had a significant p-value, a permutation test was not needed.  
7.5 Publication Bias 
For publication bias, we used the trim and fill method, as mentioned earlier. Three 
iterations were needed, which enabled us to identify and fix the asymmetry by adding 1 
extra study to balance out the others, as can be seen in Figure 11. The addition of the 
extra study made the WMD = -0.110, 95% CI -0.155 to -0.065.  
As can be seen in the funnel plot, everything is within symmetry. This suggests that there 
were no extreme positive studies that could have caused deviation. However, imputation 
was required to create more symmetry. In other words, our selection of studies may have 
been unbiased and mainly symmetrical with regards to the underlying common effect, but 
we used the trim and fill method to be certain that any existing asymmetry was addressed.   
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In conclusion, this study found that there was no heterogeneity in the pooled analysis, nor 
was there any heterogeneity in the subgroup analysis or the meta-regression. This 
indicates that the population group was fairly homogeneous and could be compared from 
one study to another. Another interesting take away is that all treatments seemed to be 
effective at treating uveitis, with antimetabolites and T-cell inhibitors reporting 
statistically significant results. However, antimetabolites were more effective at treating 
patients, demonstrating a greater change in logMAR then T-cell inhibitors. 
7.6 Strengths  
Meta-analysis is a powerful tool that can assist researchers when an overwhelming 
amount of information is present, even when the field of study is quite narrow. However, 
there can be drawbacks to conducting a meta-analysis, and it can be controversial if not 
done correctly. Methodology is the most important attribute in both a systematic review 
and a meta-analysis. Even a slight deviation or violation of the methods could lead to 
misleading results and bias.  
Our study adhered to all possible guidelines and rules of thumb from the search strategy 
in the way our meta-regression was done, with consideration of all caveats. All work was 
done very carefully, from the search strategy, to the article capturing and screening, to the 
data abstraction, to the analysis. Careful analysis of the data was important to ensure 
reliable results. The Cochrane Collaboration and the PRISMA guidelines were followed 
to ensure that the meta-analysis was completed and reported with precision (see 
Appendix A and B).  
This is the first systematic review and meta-analysis undertaken on the treatments given 
to patients that specifically have non-infectious idiopathic uveitis. We screened 2251 
citations using the inclusion/exclusion criteria. Unlike previous narrative and systematic 
reviews, our systematic review developed a meticulous search strategy with the help of 
an information specialist. There were 6 scientific databases used to collect relevant 
articles, and a comprehensive search of grey literature was also done. Strict 
inclusion/exclusion criteria were developed specific to our research question, and the 
studies were independently screened by 2 reviewers, in order to reduce potential bias. 
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The inclusion/exclusion criteria were created to ensure homogeneity in both the studies 
and the patient population. The patient population was homogenous, according to the 
following criteria: primary treatment given to the patients was orally administered in all 
studies, studies were limited by the type of previous treatments given, the locations of 
uveitis were mainly intermediate and posterior uveitis, and the disease was specific to 
idiopathic uveitis. The heterogeneity from the patient population was only in the primary 
treatment given to the patients.  
Unlike previous reviews, our study also used a quality assessment tool, the Downs and 
Black checklist. The checklist is one of the only validated checklists for methodological 
quality of observation studies. We used the checklist for all 45 studies, of which, the 28 
used in the meta-analysis were moderate studies, with some RCTs as well. This suggests 
that the studies that remained for our analysis were strong enough to ensure the integrity 
of the results.  
Alongside the systematic review, it was very important for the meta-analysis to adhere to 
the strict guidelines and accurately conduct the analysis. We anticipated that the pooled 
meta-analysis would have heterogeneity because all the studies were pooled together. 
However, there was a specific factor in the heterogeneity, which was the primary 
treatment, and therefore we needed other tests to investigate where the heterogeneity 
came from. We used subgroup analysis and meta-regression to test and quantify the 
heterogeneity. All precautions and rules were followed to ensure the integrity of the 
results. The subgroup analysis was conducted even with the subgroups that had fewer 
than 5 studies. Another method used to investigate the heterogeneity and to bypass the 
subgroup analysis problem was a meta-regression. Here, while many methods were 
considered, the best method for our meta-analysis was the Knapp and Hartung univariate 
meta-regression. Finally, we also planned to conduct a permutation test to ensure no false 
negative p-values were present in the initial test.  
7.7 Limitations 
Even though publication bias was found through the trim and fill method, with very 
minimal changes, there were no non-English studies used in our study, which is one 
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limitation that could lead to publication bias. Future studies should attempt to include 
non-English studies.  
The quality of the 45 studies used in this systematic review was mild to moderate, only 
stating frequencies of improvements to visual acuity and inflammation grade, but 
otherwise not having much statistical basis. However, the 28 studies that we used for the 
meta-analysis contained more robustness in their methodology, which helped to 
compensate for the overall quality of the 45 studies.  
Some of the data that was collected in the extraction sheets was not used in the analysis, 
in particular, the dosage, which could have played an important role in understanding the 
heterogeneity. However, dosage was left out because the dosages for treatment groups 
could not be compared, as different treatment groups required different dosages. Another 
limitation is that some of the subgroups contained fewer than 5 studies, which can cause 
bias. Generally, small subgroups such as this should not be compared to other subgroups, 
however, using meta-regression on these subgroups helped to alleviate the issue when 
assessing the data.  
Also, we could have had methodological heterogeneity with our primary outcome. It has 
been found that there is a clear correlation between the scales measuring VA. The 
regression analysis revealed a significant correlation between the visual acuity scores on 
the 2 charts (R2 = 0.8839) with a slope significantly different from 1 (P < .0001). 
However, it is also been noted that the Snellen method is not as reliable as the logMAR 
method when measuring for VA. This could lead to heterogeneity as our study had a 
variation on measuring VA. Though we standardized the scales to logMAR, the initial 
method used to measure VA could have led to methodological heterogeneity. Future 
studies should test to see whether the difference in scales resulted in different results, 
using either a subgroup or meta-regression analysis.  
Also, important to note is that even though most studies conducted on the subject level, it 
should be important to ensure that the methodology used by the studies allowed for 
correlation if there was two observations done per individual. Thus, in future studies, we 
should be stricter on the methodology of the studies, so we can ensure that studies that do 
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report two observations per individual, account for correlation and thus would lead to less 
error within the study and higher quality of the study for internal validity. 
Another limitation is that heterogeneity was not pooled by treatment group, because there 
were not enough studies in each treatment group to conduct a subgroup analysis or meta-
regression on each treatment group separately. When subgroup analysis or meta-
regression was conducted it was conducted on the pooled data. However, due to the lack 
of studies, we were unable to conduct more specific analysis, such as examining the 
heterogeneity of the covariates or subgroups that were examined in the pooled data, for 
each primary treatment group. This may limit the interpretation of the results and 
introduce complications regarding the main question this thesis wanted to answer.  
In addition to the above, no analysis was conducted on the outcome of inflammation 
grade, even though it is a better measure of improvement in the severity of uveitis. Again, 
this was a result of not having enough studies containing the information necessary to 
conduct a meta-analysis on this outcome. While this reduces the applicability of the 
results, it is a good starting point.  
Finally, one of the most significant limitations of a meta-analysis is the fact that any 
results obtained from the subgroup analysis and meta-regression are observational in 
nature. Any statistically significant or non-statistically significant result cannot be used to 
draw any concrete conclusions, but could be used to make an observation. This is 
important to keep in mind since power to detect heterogeneity in effect sizes or between 
covariates or subgroups is very low. In other words, failure to obtain a statistically 
significant difference among subgroups should never be interpreted as evidence that the 
effect is the same across subgroups. The same can be said for obtaining a statistically 
significant result. Simple failure to obtain a statistically significant effect for a covariate 
should never be interpreted as evidence that there is no relationship between the covariate 
and the effect size. 
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7.8 Possibilities for future research 
In future studies, there are a few elements that can be taken into consideration to ensure 
better results that are more viable for converting to policy. One is the inclusion of non-
English studies. If we had included studies from other languages, it would have increased 
our meta-analysis by 29 studies. Another is the inclusion of biologics as a treatment 
group. Finally, our study did not include an analytical comparison of adverse events. 
Future studies should include this element, which would facilitate a deeper understanding 
about the effectiveness of different treatments. In addition to including the above 
elements, future studies should also conduct a cost-effectiveness analysis, which is a key 
element for creating policy.  Including a cost-effectiveness model, done in accordance 
with CUS and COS, would be the final step in ensuring a comprehensive study that can 
be used to inform policy and further our understanding about off-label treatments and 
their ability to treat uveitis patients.  
7.9 Conclusion  
This systematic review and meta-analysis were conducted with the utmost care and 
accuracy. Idiopathic non-infectious uveitis patients that received 1 of 3 different 
treatment groups were the primary patient population this study examined. There were 
specific criteria used to determine which studies were included in the systematic review 
and meta-analysis. This study helped to paint a better picture about the different 
treatments administered to patients with non-infectious idiopathic uveitis. All treatments 
were found to be effective in the pooled analysis, with a logMAR of -0.11. Furthermore, 
there was an indication in the subgroups analysis that treatment was particularly 
efficacious in patients over 18, patients with intermediate uveitis, patients treated with 
antimetabolites, and patients pretreated (usually with steroids). Finally, there was 
minimal heterogeneity present, which was explained in the subgroup analysis. Future 
studies, especially those that include a cost-effectiveness analysis, will allow us to draw 
better conclusions about the most effective treatments for non-infectious idiopathic 
uveitis.  
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Appendices 
 
Appendix A: Meta-analysis of Observational Studies in Epidemiology (MOOSE) 
Checklist 
 Page # 
Reporting of background should include:  
    Problem definition 35 
    Hypothesis statement  
    Description of study outcome(s) 35-36 
    Type of exposure or intervention used 10-14 
    Type of study designs used 35 
    Study population 35-36 
Reporting of search strategy should include:  
    Qualifications of searchers (eg, librarians and investigators) 48 
    Search strategy, including time period included in the synthesis and keywords 49 
    Effort to include all available studies, including contact with authors 49 
    Databases and registries searched 48-50 
    Search software used, name and version, including special features used (eg, explosion) 65 
    Use of hand searching (eg, reference lists of obtained articles) 49 
    List of citations located and those excluded, including justification 64 
    Method of addressing articles published in languages other than English -- 
    Method of handling abstracts and unpublished studies -- 
    Description of any contact with authors -- 
Reporting of methods should include:      
    Description of relevance or appropriateness of studies assembled for assessing the hypothesis 
to be tested 
59-60 
    Rationale for the selection and coding of data (eg, sound clinical principles or convenience) 60 
    Documentation of how data were classified and coded (eg, multiple raters, blinding, and 
interrater reliability) 
58 
    Assessment of confounding (eg, comparability of cases and controls in studies where 
appropriate) 
70 
    Assessment of study quality, including blinding of quality assessors; stratification or 
regression on possible predictors of study results 
44, 62-63 
    Assessment of heterogeneity 60-65 
    Description of statistical methods (eg, complete description of fixed or random effects models, 
justification of whether the chosen models account for predictors of study results, dose-response 
models, or cumulative meta-analysis) in sufficient detail to be replicated 
57-59 
    Provision of appropriate tables and graphics 106-112 
Reporting of results should include:  
   Graphic summarizing individual study estimates and overall estimate 106-112 
   Table giving descriptive information for each study included 67-98 
    Results of sensitivity testing ( eg, subgroup analysis) 103-105 
    Indication of statistical uncertainty of findings 125-128 
Reporting of discussion should include:  
    Quantitative assessment of bias (eg, publication bias) 115 
    Justification of exclusion (eg, exclusion of non-English-language citations) 52 
    Assessment of quality of included studies 99-100 
Reporting of conclusions should include:  
    Consideration of alternative explanations for observed results 125-128 
    Generalization of the conclusions (ie, appropriate for the data presented and within the domain 
of the literature review) 
128 
    Guidelines for future research 128 
    Disclosure of funding source -- 
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Appendix B: Preferred Reporting Item for Systematic Reviews and Meta-analysis (PRISMA) guidelines 
Section/topic  # Checklist item  Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  -- 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
ii 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  33-34 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
52 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (eg, Web address), and, if 
available, provide registration information including registration number.  
-- 
Eligibility 
criteria  
6 Specify study characteristics (eg, PICOS, length of follow-up) and report characteristics (eg, years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
56-57 
Information 
sources  
7 Describe all information sources (eg, databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
55-56 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that 
it could be repeated.  
152-157 
Study 
selection  
9 State the process for selecting studies (ie, screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
52-53 
Data 
collection 
process  
10 Describe method of data extraction from reports (eg, piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from investigators.  
52-55 
Data items  11 List and define all variables for which data were sought (eg, PICOS, funding sources) and any 
assumptions and simplifications made.  
53-55, 
158 
151 
 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis.  
56 
Summary 
measures  
13 State the principal summary measures (eg, risk ratio, difference in means).  54 
Synthesis of 
results  
14 Describe the methods of handling data and combining results of studies, if done, including measures 
of consistency (eg, I2) for each meta-analysis.  
52-55 
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (eg, publication bias, 
selective reporting within studies).  
65 
Additional 
analyses  
16 Describe methods of additional analyses (eg, sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
60-64 
RESULTS   
Study 
selection  
17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons 
for exclusions at each stage, ideally with a flow diagram.  
66 
Study 
characteristics  
18 For each study, present characteristics for which data were extracted (eg, study size, PICOS, follow-
up period) and provide the citations.  
76-100 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 
12).  
101 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data 
for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
104, 116 
Synthesis of 
results  
21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
116 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  101 
Additional 
analysis  
23 Give results of additional analyses, if done (eg, sensitivity or subgroup analyses, meta-regression [see 
Item 16]).  
108-116 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main outcome; consider 
their relevance to key groups (eg, healthcare providers, users, and policy makers).  
117-128 
Limitations  25 Discuss limitations at study and outcome level (eg, risk of bias), and at review-level (eg, incomplete 
retrieval of identified research, reporting bias).  
126-128 
152 
 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for 
future research.  
130-131 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (eg, supply of data); role of 
funders for the systematic review.  
-- 
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Appendix C: Search Strategies 
 
MEDLINE (Ovid) 
 
Timespan:  
 Ovid MEDLINE(R) 1946 to July Week 1, 2012  
Ovid MEDLINE(R) Daily Update July 13, 2012  
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations July 13, 2012 
  SEARCH STRATEGY (Blue = Keywords  / Red = MeSH) 
 
 1 Uveitis or "Ocular inflammat$" or "Intraocular inflammat$" 
2 Uveitis/ OR intermediate uveitis/ OR Uveitis, Anterior/ OR Uveitis, Posterior/ 
3 1 OR 2 
4 
(Immunosuppress$ or immunomodulat$) ADJ2 (agent$1 or treatment$1 or 
drug$1 or therap$) 
5 
Immunosuppressive Agents/ or Immunosuppression/ or Immunologic 
Factors/ 
6 4 OR 5 
7 
Antimetabolite$ or Azathioprine or Methotrexate or "Mycophenolic Acid" or 
Alkylating Agent$ or Cyclophosphamide or Chlorambucil or Cyclosporine or 
Tacrolimus or Sirolimus or Rapamycin or amethopterin OR "Mycophenolate 
Mofetil" OR cytophosphane OR FK-506 OR fujimycin OR Imuran OR Azasan 
OR rheumatrex OR cellcept OR trexall OR myfortic OR cytoxan OR endoxan 
OR cytoxan OR neosar OR procytox OR revimmune OR chlorambucil or 
leukeran or "calcineurin inhibitor$" or gengraf or neoral or sandimmune or 
prograf or advagraf or protopic or rapamune 
8 
Antimetabolites/ or Azathioprine/ or Methotrexate/ or Mycophenolic Acid/ 
or Alkylating Agents/ or Cyclophosphamide/ or Chlorambucil/ or calcineurin 
inhibitor/ or Cyclosporine/ or Tacrolimus/ or Sirolimus/ or Rapamycin/ 
9 7 OR 8 
10 3 AND (6 OR 9) 
  Results = 1822  
  
Explanation of Syntax Used:  
- the dollar sign ($) finds all variations of word endings (i.e, comput$ finds computer, computing, 
etc.) 
- the number sign (#)  finds words that may appear with or without an extra letter (ie, computer# 
finds computer or computers) 
- the Adjacency Operator (ADJ ) searches for 2 or more words that appear within a specified 
number of words (or fewer) of each other and in any order (ie, "tax ADJ5 reform" would find 
instances of "tax reform" as well as "reform of income tax") 
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EMBASE (Ovid) 
Timespan:  Embase 1980 to 2012 Week 28 
  SEARCH STRATEGY (Blue = Keywords  / Red = EMTREE Terms) 
  1 Uveitis or "Ocular inflammat$" or "Intraocular inflammat$" 
2 Uveitis/ OR intermediate uveitis/ OR Uveitis, Posterior/ 
3 1 OR 2 
4 
(Immunosuppress$ or immunomodulat$) ADJ2 (agent$1 or treatment$1 or 
drug$1 or therap$) 
5 
 Immunosuppressive Agent/ or Immunosuppressive Treatment/ or 
immunomodulating agent/ 
6 4 OR 5 
7 
Antimetabolite$ or Azathioprine or Methotrexate or "Mycophenolic Acid" or 
Alkylating Agent$ or Cyclophosphamide or Chlorambucil or Cyclosporine or 
Tacrolimus or Sirolimus or Rapamycin or amethopterin OR "Mycophenolate 
Mofetil" OR cytophosphane OR FK-506 OR fujimycin OR Imuran OR Azasan OR 
rheumatrex OR cellcept OR trexall OR myfortic OR cytoxan OR endoxan OR 
cytoxan OR neosar OR procytox OR revimmune OR chlorambucil or leukeran or 
"calcineurin inhibitor$" or gengraf or neoral or sandimmune or prograf or 
advagraf or protopic or rapamune 
8 
Antimetabolites/ or Azathioprine/ or Methotrexate/ or Mycophenolic Acid/ or 
Alkylating Agents/ or Cyclophosphamide/ or Chlorambucil/ or Cyclosporine/ or 
Tacrolimus/ or Sirolimus/ or Rapamycin/ 
9 7 OR 8 
10 3 AND (6 OR 9) 
  Results = 3786 
  Explanation of Syntax Used:  
- the dollar sign ($) finds all variations of word endings (i.e, comput$ finds computer, computing, 
etc.) 
- the number sign (#)  finds words that may appear with or without an extra letter (ie, computer# 
finds computer or computers) 
- the Adjacency Operator (ADJ ) searches for 2 or more words that appear within a specified 
number of words (or fewer) of each other and in any order (ie, "tax ADJ5 reform" would find 
instances of "tax reform" as well as "reform of income tax") 
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CINAHL (EBSCO) 
Timespan: 1982-present 
  SEARCH STRATEGY (Blue = Keywords  / Red = CINAL Subject Terms) 
  1 Uveitis or "Ocular inflammat*" or "Intraocular inflammat*" 
2 
(MH "Uveitis") OR (MH "Uveitis, Anterior") OR (MH "Uveitis, 
Intermediate") OR (MH "Uveitis, Posterior") 
3 1 OR 2 
4 
(Immunosuppress* or immunomodulat*) N2 (agent# or treatment# or 
drug# or therap*) 
5 
(MH "Immunosuppressive Agents") OR (MH "Immunosuppression") OR 
(MH "Immunologic Factors")   
6 4 OR 5 
7 
Antimetabolite# or Azathioprine or Methotrexate or "Mycophenolic Acid" 
or Alkylating Agent# or Cyclophosphamide or Chlorambucil or Cyclosporine 
or Tacrolimus or Sirolimus or Rapamycin or amethopterin OR 
"Mycophenolate Mofetil" OR cytophosphane OR FK-506 OR fujimycin OR 
Imuran OR Azasan OR rheumatrex OR cellcept OR trexall OR myfortic OR 
cytoxan OR endoxan OR cytoxan OR neosar OR procytox OR revimmune 
OR chlorambucil or leukeran or "calcineurin inhibitor#" or gengraf or 
neoral or sandimmune or prograf or advagraf or protopic or rapamune 
8 
(MH "Antimetabolites")  OR (MH "Azathioprine")  OR (MH "Methotrexate")  
OR (MH "Mycophenolate Mofetil") OR (MH "Mycophenolic Acid")  OR (MH 
"Cyclophosphamide")  OR (MH "Alkylating Agents")  OR (MH 
"Cyclosporine")  OR (MH "Sirolimus")   
9 7 OR 8 
10 (3) AND (6 OR 9) 
  Results = 89  
  
Explanation of Syntax Used:  
- the asterisk sign (*) finds all variations of word endings (i.e, comput* finds computer, 
computing, etc.) 
- the number sign (#)  finds words that may appear with or without an extra letter (ie, computer# 
finds computer or computers) 
- the Near Operator (N ) searches for 2 or more words that appear within a specified number of 
words (or fewer) of each other and in any order (ie, "tax N5 reform" would find instances of 
"tax reform" as well as "reform of income tax") 
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COCHRANE LIBRARY 
 
Timespan: 
 EBM Reviews - Cochrane Database of Systematic Reviews 2005 to July 2012  
EBM Reviews - ACP Journal Club 1991 to July 2012  
EBM Reviews - Database of Abstracts of Reviews of Effects 3rd Quarter 2012  
EBM Reviews - Cochrane Central Register of Controlled Trials July 2012  
EBM Reviews - Cochrane Methodology Register 3rd Quarter 2012  
EBM Reviews - Health Technology Assessment 3rd Quarter 2012  
EBM Reviews - NHS Economic Evaluation Database 3rd Quarter 2012 
  SEARCH STRATEGY (all keywords) 
 
 1 Uveitis or "Ocular inflammat$" or "Intraocular inflammat$" 
2 
(Immunosuppress$ or immunomodulat$) ADJ2 (agent$1 or treatment$1 or 
drug$1 or therap$) 
3 
Antimetabolite$ or Azathioprine or Methotrexate or "Mycophenolic Acid" or 
Alkylating Agent$ or Cyclophosphamide or Chlorambucil or Cyclosporine or 
Tacrolimus or Sirolimus or Rapamycin or amethopterin OR "Mycophenolate 
Mofetil" OR cytophosphane OR FK-506 OR fujimycin OR Imuran OR Azasan 
OR rheumatrex OR cellcept OR trexall OR myfortic OR cytoxan OR endoxan 
OR cytoxan OR neosar OR procytox OR revimmune OR chlorambucil or 
leukeran or "calcineurin inhibitor$" or gengraf or neoral or sandimmune or 
prograf or advagraf or protopic or rapamune 
5 1 AND (2 OR 3) 
  Results = 85 
  
Explanation of Syntax Used:  
- the dollar sign ($) finds all variations of word endings (i.e, comput$ finds computer, computing, 
etc.) 
- the number sign (#)  finds words that may appear with or without an extra letter (ie, computer# 
finds computer or computers) 
- the Adjacency Operator (ADJ ) searches for 2 or more words that appear within a specified 
number of words (or fewer) of each other and in any order (ie, "tax ADJ5 reform" would find 
instances of "tax reform" as well as "reform of income tax") 
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BIOSIS Previews 
Timespan: 1926-present (updated 2012-07-13) 
  SEARCH STRATEGY 
  
 
Topic=(Uveitis or "Ocular inflammat*" or "Intraocular inflammat*")  
 
AND  
 
Topic=((Immunosuppress* or immunomodulat*) NEAR/1 (Agent& or Treatment$ or drug$ or 
therap*))  
 
AND  
 
Topic=(Antimetabolite$ or Azathioprine or Methotrexate or "Mycophenolic Acid" or 
Alkylating Agent$ or Cyclophosphamide or Chlorambucil or Cyclosporine or Tacrolimus or 
Sirolimus or Rapamycin or amethopterin OR "Mycophenolate Mofetil" OR cytophosphane 
OR FK-506 OR fujimycin OR Imuran OR Azasan OR rheumatrex OR cellcept OR trexall OR 
myfortic OR cytoxan OR endoxan OR cytoxan OR neosar OR procytox OR revimmune OR 
chlorambucil or leukeran or "calcineurin inhibitor$" or gengraf or neoral or sandimmune or 
prograf or advagraf or protopic or rapamune) 
 
AND  
 
AND Concept Codes=(Pathology - Inflammation "and" inflammatory disease OR Pathology - 
Inflammation "and" inflammatory disease) 
  Results = 112 
  Explanation of Syntax Used:  
- the asterisk sign (*) finds all variations of word endings (i.e, comput* finds computer, 
computing, etc.) 
- the dollar sign ($)  finds words that may appear with or without an extra letter (ie, computer$ 
finds computer or computers) 
- the Near Operator (N) searches for 2 or more words that appear within a specified number of 
words (or fewer) of each other and in any order (ie, "tax N5 reform" would find instances of 
"tax reform" as well as "reform of income tax") 
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Web of Science 
Timespan: 1898-present (updated 2012-07-13) 
includes Citation Databases: 
 
Science Citation Index Expanded (SCI-EXPANDED) --1945-present 
 
Social Sciences Citation Index (SSCI) --1898-present 
 
Arts & Humanities Citation Index (A&HCI) --1975-present 
 
Conference Proceedings Citation Index- Science (CPCI-S) --1990-present 
 
Conference Proceedings Citation Index- Social Science & Humanities (CPCI-SSH) --1990-
present 
  SEARCH STRATEGY 
  
 
Topic=(Uveitis or "Ocular inflammat*" or "Intraocular inflammat*")  
 
AND  
 
Topic=((Immunosuppress* or immunomodulat*) NEAR/1 (Agent& or Treatment$ or drug$ or 
therap*))  
 
AND  
 
Topic=(Antimetabolite$ or Azathioprine or Methotrexate or "Mycophenolic Acid" or 
Alkylating Agent$ or Cyclophosphamide or Chlorambucil or Cyclosporine or Tacrolimus or 
Sirolimus or Rapamycin or amethopterin OR "Mycophenolate Mofetil" OR cytophosphane 
OR FK-506 OR fujimycin OR Imuran OR Azasan OR rheumatrex OR cellcept OR trexall OR 
myfortic OR cytoxan OR endoxan OR cytoxan OR neosar OR procytox OR revimmune OR 
chlorambucil or leukeran or "calcineurin inhibitor$" or gengraf or neoral or sandimmune or 
prograf or advagraf or protopic or rapamune) 
  Results = 275 
  Explanation of Syntax Used:  
- the asterisk sign (*) finds all variations of word endings (i.e, comput* finds computer, 
computing, etc.) 
- the dollar sign ($)  finds words that may appear with or without an extra letter (ie, computer$ 
finds computer or computers) 
- the Near Operator (N) searches for 2 or more words that appear within a specified number of 
words (or fewer) of each other and in any order (ie, "tax N5 reform" would find instances of 
"tax reform" as well as "reform of income tax") 
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Appendix D: Study Eligibility Criteria 
Level 1 Screening: 
1. Does the study look at non-infectious idiopathic uveitis in humans? 
2. Is it a primary study? 
3. Does the study look at immunosuppressive treatments: antimetabolites, alkylating 
agents, T-lymphocytes inhibitors? 
4. Was the study conducted in North America, Western Europe, Hong Kong, Japan, 
New Zealand, Australia, and Singapore? 
*Answer to all questions must be a yes in order to be included for level 2 screening. 
 
Level 2 Screening: 
1. Does the study look at non-infectious idiopathic uveitis (keep studies that have 
50% or more of patients with non-infectious idiopathic uveitis or Juvenile 
rheumatoid arthritis associated with uveitis)? Studies with 50% or more patients 
with these diseases were excluded from study: 
- Behects disease 
- Vogt-Koyanagi-Harada  
- HLA B27  
- Serpiginous choroiditis  
- Cystoid macular oedema  
- Atopic keratoconjunctivitis  
- Vasculitis  
- ocular cicatrical Pemphiod  
- Wegener's granulomatosis  
- Sclerosis  
- Sarcoidosis  
2. Location of disease either posterior or intermediate or panuvitis. If 50 % or more 
patients have anterior uveitis, the study is excluded. 
3. Is it a primary study? 
4. More than 5 patients? 
5. The study population had oral treatment given 
6. Does the study look at immunosuppressive treatments: antimetabolites, alkylating 
agents, T-lymphocytes inhibitors? 
7. Does the study report any one of these outcomes: Visual acuity, inflammation 
grade, relapse rate, corticosteroid sparing rate and/or adverse events? 
8. Was the study conducted in North America, Western Europe, Hong Kong, Japan, 
New Zealand, Australia, and Singapore? 
9.  Is the study in English?
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Appendix E: Data Extraction Form 
Reviewer’s Initial: 
(Please check the second page if terminology is unclear) 
Study Identification Method Participant Characteristics 
Baseline Characteristics 
(Before Treatment) 
Treatment 
Outcomes 
(After treatment) 
Citation (author, 
year):  
 
Study 
objective:  
 
Study 
design:  
Site(s):  
 
Inclusion 
criteria:  
 
Exclusion 
criteria:  
 
Data 
collection 
technique:  
 
Date(s) of 
data 
collection:  
N (Full) =           
Ni (idiopathic uveitis) =  
Mean age:             
 % Female:  
Race/ethnicity (and %):           
Geographic location (of study):  
Mean Follow Up (months): 
Lost to follow up: 
 
 
 
Location of Uveitis: 
 
Cause of Uveitis: 
 
Type of Uveitis: 
 
Severity of Uveitis: 
     Measured via inflammation    
grade 
 
Or/And 
 
Visual Acuity (LogMAR): 
 
Any condition alongside Uveitis: 
   
Any previous treatment given: 
 
If so, which type: 
 
What dosage: 
 
 
  
 
  
  
  
 
Treatment given: 
 
Dosage (per week):  
 
Length of time: 
 
Concurrent Treatment: 
 
Dosage (per week): 
 
Length of time: 
 
Is steroid give 
concurrently?  
    Yes  
     No 
 
If yes, what dosage: 
 
Length of time: 
 
Pre and Post Visual Acuity 
 
(given either in % or the 
number of patients) 
 
Reduction in Severity 
Via: 
Visual Acuity: 
Or/and 
Inflammation grade: 
 
Steroid Usage: 
Discontinuation of Steroids 
completely 
Or  
Reduction in dosage of 
steroids 
     Dosage was reduced to: 
 
Number of people that 
relapsed once within the 
followup period: 
 
Number of people that 
relapsed more than once: 
 
Adverse events (list them 
with the number of patients 
that had the individual 
adverse event): 
N (Full) = total number of patients considered. Ni= Total number of patients with idiopathic uveitis 
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Appendix F: Downs and Black Checklist for Study Quality 
 
Checklist for measuring study quality 
Reporting 
1. Is the hypothesis/aim/objective of the study 
clearly described? 
yes 1 
no 0 
 
2. Are the main outcomes to be measured clearly 
described in the Introduction or Methods 
section? 
If the main outcomes are first mentioned in the 
Results section, the question should be 
answered no. 
yes 1 
no 0 
 
3. Are the characteristics of the patients included 
in the study clearly described? 
In cohort studies and trials, inclusion and/or 
exclusion criteria should be given. In case-
control studies, a case-definition and the 
source for controls should be given. 
yes 1 
no 0 
 
4. Are the interventions of interest clearly 
described? 
Treatments and placebo  (where relevant) that 
are to be compared should be clearly described 
yes 2 
partially 1 
no 0 
 
5. Are the distributions of principal confounders in 
each group of subjects to be compared clearly 
described? 
A list of principal confounders is provided. 
yes 1 
no 0 
 
6. Are the main findings   of the study clearly 
described? 
Simple outcome data (including denominators 
and numerators) should be reported for all 
major findings so that the reader can check the 
major analyses and conclusions. (This question 
does not cover statistical tests which are 
considered below.) 
yes 1 
no 0 
 
7. Does the study provide estimates of the random 
variability in the data for the main outcomes? 
In non-normally distributed data the inter-
quartile range of results should be reported. In 
normally distributed data the standard error, 
standard deviation or confidence intervals 
should be reported. If the distribution of the 
data is not described, it must be assumed that 
the estimates used were appropriate and the 
question should be answered yes. 
yes 1 
no 0 
 
8. Have all important adverse events that may be a 
consequence of the intervention been reported? 
This should be answered yes if the study 
demonstrates that there was a comprehensive 
attempt to measure adverse events. (A list of 
possible adverse events is provided.) 
yes 1 
no 0 
 
9. Have the characteristics of patients lost   to 
follow-up been described? 
This should be answered yes where there were 
no losses to follow-up or where losses to 
follow-up were so small that findings would be 
unaffected by their inclusion. This should be 
answered no where a study does not report the 
number of patients lost to follow-up. 
yes 1 
no 0 
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10. Have actual probability values been reported 
(e.g. 0.035 rather than <0.05) for the main 
outcomes except where the probability value is 
less than 0.001? 
yes 1 
no 0 
 
External validity 
All the following criteria attempt to address the 
representativeness of the findings of the study and 
whether they may be generalized to the 
population from which the study subjects were 
derived. 
11. Were the subjects asked to participate in the 
study representative of the entire population 
from which they were recruited? 
The study must identify the source population 
for patients and describe how the patients 
were selected.  Patients would be 
representative if they comprised the entire 
source population exists. Where a study does 
not report the proportion of the source 
population from which the patients are 
derived, the question should be answered as 
unable to determine. 
yes 1 
no 0 
Unable to determine 0 
 
12. Were those subjects who were prepared to 
participate representative of the entire 
population from which they were recruited? 
The proportion of those asked who agreed 
should   be stated. Validation that the sample 
was representative would include 
demonstrating that the distribution of the main 
confounding factors was the same in the study 
sample and the source population. 
yes 1 
no 0 
Unable to determine 0 
 
13. Were the stay, places, and facilities where the 
patients were treated, representative of the 
treatment the majority of patients receive? 
For the question to be answered yes the study 
should demonstrate that the intervention was 
representative of that in use in the source 
population. The question should be answered 
no if, for example, the intervention was 
undertaken in a specialist centre 
unrepresentative of the hospitals most of the 
source population would attend. 
yes 1 
no 0 
Unable to determine 0 
 
Internal validity — bias 
14. Was an attempt made to blind study subjects to 
the intervention they have received? 
For studies where the patients would have no 
way of knowing which intervention they 
received, this should be answered yes. 
yes 1 
no 0 
Unable to determine 0 
 
15. Was an attempt made to blind those measuring 
the main outcomes of the intervention? 
yes 1 
no 0 
Unable to determine 0 
 
16. If any of the results of the study were based on 
“data dredging”, was this made clear? 
Any analyses that had not been planned at the 
outset of the study should be clearly indicated. 
If no retrospective unplanned subgroup 
analyses were reported, then answer yes. 
yes 1 
no 0 
Unable to determine 0 
 
17. In trials and cohort studies, do the analyses 
adjust for different lengths of follow-up of 
patients, or in case-control studies, is the time 
period between the intervention and outcome the 
same for cases and controls? 
Where follow-up was the same for all study 
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patients the answer should yes. If different 
lengths of follow-up were adjusted for by, for 
example, survival analysis the answer should be 
yes. Studies where differences in follow-up are 
ignored should be answered no. 
yes 1 
no 0 
Unable to determine 0 
 
18. Were the statistical tests used to assess the main 
outcomes appropriate? 
The statistical techniques used must be 
appropriate to the data. For example non- 
parametric methods should be used for small 
sample sizes. Where little statistical analysis 
has been undertaken but where there is no 
evidence of bias, the question should be 
answered yes. If the distribution of the data 
(normal or not) is not described it must be 
assumed that the estimates used were 
appropriate and the question should be 
answered yes. 
yes 1 
no 0 
Unable to determine 0 
 
19. Was compliance with the intervention/s reliable? 
Where there was non-compliance with the 
allocated treatment or where there was 
contamination of one group, the question 
should be answered no. For studies where the 
effect of any misclassification was likely to bias 
any association to the null, the question should 
be answered yes. 
yes 1 
no 0 
Unable to determine 0 
 
20. Were the main outcome measures used accurate 
(valid and reliable)? 
For studies where the outcome measures are 
clearly described, the question should be 
answered yes. For studies which refer to other 
work or that demonstrates the outcome 
measures  are accurate, the question should be 
answered  as yes. 
yes 1 
no 0 
Unable to determine 0 
 
Internal validity — confounding (selection bias) 
21. Were the patients in different intervention 
groups (trials and cohort studies) or were the 
cases and controls (case-control studies) 
recruited from the same population? 
For example, patients for all comparison groups 
should be selected from the same hospital. The 
question should be answered unable to 
determine for cohort and case-control studies 
where there is no information concerning the 
source of patients included in the study. 
yes 1 
no 0 
Unable to determine 0 
 
22. Were study subjects in different intervention 
groups (trials and cohort studies) or were the 
cases and controls (case-control studies) 
recruited over the same period of time? 
For a study which does not specify the time 
period over which patients were recruited, the 
question should be answered as unable to 
determine. 
yes 1 
no 0 
Unable to determine 0 
 
23. Were study subjects randomized to intervention 
groups? 
Studies which state that subjects were 
randomized should be answered yes except 
where method of randomization would not 
ensure random allocation.  For example 
alternate   allocation   would score no because it 
is predictable. 
yes 1 
no 0 
Unable to determine 0 
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Size of smallest intervention group 
 
A <n1 0 
B n1–n2 1 
C n3–n4 2 
D n5–n6 3 
E n7–n8 4 
F n + 5 
 
24. Was the randomized intervention assignment 
concealed from both patients and health care 
stay until recruitment was complete and 
irrevocable? 
All non-randomized studies should be 
answered no. If assignment was concealed from 
patients but not from stay, it should be 
answered no. 
yes 1 
no 0 
Unable to determine 0 
 
25. Was there adequate adjustment for confounding 
in the analyses from which the main findings 
were drawn? 
This question should be answered no for trials 
if: the main conclusions of the study were based 
on analyses of treatment rather than intention 
to treat; the distribution of known confounders 
in the different treatment groups was not 
described; or the distribution of known 
confounders differed between the treatment 
groups but was not taken into account in the 
analyses. In non-randomized studies if the 
effect of the main confounders was not 
investigated or confounding was demonstrated 
but no adjustment was made in the final 
analyses the question should be answered as 
no. 
yes 1 
no 0 
Unable to determine 0 
 
26. Were losses of patients to follow-up taken into 
account? 
If the numbers of patients lost to follow-up are 
not reported, the question should be answered 
as unable to determine. If the proportion lost to 
follow-up was too small to affect the main 
findings, the question should be answered yes. 
yes 1 
no 0 
Unable to determine 0 
 
Power 
27. Did the study have sufficient power to detect a 
clinically important event where the probability 
value for a difference being due to chance is less 
than 5%? 
Sample sizes have been calculated to detect a 
difference of x% and y%. 
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